{
    "__patient_identifiers_list_v1__": "[{\"patient\": \"AII-11\", \"family\": \"Family A\"}, {\"patient\": \"BIII-8\", \"family\": \"Family B\"}, {\"patient\": \"CII-3\", \"family\": \"Family C\"}, {\"patient\": \"D\", \"family\": null}, {\"patient\": \"AII-12\", \"family\": \"Family A\"}, {\"patient\": \"AIII-5\", \"family\": \"Family A\"}, {\"patient\": \"AIII-6\", \"family\": \"Family A\"}]",
    "Regarding patient 'AII-11' from family 'Family A': Who is the first author and what is the publication year?": "Based *only* on the information contained within the provided document:\n\nThe first author is Maya Ando.\nThe publication year is 2012.",
    "Regarding patient 'AII-11' from family 'Family A': Any general comments about the study?": "Based on the information contained within the provided document:\n\nPatient AII-11 is the proband (index patient) from Family A, one of three families identified in the study with Autosomal Dominant Parkinson's Disease (ADPD) carrying the heterozygous p.D620N mutation in the VPS35 gene.\n\nGeneral comments about the study related to patient AII-11 include:\n*   Analysis of patient AII-11 and his relatives helped detect one disease allele.\n*   Haplotype analysis was conducted on patient AII-11. The chromosomal phase could be determined for patient AII-11 (Family A).\n*   Comparison of AII-11's haplotype with other mutation carriers (BIII-8, CII-3, D) indicated different genotypes at a locus near VPS35 (D16S3105), suggesting at least 3 independent mutational events or founders for the p.D620N mutation in the Japanese patients studied. While AII-11 and BIII-8 might share a common founder, this was inconclusive.\n*   Patient AII-11's clinical features (onset at age 62, tremor-predominant PD, development of cognitive dysfunction after 15 years) contributed to the study's overall finding that patients with the VPS35 mutation showed typical tremor-predominant PD, which could include late-stage dementia. His brain MRI and cardiac MIBG scintigraphy were normal.",
    "Regarding patient 'AII-11' from family 'Family A': What is the family ID?": "Based on the information in the document:\n\nThe family ID for patient 'AII-11' is **A**.\n\nThis is indicated in Figure 1, where patient AII-11 is shown in pedigree A, and confirmed in the text on page 4 which states: \"We were able to determine the chromosomal phase only in patient AII-11 (family A).\"",
    "Regarding patient 'AII-11' from family 'Family A': What is the individual ID within the family?": "Based on the information in the provided document:\n\nThe individual ID for patient 'AII-11' within Family A is **II-11**.\n\nThis is indicated in Figure 1, Pedigree A, where the individual marked with an arrow (proband) and an asterisk is labeled as \"II 11\". The text also refers to this patient as \"AII-11\" (e.g., Table 1, Table 2, page 3 text).",
    "Regarding patient 'AII-11' from family 'Family A': Are the parents consanguineous?": "Based *only* on the information contained within the provided document:\n\nNo, the parents of patient 'AII-11' from 'Family A' were not consanguineous.\n\nThe document states on page 4, at the end of the first paragraph describing the clinical cases: \"All affected patients were born to noncon-sanguineous parents.\" Patient AII-11 is listed as an affected patient in Figure 1 and Table 2.",
    "Regarding patient 'AII-11' from family 'Family A': Is there a family history of the disease?": "Yes, based on the information in the document, patient 'AII-11' from family 'Family A' has a family history of the disease.\n\nSpecifically, Figure 1A shows the pedigree for Family A. Patient AII-11 (indicated by the arrow and asterisk) is affected. The pedigree shows that his father (AI-1) was affected, and several of his siblings (II-2, II-3, II-4, II-8) were also affected. Furthermore, a nephew and niece (III-1 and III-2) were affected.\n\nThe text on page 3 also explicitly states: \"His father and 4 of 8 siblings were diagnosed with PD (Fig. 1A)... His nephew and niece were also diagnosed with PD...\".",
    "Regarding patient 'AII-11' from family 'Family A': Number of mutation-negative but affected family members?": "Information not found.\n\nRationale: The document identifies patient AII-11 from Family A and shows the pedigree in Figure 1A. Affected family members are indicated by filled symbols. Asterisks indicate individuals analyzed for the mutation and/or haplotype. In Family A, affected individuals include I-1 (father, deceased, untested), II-2 (sibling, tested), II-3 (sibling, tested), II-4 (sibling, deceased, untested), II-5 (sibling, deceased, untested), III-1 (nephew, tested), and III-2 (niece, tested), in addition to the proband AII-11 (tested, positive). While the document states these relatives were analyzed (tested), it does not provide the specific mutation results (positive or negative) for any family member of AII-11 other than AII-11 himself, who is positive for the p.D620N mutation. Without knowing the mutation status of the other tested, affected family members, it is impossible to determine how many, if any, were mutation-negative but affected based *only* on the provided text.",
    "Regarding patient 'AII-11' from family 'Family A': Number of mutation-negative and unaffected family members?": "Information not found.\n\nRationale: Figure 1A shows the pedigree for Family A, including patient AII-11. Several family members are marked with an asterisk, indicating they were \"analyzed for the p.D620N mutation and/or haplotype\". Among these analyzed individuals, four (III-1, III-2, III-3, III-4) are shown as unaffected (open symbols). However, the document does not explicitly state the mutation test results (positive or negative) for these specific unaffected individuals. It only confirms the presence of the mutation in affected patient AII-11 and discusses haplotype sharing, but does not list the mutation status for every analyzed family member.",
    "Regarding patient 'AII-11' from family 'Family A': What is the sex of the individual?": "Based on the information provided in the document:\n\n*   **Figure 1A:** Shows the pedigree for Family A. Individual II-11 is represented by a square symbol. The figure legend states that a square symbol represents a 'male'.\n*   **Page 3, Clinical Presentation section:** The text states, \"Patient AII-11 was a 77-year-old man...\"\n\nTherefore, the sex of individual 'AII-11' from 'Family A' is **male**.",
    "Regarding patient 'AII-11' from family 'Family A': What was the age at onset of symptoms? (Enter -99 if unknown)": "Based on the information in Table 2 and the \"Clinical Presentation\" section on page 3, the age at disease onset for patient AII-11 was 62.",
    "Regarding patient 'AII-11' from family 'Family A': What is the current age or age at last examination?": "Based on the information provided in the document:\n\nPatient AII-11 was 77 years old, as stated in the \"Clinical Presentation\" section on page 3: \"Patient AII-11 was a 77-year-old man who developed right upper limb rest tremor at age 62.\" This is corroborated by Table 2, which lists Age at disease onset as 62 years and Disease duration as 15 years (62 + 15 = 77).",
    "Regarding patient 'AII-11' from family 'Family A': Was the individual alive at last follow-up? (Y/N)": "Y",
    "Regarding patient 'AII-11' from family 'Family A': What was the disease duration in years?": "Based on the information contained within the provided document:\n\nPatient 'AII-11' is listed in Table 2 (\"Clinical features of patients with p.D620N mutation\"). The row \"Disease duration (y)\" for patient AII-11 shows the value **15**.",
    "Regarding patient 'AII-11' from family 'Family A': Did the patient have parkinsonism?": "Based on the information contained within the provided document:\n\nYes, the patient 'AII-11' from 'Family A' had parkinsonism.\n\n*   **Figure 1 (Page 3):** Patient AII-11 is marked with a closed symbol in the pedigree for Family A, indicating an \"affected member\".\n*   **Table 2 (Page 3):** This table details the \"Clinical features of patients with p.D620N mutation\", including patient AII-11. It lists positive signs (+) for resting tremor, bradykinesia, rigidity, gait disturbance, postural instability, and clinical response to levodopa, which are characteristic features of parkinsonism.\n*   **Clinical Presentation Text (Page 3):** This section describes patient AII-11 as having \"developed right upper limb rest tremor at age 62\". Rest tremor is a cardinal sign of parkinsonism. The text further describes relatives of AII-11 as having \"levodopa-responsive typical parkinsonism\".",
    "Regarding patient 'AII-11' from family 'Family A': Any non-motor symptoms associated with parkinsonism?": "Based on the information contained within the provided document:\n\nYes, patient AII-11 experienced several non-motor symptoms associated with parkinsonism. These include:\n\n*   Orthostatic hypotension\n*   Incontinence\n*   Urinary urgency\n*   Sleep benefit\n*   Progressive dysphagia (requiring gastrostomy)\n*   Cognitive dysfunction (developed later in the disease course, at age 75)",
    "Regarding patient 'AII-11' from family 'Family A': Any autonomic symptoms present?": "Based on the information contained within the provided document:\n\nYes, patient 'AII-11' from family 'Family A' presented with the following autonomic symptoms:\n*   Orthostatic hypotension\n*   Incontinence\n*   Urinary urgency\n\nThis information is found in Table 2, \"Clinical features of patients with p.D620N mutation\".",
    "Regarding patient 'AII-11' from family 'Family A': Was depression present?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': Did the patient have dementia or significant cognitive impairment?": "Based on the information in the document:\n\nYes, patient AII-11 developed dementia.\n\n*   **Table 2 (Clinical features of patients with p.D620N mutation):** Lists 'Dementia' with a '+' sign for patient AII-11.\n*   **Page 3, Clinical Presentation section:** States, \"At age 75, he underwent gastrostomy for progressive dysphagia, then developed cognitive dysfunction without hallucination.\"\n*   **Page 4, Discussion section:** States, \"...dementia may occur in patients with a long disease course, similar to patient AII-11, who had PD for 15 years.\"",
    "Regarding patient 'AII-11' from family 'Family A': List all *motor* symptoms observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Rigidity: yes; Tremor: no; Bradykinesia: yes.": "Based *only* on the information contained within the provided document (specifically Table 2):\n\nResting tremor: yes\nBradykinesia: yes\nRigidity: yes\nGait disturbance: yes\nPostural instability: yes\nLevodopa-induced dyskinesia: yes\nDystonia at onset: no",
    "Regarding patient 'AII-11' from family 'Family A': List all *non-motor* symptoms (like cognitive, autonomic, psychiatric, sleep, sensory) observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Depression: yes; Anosmia: no; RBD: yes; Constipation: yes.": "Based *only* on the information contained within the provided document:\n\nThe following non-motor symptoms were observed for patient AII-11:\n\nOrthostatic hypotension: yes\nIncontinence: yes\nUrinary urgency: no\nSleep benefit: yes\nHallucination: no\nOther psychosis: no\nDementia: yes",
    "Regarding patient 'AII-11' from family 'Family A': What is the first gene with a pathogenic variant found in the patient?": "Based on the information contained within the provided document:\n\nThe first gene reported in this document with a pathogenic variant found in patient 'AII-11' from 'Family A' is **VPS35**.\n\nSpecifically, the document states on page 3: \"One disease allele was detected by analyzing patient AII-11 and his relatives. Patients AII-11 [...] carried at least the same single allele of microsatellites in the flanking region of VPS35 (Table 1).\" Table 1 further specifies that patient AII-11 has the 'A' allele for the 'VPS35 p.D620N' mutation, which the paper identifies as pathogenic.",
    "Regarding patient 'AII-11' from family 'Family A': What is the second gene with a pathogenic variant found in the patient (if any)?": "Information not found.\n\nThe document confirms patient AII-11 from Family A has the p.D620N mutation in the *VPS35* gene (Page 3, Table 1 and Fig 1A). It also states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (Page 3). While other PD-related genes (SNCA, PARK2, PINK1, PARK7, LRRK2, PLA2G6) are mentioned (Page 2), the document only states that *some* subjects were previously confirmed negative for mutations in these genes, not that patient AII-11 specifically was tested for all of them or found to have a pathogenic variant in a second gene. Therefore, the document does not contain information about a second gene with a pathogenic variant found in patient AII-11.",
    "Regarding patient 'AII-11' from family 'Family A': What is the third gene with a pathogenic variant found in the patient (if any)?": "Information not found.\n\nThe document identifies patient AII-11 from Family A as having the p.D620N mutation in the *VPS35* gene (Page 3, Figure 1, Table 1, Table 2, and associated text). However, the document does not provide information regarding any other specific pathogenic gene variants found in this particular patient.",
    "Regarding patient 'AII-11' from family 'Family A': What is the DNA-level mutation? (Primary mutation)": "Based only on the information contained within the provided document:\n\nThe DNA-level mutation for patient 'AII-11' from 'Family A' is **c.1858G>A** (in the VPS35 gene).\n\n*Supporting information from the document:*\n*   Figure 1 shows patient AII-11 belongs to Family A, which carries the VPS35 p.D620N mutation.\n*   Table 1 confirms patient AII-11 carries the p.D620N mutation.\n*   Page 2, left column, paragraph 3 states: \"Mutation of c.1858G>A (p.D620N) was identified...\"\n*   Page 2, right column, \"Genetic Analysis\" section mentions genotyping for \"c.1858G>A (p.D620N) mutation\".\n*   Page 4, left column, paragraph 2 states: \"...the substitution of VPS35 c.1858G>A (p.D620N) occurs...\"",
    "Regarding patient 'AII-11' from family 'Family A': What is the protein-level effect of the mutation?": "Based on the information in the document:\n\nThe mutation found in patient AII-11 from Family A is identified as **p.D620N** in the VPS35 gene (Table 1, Figure 1, Results section). The document describes this as a **heterozygous missense p.D620N mutation** (Results section, page 2) and refers to the **p.D620N substitution** (Abstract, Discussion section page 4). This indicates that at the protein level, the amino acid at position 620 has been changed from Aspartic acid (D) to Asparagine (N).",
    "Regarding patient 'AII-11' from family 'Family A': What is the zygosity of the first mutation?": "Based on the information contained within the provided document:\n\nThe document states on page 4, in the first paragraph of the Discussion section: \"We detected the **heterozygous** p.D620N mutation of VPS35 in 3 ADPD families and 1 SPD patient with East Asian ancestry.\" Patient AII-11 belongs to Family A, one of the ADPD families mentioned (as shown in Figure 1A and Table 1/2). The document also mentions on page 3 that \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35,\" indicating this was the only mutation found in this gene for these patients within the scope of the analysis performed.\n\nTherefore, the zygosity of the first (and only reported) mutation (p.D620N) for patient AII-11 is **heterozygous**.",
    "Regarding patient 'AII-11' from family 'Family A': Second mutation (cDNA), if any?": "Based *only* on the information contained within the provided document:\n\nPatient AII-11 was found to carry the heterozygous p.D620N mutation in the VPS35 gene. The document explicitly states on page 3: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\"\n\nTherefore, no second mutation was reported for patient AII-11.",
    "Regarding patient 'AII-11' from family 'Family A': Second mutation protein change?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': Zygosity of second mutation?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': Third mutation (cDNA), if any?": "Based on the information contained within the provided document:\n\nPatient AII-11 from Family A was identified as carrying the heterozygous missense p.D620N mutation in the VPS35 gene (page 3, Fig 1 and text below). The text explicitly states: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (page 3, paragraph below Fig 1).\n\nTherefore, regarding a third mutation (cDNA) for patient AII-11, the information indicates none were found in the VPS35 exons.",
    "Regarding patient 'AII-11' from family 'Family A': Third mutation protein change?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': Zygosity of third mutation?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': Which genome build/transcript was used?": "Based *only* on the information contained within the provided document:\n\nThe RefSeq accession number **NM_018206.4** for the VPS35 gene was used. The document does not specify a particular genome build.",
    "Regarding patient 'AII-11' from family 'Family A': What is the physical genomic location of the mutation?": "Information not found.\n\nThe document identifies the mutation in patient AII-11 as p.D620N (c.1858G>A) located in exon 15 of the VPS35 gene. Table 1 provides haplotype analysis using markers located on Chromosome 16 (indicated by D16S* and Chr16_* markers) in the vicinity of the VPS35 gene (e.g., D16S3105 is noted as being very close). However, the specific physical base pair coordinate on the chromosome for the mutation itself is not stated in the document.",
    "Regarding patient 'AII-11' from family 'Family A': Include this patient in MDSGene?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': Any additional comments about this patient?": "Based on the information contained within the provided document:\n\nPatient AII-11 from Family A is a 77-year-old man who developed right upper limb rest tremor at age 62. He carries the heterozygous p.D620N mutation in the VPS35 gene. His clinical features include typical parkinsonism symptoms (resting tremor, bradykinesia, rigidity, gait disturbance, postural instability) that responded to levodopa, along with wearing off, asymmetry at onset, orthostatic hypotension, incontinence, urinary urgency, levodopa-induced dyskinesia, and sleep benefit. At age 75, he underwent gastrostomy for progressive dysphagia and later developed cognitive dysfunction without hallucination. His brain MRI was normal. Cardiac MIBG scintigraphy, performed at age 76, showed an H/M ratio (E/L) of 2.38/2.68 and a washout ratio of 4.15%. Single-photon emission computed tomography (SPECT) of cerebral blood flow showed no reduction in blood flow in the basal ganglia. His father and 4 of 8 siblings were diagnosed with PD, presenting with levodopa-responsive typical parkinsonism. Haplotype analysis was performed, and the chromosomal phase for the mutation was determined in this patient. He is considered the proband for Family A.",
    "Regarding patient 'AII-11' from family 'Family A': What was the initial symptom of the patient?": "Based on the information in the document:\n\nPatient AII-11 developed **right upper limb rest tremor** at age 62.",
    "Regarding patient 'AII-11' from family 'Family A': What was the second initial symptom of the patient (if applicable)?": "Based *only* on the information contained within the provided document:\n\nThe document states on page 3, under 'Clinical Presentation': \"Patient AII-11 was a 77-year-old man who developed right upper limb rest tremor at age 62.\" This identifies the first initial symptom.\n\nThe document does not specify the second initial symptom that Patient AII-11 developed. Table 2 lists several symptoms present in Patient AII-11, but does not indicate the order of their onset after the initial symptom.\n\nTherefore, the answer is: **Information not found**.",
    "Regarding patient 'AII-11' from family 'Family A': What was the third initial symptom of the patient (if applicable)?": "Information not found.\n\nThe document states that patient AII-11 \"developed right upper limb rest tremor at age 62\". While Table 2 lists other symptoms experienced by the patient (such as bradykinesia, rigidity, gait disturbance, etc.), it does not specify the order in which the *initial* symptoms appeared beyond the first one mentioned (tremor).",
    "Regarding patient 'BIII-8' from family 'Family B': Who is the first author and what is the publication year?": "Based on the information contained within the document:\n\n*   **First Author:** Maya Ando\n*   **Publication Year:** 2012",
    "Regarding patient 'BIII-8' from family 'Family B': Any general comments about the study?": "Based *only* on the information contained within the provided document:\n\nPatient BIII-8 from Family B is described as having developed upper limb rest tremor at age 55. At the time of the study, his disease duration was 2 years. Clinical features included resting tremor, bradykinesia, rigidity, gait disturbance, postural instability, clinical response to levodopa, and asymmetry at onset. His Brain MRI was within normal limits (WNL). Cardiac MIBG scintigraphy was not performed.\n\nHaplotype analysis showed that patient BIII-8 carried at least the same single allele of microsatellites in the flanking region of VPS35 as patient AII-11 (from Family A). However, the study notes that it was inconclusive whether the p.D620N mutation possibly shared a common founder between families A and B because the chromosomal phase of patient BIII-8 was undetermined. Further detailed genetic analyses of other family members are needed for Family B to determine the chromosomal phase.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the family ID?": "Based on the information contained within the provided document:\n\nThe family ID for patient 'BIII-8' is **B**.\n\nThis is determined from:\n1.  Figure 1, which shows pedigree 'B' containing individual 'III-8' (marked with an asterisk).\n2.  Table 1 and Table 2, which list 'BIII-8' as a patient ID.\n3.  The text on page 3 which refers to \"Patients AII-11 and BIII-8\". Patient AII-11 is shown in pedigree A (Family A), and patient BIII-8 is shown in pedigree B (Family B).\n4.  The text on page 4 refers to \"Japanese ADPD families A and B\" and discusses the relationship between patients from these families.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the individual ID within the family?": "Based on the information contained within the document:\n\nThe individual ID for patient 'BIII-8' from family 'Family B' is **BIII-8**.\n\nThis identifier is used consistently in Figure 1, Table 1, Table 2, and the accompanying text to refer to this specific individual within the context of Family B.",
    "Regarding patient 'BIII-8' from family 'Family B': Are the parents consanguineous?": "Based on the information contained within the provided document:\n\nOn page 4, in the first paragraph under the heading 'Discussion', the text states: \"All affected patients were born to noncon-sanguineous parents.\" Patient BIII-8 is listed as an affected patient in Figure 1, Table 1, and Table 2.\n\nTherefore, according to the document, the parents of patient BIII-8 are nonconsanguineous.",
    "Regarding patient 'BIII-8' from family 'Family B': Is there a family history of the disease?": "Based *only* on the information contained within the provided document:\n\nYes, there is a family history of the disease. Figure 1B shows the pedigree for Family B. Patient BIII-8 (indicated by *8 under generation III) is shown as affected (closed symbol). His mother (II-5) and two aunts (II-1, II-3) are also shown as affected (closed symbols). The text on page 3 also explicitly states: \"The mother and aunts of patient BIII-8 [...] also developed PD (Fig. 1B, C).\"",
    "Regarding patient 'BIII-8' from family 'Family B': Number of mutation-negative but affected family members?": "Information not found.\n\nThe provided document identifies patient BIII-8 from Family B as affected and carrying the p.D620N mutation (Figure 1B, Table 1, Table 2). Figure 1B shows that the mother (II-2) and three aunts (II-3, II-4, II-5) of BIII-8 are also affected. However, the figure legend indicates that only individuals marked with an asterisk (*) were analyzed for the mutation, and in Family B, only BIII-8 is marked with an asterisk. Therefore, the mutation status of the other affected family members (II-2, II-3, II-4, II-5) is not provided in the document.",
    "Regarding patient 'BIII-8' from family 'Family B': Number of mutation-negative and unaffected family members?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the sex of the individual?": "Based on the information in the document:\n\nFigure 1 shows pedigrees for families with the VPS35 p.D620N mutation. Pedigree B includes patient 'BIII-8', who is represented by a square symbol. According to the legend for Figure 1, a square represents a male.\n\nTherefore, the sex of the individual 'BIII-8' is **Male**.",
    "Regarding patient 'BIII-8' from family 'Family B': What was the age at onset of symptoms? (Enter -99 if unknown)": "Based *only* on the information contained within the provided document:\n\nThe age at onset of symptoms for patient 'BIII-8' from family 'Family B' is **55**.\n\nThis information is found in Table 2, under the column \"Patient ID\" BIII-8, in the row \"Age at disease onset (y)\".",
    "Regarding patient 'BIII-8' from family 'Family B': What is the current age or age at last examination?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': Was the individual alive at last follow-up? (Y/N)": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What was the disease duration in years?": "Based on the information in Table 2, the disease duration for patient 'BIII-8' was 2 years.",
    "Regarding patient 'BIII-8' from family 'Family B': Did the patient have parkinsonism?": "Based on the information contained within the provided document:\n\nYes, patient 'BIII-8' from family 'Family B' had parkinsonism.\n\n*   **Figure 1 (page 3):** Shows the pedigree for Family B. Patient BIII-8 is marked with a filled square, which the legend indicates means \"affected member\".\n*   **Table 2 (page 3):** Lists the clinical features for patient BIII-8, including resting tremor (+), bradykinesia (+), and rigidity (+), which are cardinal signs of parkinsonism. It also notes a positive clinical response to levodopa.\n*   **Clinical Presentation section (page 3):** States that \"Patients BIII-8 and CII-3 both developed upper limb rest tremor at ages 34 and 55, respectively.\" It also mentions that the mother and aunts of patient BIII-8 developed PD (Parkinson's Disease).",
    "Regarding patient 'BIII-8' from family 'Family B': Any non-motor symptoms associated with parkinsonism?": "Based on the information contained within the provided document:\n\nYes, Table 2 on page 3 lists clinical features for patient BIII-8. Regarding non-motor symptoms:\n\n*   Orthostatic hypotension: Negative (-)\n*   Incontinence: Negative (-)\n*   Urinary urgency: Negative (-)\n*   Sleep benefit: Positive (+)\n*   Hallucination: Negative (-)\n*   Other psychosis: Negative (-)\n*   Dementia: Negative (-)",
    "Regarding patient 'BIII-8' from family 'Family B': Any autonomic symptoms present?": "Based on the information in Table 2, patient BIII-8 did not present with the listed autonomic symptoms:\n\n*   Orthostatic hypotension: - (absent)\n*   Incontinence: - (absent)\n*   Urinary urgency: - (absent)",
    "Regarding patient 'BIII-8' from family 'Family B': Was depression present?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': Did the patient have dementia or significant cognitive impairment?": "Based on the information in the document:\n\nTable 2 (\"Clinical features of patients with p.D620N mutation\") lists patient BIII-8. In the row labeled 'Dementia', the entry for patient BIII-8 is 'âˆ’'.\n\nTherefore, the patient BIII-8 did not have dementia according to the provided document. The document does not use the specific term \"significant cognitive impairment\" as a separate clinical feature listed for this patient, but the absence ('-') of dementia listed in Table 2 indicates no dementia was noted.",
    "Regarding patient 'BIII-8' from family 'Family B': List all *motor* symptoms observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Rigidity: yes; Tremor: no; Bradykinesia: yes.": "Based on the information in Table 2 on page 3:\n\nResting tremor: yes\nBradykinesia: yes\nRigidity: yes\nGait disturbance: yes\nPostural instability: no\nDystonia at onset: no",
    "Regarding patient 'BIII-8' from family 'Family B': List all *non-motor* symptoms (like cognitive, autonomic, psychiatric, sleep, sensory) observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Depression: yes; Anosmia: no; RBD: yes; Constipation: yes.": "Based *only* on the information contained within the provided document (specifically Table 2), the following non-motor symptoms were assessed for patient 'BIII-8' from family 'Family B':\n\nOrthostatic hypotension: no\nIncontinence: no\nUrinary urgency: no\nSleep benefit: yes\nHallucination: no\nOther psychosis: no\nDementia: no",
    "Regarding patient 'BIII-8' from family 'Family B': What is the first gene with a pathogenic variant found in the patient?": "Based only on the information contained within the provided document:\n\nThe first gene with a pathogenic variant found in patient 'BIII-8' from 'Family B' is **VPS35**.\n\n*   Figure 1B shows the pedigree for Family B, including patient BIII-8.\n*   Table 1 (\"Haplotype analysis of VPS35 p.D620N mutation carriers\") lists patient BIII-8 and indicates they carry the \"A/G\" genotype for \"VPS35 p.D620N\", signifying heterozygosity for this variant in the VPS35 gene.\n*   The text repeatedly refers to the p.D620N mutation in VPS35 as pathogenic (e.g., page 2: \"One missense mutation has been reported to be pathogenic for PD.3,4 Mutation of c.1858G>A (p.D620N)...\"; page 3: \"The p.D620N has been reported previously as a pathogenic mutation for familial PD.3,4,6\").\n*   The study confirms that patients found with the p.D620N mutation did not have other variants in the VPS35 gene (page 3: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\").",
    "Regarding patient 'BIII-8' from family 'Family B': What is the second gene with a pathogenic variant found in the patient (if any)?": "Information not found.\n\nThe document confirms that patient BIII-8 has the p.D620N mutation in the *VPS35* gene (Table 1, Figure 1, page 3 text). It also states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (page 3). While the study mentions that some subjects were previously screened for mutations in *SNCA, PARK2, PINK1, PARK7, LRRK2, and PLA2G6* (page 2), it does not provide specific results for patient BIII-8 regarding these or any other genes besides *VPS35*. Therefore, based only on the provided document, there is no information about a second gene with a pathogenic variant found in patient BIII-8.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the third gene with a pathogenic variant found in the patient (if any)?": "Information not found.\n\nThe document confirms that patient BIII-8 from Family B has the heterozygous p.D620N mutation in the *VPS35* gene (Table 1, page 3; Figure 1, page 3). The text also states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (page 3). While other PD-related genes (*SNCA, PARK2, PINK1, PARK7, LRRK2, PLA2G6*) are mentioned in the Methods section (page 2) as having been tested in *some* subjects, the document does not state that patient BIII-8 was tested for these, nor does it report any other pathogenic variants found in patient BIII-8 in any gene other than *VPS35*. Therefore, based only on the provided text, information about a second or third gene with a pathogenic variant in patient BIII-8 is not available.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the DNA-level mutation? (Primary mutation)": "Based on the information in the document:\n\nThe document identifies the protein-level mutation in patients from families A, B, and C as p.D620N in the VPS35 gene (Figure 1 caption, Table 1).\n\nThe document explicitly states the corresponding DNA-level change for the p.D620N mutation is c.1858G>A (Page 2, Genetic Analysis section; Page 4, Discussion section).\n\nTable 1 confirms that patient BIII-8 is a carrier of the p.D620N mutation, showing the genotype as A/G, indicating heterozygosity for the c.1858G>A change.\n\nTherefore, the DNA-level mutation (primary mutation) for patient BIII-8 from Family B is **c.1858G>A** in the VPS35 gene.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the protein-level effect of the mutation?": "Based on the information contained within the provided document:\n\nPatient BIII-8 from Family B carries the heterozygous missense mutation p.D620N in the VPS35 gene (Table 1 and Table 2). This notation indicates that at amino acid position 620 of the VPS35 protein, the normal Aspartic Acid (D) residue is substituted with an Asparagine (N) residue. The document refers to this as a \"missense p.D620N mutation\" (Results section) or \"p.D620N substitution\" (Abstract).",
    "Regarding patient 'BIII-8' from family 'Family B': What is the zygosity of the first mutation?": "Based on the information in the document:\n\n*   Page 2, Results section, first paragraph: \"We detected the heterozygous missense p.D620N mutation in 3 unrelated patients with ADPD...\" Patient BIII-8 belongs to Family B, which is one of the ADPD families studied (as indicated by Figure 1B and Table 1).\n*   Table 1 shows the genotype for patient BIII-8 at the \"VPS35 p.D620N\" locus as \"A/G\", which indicates a heterozygous state for the c.1858G>A mutation.\n\nTherefore, the zygosity of the p.D620N mutation (the mutation detected in this patient according to the document) is heterozygous.",
    "Regarding patient 'BIII-8' from family 'Family B': Second mutation (cDNA), if any?": "Based *only* on the information contained within the provided document:\n\nPatient BIII-8 was found to carry the heterozygous p.D620N mutation (Table 1 shows 'A/G' for VPS35 p.D620N). The document states on page 3, under Results: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\"\n\nTherefore, regarding a second mutation for patient BIII-8: **None reported.**",
    "Regarding patient 'BIII-8' from family 'Family B': Second mutation protein change?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': Zygosity of second mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': Third mutation (cDNA), if any?": "Based on the information contained within the provided document:\n\nPatient BIII-8 from Family B carries the heterozygous p.D620N mutation (corresponding to c.1858G>A) in the VPS35 gene. The document states on page 3: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\"\n\nTherefore, regarding a third mutation (cDNA) for patient BIII-8, the answer is **None**.",
    "Regarding patient 'BIII-8' from family 'Family B': Third mutation protein change?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': Zygosity of third mutation?": "Based on the information in the document:\n\nThe document identifies the p.D620N mutation (c.1858G>A) in patient BIII-8. Table 1, under the row \"VPS35 p.D620N\" and column \"BIII-8\", shows the genotype as \"A/G\". This indicates the presence of both the reference allele (G) and the mutated allele (A).\n\nTherefore, the zygosity is **Heterozygous**.",
    "Regarding patient 'BIII-8' from family 'Family B': Which genome build/transcript was used?": "Based *only* on the information contained within the provided document:\n\nThe \"Genetic Analysis\" section on page 2 states that the analysis of VPS35 variants used the RefSeq accession number **NM_018206.4**. This transcript identifier was used for the study which included patient BIII-8.\n\nThe document does not specify a genome build (e.g., hg19, GRCh37).",
    "Regarding patient 'BIII-8' from family 'Family B': What is the physical genomic location of the mutation?": "Information not found.\n\nThe document identifies the mutation in patient BIII-8 as p.D620N (specifically c.1858G>A) in the VPS35 gene (Table 1, Figure 1, Table 2). Haplotype analysis using markers like D16S3105 (Table 1) places the VPS35 gene in a region on Chromosome 16 (e.g., Chr16_45.333M, Chr16_45.615M, etc., listed in Table 1). However, the document does not state the precise physical genomic coordinates (e.g., the specific base pair position on Chromosome 16) for this mutation.",
    "Regarding patient 'BIII-8' from family 'Family B': Include this patient in MDSGene?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': Any additional comments about this patient?": "Based on the information in the document:\n\nPatient BIII-8 from Family B carries the heterozygous p.D620N mutation in VPS35. Clinically, they developed upper limb rest tremor at age 55. At the time of the study, the disease duration was 2 years. Key clinical features include resting tremor, bradykinesia, rigidity, positive clinical response to levodopa, and asymmetry at onset. They did not exhibit gait disturbance, postural instability, wearing off, orthostatic hypotension, or other non-motor symptoms listed in Table 2. Brain MRI was within normal limits, and cardiac MIBG scintigraphy was not performed. The patient's mother and aunts also developed Parkinson's Disease. Haplotype analysis showed BIII-8 carried at least the same single allele of microsatellites in the flanking region of VPS35 as patient AII-11, but the chromosomal phase could not be determined, making a shared common founder with Family A inconclusive.",
    "Regarding patient 'BIII-8' from family 'Family B': What was the initial symptom of the patient?": "Based on the information provided in the document:\n\nThe initial symptom of patient 'BIII-8' was upper limb rest tremor, which developed at age 55.",
    "Regarding patient 'BIII-8' from family 'Family B': What was the second initial symptom of the patient (if applicable)?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What was the third initial symptom of the patient (if applicable)?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': Who is the first author and what is the publication year?": "Based only on the information contained within the provided document:\n\nThe first author is Maya Ando and the publication year is 2012.",
    "Regarding patient 'CII-3' from family 'Family C': Any general comments about the study?": "Based *only* on the information contained within the provided document:\n\nThe study identified patient CII-3 from Family C as carrying the heterozygous missense p.D620N mutation in the VPS35 gene. Haplotype analysis was performed on CII-3. The analysis suggested that the p.D620N mutation in patient CII-3 (Family C) probably occurred independently from the mutation in patient AII-11 (Family A) and patient D, based on different genotypes at the D16S3105 locus. This finding contributed to the study's suggestion of at least 3 independent founders or de novo mutations for p.D620N in the Japanese patients studied. The study also noted that detailed genetic analyses of other family members from Family C are needed in future studies to determine the chromosomal phase of the mutation.",
    "Regarding patient 'CII-3' from family 'Family C': What is the family ID?": "Based on the information contained within the provided document:\n\nThe family ID is **C**.\n\n*Rationale*: Figure 1 on page 3 displays pedigrees for families involved in the study. The third pedigree shown is explicitly labeled with the letter 'C'. The text on page 4, second column, also refers to \"...patient CII-3 (family C)...\".",
    "Regarding patient 'CII-3' from family 'Family C': What is the individual ID within the family?": "Based on Figure 1, Pedigree C, the individual ID within the family is **II-3**.",
    "Regarding patient 'CII-3' from family 'Family C': Are the parents consanguineous?": "Based on the information contained within the provided document:\n\nThe text on page 4 states: \"All affected patients were born to noncon-sanguineous parents.\"\n\nPatient CII-3 is listed as an affected patient carrying the p.D620N mutation (Figure 1C, Table 1, Table 2, text on page 3 and 4).\n\nTherefore, based on the document, the parents of patient CII-3 are **not consanguineous**.",
    "Regarding patient 'CII-3' from family 'Family C': Is there a family history of the disease?": "Based on the information in the document:\n\nYes, there is a family history of the disease. The text on page 4 states, \"and the father of patient CII-3 also developed PD (Fig. 1B, C).\" Figure 1C also shows the father (individual I-1 in the Family C pedigree) as an affected member (closed square).",
    "Regarding patient 'CII-3' from family 'Family C': Number of mutation-negative but affected family members?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': Number of mutation-negative and unaffected family members?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What is the sex of the individual?": "Based on the information in the provided document:\n\nFigure 1 on page 3 shows the pedigrees of the families studied. Pedigree C represents 'Family C'. Within this pedigree, individual 'II-3' (labelled as *CII-3*) is represented by a square symbol. The legend for Figure 1 states: \"square, male; circle, female; diamond, unspecified sex\".\n\nTherefore, the sex of individual 'CII-3' from 'Family C' is **male**.",
    "Regarding patient 'CII-3' from family 'Family C': What was the age at onset of symptoms? (Enter -99 if unknown)": "Based on the information in Table 2 (\"Clinical features of patients with p.D620N mutation\"), the age at disease onset for patient CII-3 was 34 years.",
    "Regarding patient 'CII-3' from family 'Family C': What is the current age or age at last examination?": "Based on the information in Table 2 (\"Clinical features of patients with p.D620N mutation\"), patient CII-3 had an age at disease onset of 34 years and a disease duration of 7 years at the time of examination.\n\nTherefore, the age at last examination was 34 + 7 = 41 years.",
    "Regarding patient 'CII-3' from family 'Family C': Was the individual alive at last follow-up? (Y/N)": "Y",
    "Regarding patient 'CII-3' from family 'Family C': What was the disease duration in years?": "Based on the information in Table 2: \"Clinical features of patients with p.D620N mutation\", patient CII-3 had a disease duration of 7 years.",
    "Regarding patient 'CII-3' from family 'Family C': Did the patient have parkinsonism?": "Yes, the document indicates that patient 'CII-3' from family 'Family C' had parkinsonism.\n\nTable 2, \"Clinical features of patients with p.D620N mutation\", includes a column for patient CII-3 and lists the presence (+) of resting tremor, bradykinesia, rigidity, gait disturbance, and postural instability. These are characteristic symptoms of parkinsonism. Furthermore, the text on page 4 states that the clinical symptoms of the patients with the VPS35 mutation (which includes CII-3) \"closely resembled the idiopathic PD form, with tremor-dominant dopa-responsive parkinsonism\".",
    "Regarding patient 'CII-3' from family 'Family C': Any non-motor symptoms associated with parkinsonism?": "Based on the information in Table 2:\n\n*   **Sleep benefit:** Yes (+)\n*   **Orthostatic hypotension:** No (-)\n*   **Incontinence:** No (-)\n*   **Urinary urgency:** No (-)\n*   **Hallucination:** No (-)\n*   **Other psychosis:** No (-)\n*   **Dementia:** No (-)",
    "Regarding patient 'CII-3' from family 'Family C': Any autonomic symptoms present?": "Based on the information in Table 2, patient CII-3 presented with urinary urgency (+), but did not present with orthostatic hypotension (-) or incontinence (-).\n\nTherefore, the answer is: Yes, urinary urgency was present.",
    "Regarding patient 'CII-3' from family 'Family C': Was depression present?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': Did the patient have dementia or significant cognitive impairment?": "Based on the information in the document:\n\nTable 2, \"Clinical features of patients with p.D620N mutation,\" lists patient CII-3. In the row labeled \"Dementia,\" the entry for patient CII-3 is '-'. This indicates the absence of dementia.\n\nTherefore, the patient CII-3 did not have dementia. The document does not specifically use the term \"significant cognitive impairment\" for this patient, but dementia was assessed and found absent.",
    "Regarding patient 'CII-3' from family 'Family C': List all *motor* symptoms observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Rigidity: yes; Tremor: no; Bradykinesia: yes.": "Based *only* on the information contained within the provided document (specifically Table 2 on page 3):\n\nResting tremor: yes\nBradykinesia: yes\nRigidity: yes\nGait disturbance: yes\nPostural instability: yes\nWearing off: yes\nLevodopa-induced dyskinesia: yes\nDystonia at onset: no\nGaze palsy: no",
    "Regarding patient 'CII-3' from family 'Family C': List all *non-motor* symptoms (like cognitive, autonomic, psychiatric, sleep, sensory) observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Depression: yes; Anosmia: no; RBD: yes; Constipation: yes.": "Based *only* on the information contained within the provided document:\n\nThe following non-motor symptoms are listed for patient CII-3 in Table 2:\n\n*   Orthostatic hypotension: no\n*   Incontinence: no\n*   Urinary urgency: no\n*   Sleep benefit: no\n*   Hallucination: no\n*   Other psychosis: no\n*   Dementia: no",
    "Regarding patient 'CII-3' from family 'Family C': What is the first gene with a pathogenic variant found in the patient?": "Based *only* on the information contained within the provided document:\n\nThe document identifies patient CII-3 from Family C as having the p.D620N mutation (Table 2, Figure 1C). Table 1 explicitly lists this mutation under the heading \"VPS35 p.D620N\" for patient CII-3. Therefore, the first gene with a pathogenic variant found in patient CII-3, according to this document, is **VPS35**.",
    "Regarding patient 'CII-3' from family 'Family C': What is the second gene with a pathogenic variant found in the patient (if any)?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the third gene with a pathogenic variant found in the patient (if any)?": "Based *only* on the information contained within the provided document:\n\nThe document identifies patient CII-3 from Family C as having a heterozygous p.D620N mutation in the *VPS35* gene (Fig. 1C, Table 1, Table 2, Page 3 Results section). The document states that \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" (Page 3, Results).\n\nWhile the Methods section mentions that \"Some of the selected subjects had been confirmed negative for SNCA, PARK2, PINK1, PARK7, LRRK2, and PLA2G6 mutations,\" it does not state specifically that patient CII-3 was tested for these genes, nor does it state that any other pathogenic variants were found in *any* other gene for this patient. The document focuses primarily on the *VPS35* gene.\n\nTherefore, the document only identifies *one* gene (*VPS35*) with a pathogenic variant in patient CII-3. Information about a second or third gene with a pathogenic variant in this patient is not provided.\n\nInformation not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the DNA-level mutation? (Primary mutation)": "Based on the information in the document:\n\nThe document identifies patient CII-3 from Family C as having the p.D620N mutation (Table 1, Table 2, Figure 1).\n\nPage 2, under \"Genetic Analysis\", explicitly states that the p.D620N mutation corresponds to the DNA-level change **c.1858G>A**.\n\nPage 4, under \"Discussion\", also states \"the substitution of VPS35 **c.1858G>A (p.D620N)**\".\n\nTherefore, the DNA-level mutation (primary mutation) for patient CII-3 from Family C is **c.1858G>A**.",
    "Regarding patient 'CII-3' from family 'Family C': What is the protein-level effect of the mutation?": "Based on the information in the document:\n\nPatient CII-3 was detected to have the heterozygous missense **p.D620N** mutation in the VPS35 gene (Table 1, Page 3; Figure 1, Page 3; Discussion, Page 4).\n\nThe protein-level effect described by the nomenclature 'p.D620N' is a substitution where the Aspartic acid (D) at amino acid position 620 is replaced by Asparagine (N).",
    "Regarding patient 'CII-3' from family 'Family C': What is the zygosity of the first mutation?": "Based on the information contained within the provided document:\n\nPatient CII-3 was detected with the heterozygous missense p.D620N mutation (page 2, Results; Table 1 shows the genotype as A/G). As this is the only mutation mentioned for this patient within the VPS35 gene in the document, the zygosity of the first (and only reported) mutation is heterozygous.\n\nTherefore, the zygosity of the first mutation for patient CII-3 is **heterozygous**.",
    "Regarding patient 'CII-3' from family 'Family C': Second mutation (cDNA), if any?": "Based on the information contained within the provided document:\n\nThe document identifies patient CII-3 from Family C as having the heterozygous p.D620N mutation (corresponding to c.1858G>A) in the VPS35 gene (see Fig 1C, Table 1, Table 2, and page 3 Results section).\n\nRegarding a second mutation, the text on page 3, under the \"Results\" section, states: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\"\n\nTherefore, based *only* on the provided document, no second mutation was found for patient CII-3.",
    "Regarding patient 'CII-3' from family 'Family C': Second mutation protein change?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': Zygosity of second mutation?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': Third mutation (cDNA), if any?": "Based only on the information contained within the provided document:\n\nPatient CII-3 was found to have the heterozygous p.D620N mutation (c.1858G>A) in the VPS35 gene. The document states: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, no third mutation is reported for patient CII-3 in this document.",
    "Regarding patient 'CII-3' from family 'Family C': Third mutation protein change?": "Information not found.\n\nThe document identifies patient CII-3 from Family C as having the heterozygous missense mutation p.D620N in the VPS35 gene (Page 3, Table 1 and Table 2; Page 4, Discussion). It states that patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35 (Page 3, Results section). There is no mention of any second or third mutation protein change for patient CII-3.",
    "Regarding patient 'CII-3' from family 'Family C': Zygosity of third mutation?": "Based on the information contained within the provided document:\n\nPatient CII-3 from Family C was detected to have the p.D620N mutation (Figure 1C, Table 1). The Results section (page 2) states, \"We detected the heterozygous missense p.D620N mutation in 3 unrelated patients with ADPD...\". Family C is presented as one of the families with autosomal dominant PD (ADPD). Additionally, Table 1 shows the genotype for the VPS35 p.D620N mutation in patient CII-3 as \"A/G\", which indicates heterozygosity.\n\nTherefore, the zygosity is **Heterozygous**.",
    "Regarding patient 'CII-3' from family 'Family C': Which genome build/transcript was used?": "Based only on the information contained within the provided document:\n\nThe document states in the \"Genetic Analysis\" section (page 2) that the analysis of *VPS35* used \"RefSeq accession number NM_018206.4\". This transcript reference was used for the genetic analysis performed on patients, which included patient CII-3.\n\nHowever, the document does not specify which genome build (e.g., hg19, GRCh37, hg38) was used.\n\nTherefore, the complete information regarding both genome build and transcript is not available.\n\nInformation not found.",
    "Regarding patient 'CII-3' from family 'Family C': What is the physical genomic location of the mutation?": "Based on the information in the provided document:\n\nThe mutation in patient CII-3 is p.D620N in the *VPS35* gene. Table 1 provides haplotype analysis using microsatellite markers flanking the *VPS35* gene. Several of these markers are explicitly located on Chromosome 16 (Chr16_45.333M, Chr16_45.615M, Chr16_45.806M, Chr16_45.835M, Chr16_45.855M) within the ~45 Megabase (Mb) region. Furthermore, the text on page 4 states that marker D16S3105 (also listed in Table 1) is located approximately 1.5 kb centromeric of *VPS35*.\n\nTherefore, the physical genomic location of the mutation is on **Chromosome 16**, within the region flanked by the markers listed in Table 1 (approximately the 45 Mb region).",
    "Regarding patient 'CII-3' from family 'Family C': Include this patient in MDSGene?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': Any additional comments about this patient?": "Based on the information contained within the provided document:\n\nYes, there are additional comments regarding patient 'CII-3' from 'Family C':\n\n*   Patient CII-3 carries the heterozygous p.D620N mutation in the VPS35 gene.\n*   Haplotype analysis suggests the p.D620N mutation in patient CII-3 (Family C) likely occurred independently from the mutation in patient AII-11 (Family A), based on a different genotype at the D16S3105 locus. Determining the chromosomal phase requires further genetic analysis of family members.\n*   Patient CII-3 developed upper limb rest tremor at age 34.\n*   Clinical features at the time of assessment (disease duration 7 years) included: resting tremor, bradykinesia, rigidity, gait disturbance, postural instability, clinical response to levodopa, wearing off, asymmetry at onset, and levodopa-induced dyskinesia. Orthostatic hypotension, incontinence, urinary urgency, sleep benefit, dystonia at onset, hyperreflexia, hallucination, other psychosis, dementia, and gaze palsy were absent.\n*   Brain MRI was within normal limits (WNL).\n*   Cardiac MIBG scintigraphy was not performed.\n*   The father of patient CII-3 also developed Parkinson's Disease (PD).\n*   Patient CII-3 was born to nonconsanguineous parents.",
    "Regarding patient 'CII-3' from family 'Family C': What was the initial symptom of the patient?": "Based *only* on the information contained within the provided document:\n\nThe initial symptom of patient 'CII-3' from family 'Family C' was upper limb rest tremor.\n\n**(Supporting text from page 3, Clinical Presentation section):** \"Patients BIII-8 and CII-3 both developed upper limb rest tremor at ages 34 and 55, respectively.\" Table 2 confirms patient CII-3 had an age at disease onset of 34 years.",
    "Regarding patient 'CII-3' from family 'Family C': What was the second initial symptom of the patient (if applicable)?": "Information not found.\n\nThe document states that patient CII-3 developed upper limb rest tremor at age 34 (page 3, Clinical Presentation section). Table 2 lists other symptoms present in patient CII-3 (Bradykinesia, Rigidity, Gait disturbance, Levodopa-induced dyskinesia), but the document does not specify the order in which these symptoms appeared after the initial rest tremor.",
    "Regarding patient 'CII-3' from family 'Family C': What was the third initial symptom of the patient (if applicable)?": "Based *only* on the information contained within the provided document:\n\nThe document states in the 'Clinical Presentation' section on page 3 that patient CII-3 \"developed upper limb rest tremor at age 34\". Table 2 lists several symptoms present for patient CII-3, including resting tremor, bradykinesia, rigidity, gait disturbance, and postural instability. However, the document does not specify the chronological order of the initial symptoms beyond identifying upper limb rest tremor as the symptom at onset.\n\nTherefore, the third initial symptom is: **Information not found**.",
    "Regarding patient 'D': Who is the first author and what is the publication year?": "Based *only* on the information contained within the provided document:\n\nThe document describes a study involving several patients, including one designated as 'Patient D'. This document itself is the publication concerning Patient D.\n\n*   The first author listed on the document is Maya Ando.\n*   The publication year indicated in the document (e.g., in the abstract copyright and page footers) is 2012.\n\nTherefore, regarding patient 'D', the first author is Maya Ando and the publication year is 2012.",
    "Regarding patient 'D': Any general comments about the study?": "Based on the information contained within the provided document:\n\nPatient D carried the heterozygous p.D620N mutation in the VPS35 gene. Patient D developed upper limb rest tremor at age 42 and had no family history of Parkinson's Disease (PD), leading to a categorization as Sporadic PD (SPD). At age 60, Patient D underwent subthalamic nucleus deep brain stimulation (STN-DBS) due to disabling motor fluctuation and dyskinesia refractory to pharmacological treatment. Patient D was born to nonconsanguineous parents. Haplotype analysis suggested that the p.D620N mutation in Patient D likely occurred independently compared to the mutations found in families A/B and C within the study. Clinical features included tremor, bradykinesia, rigidity, gait disturbance, postural instability, response to levodopa with wearing off, asymmetry at onset, orthostatic hypotension, incontinence, urinary urgency, and levodopa-induced dyskinesia. Brain MRI was within normal limits.",
    "Regarding patient 'D': What is the family ID?": "Information not found",
    "Regarding patient 'D': What is the individual ID within the family?": "Information not found.\n\nRationale: The document identifies four patients with the p.D620N mutation: AII-11, BIII-8, CII-3, and D (Table 2). Patients AII-11, BIII-8, and CII-3 belong to families A, B, and C, respectively, as shown in the pedigrees (Fig. 1) and haplotype analysis (Table 1), and their IDs reflect their position within these families. Patient D, however, is described as having sporadic PD (SPD) with no family history (page 4, left column, first paragraph and right column, third paragraph). While 'D' serves as an identifier for this patient throughout the study, the document does not provide an ID indicating their position *within a family structure* like the other patients, because no affected family is documented for patient D in this paper.",
    "Regarding patient 'D': Are the parents consanguineous?": "Based on the information contained within the provided document:\n\nOn page 4, the text states: \"Patient D, who developed upper limb rest tremor at age 42, had no family history of PD... All affected patients were born to nonconÂ­sanguineous parents.\"\n\nTherefore, the parents of patient 'D' are nonconsanguineous.",
    "Regarding patient 'D': Is there a family history of the disease?": "",
    "Regarding patient 'D': Number of mutation-negative but affected family members?": "",
    "Regarding patient 'D': Number of mutation-negative and unaffected family members?": "Information not found",
    "Regarding patient 'D': What is the sex of the individual?": "Based *only* on the information contained within the provided document:\n\nOn page 4, in the second paragraph of the Discussion section, the text states: \"Because the family history of patient D was unknown, **she** was categorized as SPD.\"\n\nTherefore, the sex of the individual is female.",
    "Regarding patient 'D': What was the age at onset of symptoms? (Enter -99 if unknown)": "42",
    "Regarding patient 'D': What is the current age or age at last examination?": "Based on the information in Table 2 (\"Clinical features of patients with p.D620N mutation\"), patient D had:\n*   Age at disease onset (y): 42\n*   Disease duration (y): 21\n\nTherefore, the age at last examination reported in the study is 42 + 21 = 63 years.",
    "Regarding patient 'D': Was the individual alive at last follow-up? (Y/N)": "Information not found",
    "Regarding patient 'D': What was the disease duration in years?": "Based on the information in Table 2, the disease duration for patient 'D' was 21 years.",
    "Regarding patient 'D': Did the patient have parkinsonism?": "Based *only* on the information contained within the provided document:\n\nYes, patient 'D' had parkinsonism.\n\n*   Patient D is described as having Sporadic PD (SPD) (page 3, Figure 1 caption; page 4, Discussion section). Parkinson's Disease (PD) is a type of parkinsonism.\n*   Table 2 on page 3 lists clinical features for patient D, including the presence (+) of resting tremor, bradykinesia, rigidity, gait disturbance, and postural instability, which are the characteristic motor disturbances of parkinsonism mentioned on page 2.",
    "Regarding patient 'D': Any non-motor symptoms associated with parkinsonism?": "Based on the information contained within the provided document:\n\nTable 2 lists clinical features for patients, including patient D. For patient D, the table indicates the absence (-) of the following potential non-motor symptoms:\n*   Orthostatic hypotension\n*   Incontinence\n*   Urinary urgency\n*   Dystonia at onset\n*   Hyperreflexia\n*   Hallucination\n*   Other psychosis\n*   Dementia\n\nThe status of \"Sleep benefit\" for patient D is listed as \"Unknown\".\n\nTherefore, the document states that most listed non-motor symptoms were absent in patient D, while the status of sleep benefit was unknown.",
    "Regarding patient 'D': Any autonomic symptoms present?": "Based on the information in Table 2 (\"Clinical features of patients with p.D620N mutation\") on page 3:\n\n*   Orthostatic hypotension: - (Absent)\n*   Incontinence: - (Absent)\n*   Urinary urgency: + (Present)\n\nTherefore, regarding patient 'D', urinary urgency (an autonomic symptom) was present.",
    "Regarding patient 'D': Was depression present?": "Information not found.",
    "Regarding patient 'D': Did the patient have dementia or significant cognitive impairment?": "Information not found.",
    "Regarding patient 'D': List all *motor* symptoms observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Rigidity: yes; Tremor: no; Bradykinesia: yes.": "Based *only* on the information contained within the provided document:\n\nResting tremor: yes\nBradykinesia: yes\nRigidity: yes\nGait disturbance: yes\nPostural instability: yes\nLevodopa-induced dyskinesia: yes\nMotor fluctuation: yes (Described as 'Wearing off' in Table 2 and 'disabling motor fluctuation' on page 4)\nDystonia at onset: no",
    "Regarding patient 'D': List all *non-motor* symptoms (like cognitive, autonomic, psychiatric, sleep, sensory) observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Depression: yes; Anosmia: no; RBD: yes; Constipation: yes.": "Based *only* on the information contained within the provided document:\n\nThe following non-motor symptoms were assessed for patient 'D' according to Table 2:\n\n*   Orthostatic hypotension: no\n*   Incontinence: no\n*   Urinary urgency: no\n*   Sleep benefit: no\n*   Hyperreflexia: no\n*   Hallucination: no\n*   Other psychosis: no\n*   Dementia: no\n*   Gaze palsy: no\n\nInformation on other potential non-motor symptoms (such as anosmia, RBD, constipation, depression, anxiety, fatigue, sensory symptoms like pain) for patient 'D' is not found in the document.",
    "Regarding patient 'D': What is the first gene with a pathogenic variant found in the patient?": "Based only on the information contained within the provided document:\n\nThe document identifies patient 'D' as having the p.D620N mutation in the **VPS35** gene (see Table 1, Table 2, and text on pages 3 and 4). The study focused on screening for mutations in the VPS35 gene and reported this finding for patient D. The document does not mention any other genes being found with pathogenic variants in patient D, nor does it specify the temporal order of gene discovery if others were screened. Therefore, the first gene mentioned in this document with a pathogenic variant found in patient D is VPS35.",
    "Regarding patient 'D': What is the second gene with a pathogenic variant found in the patient (if any)?": "Information not found",
    "Regarding patient 'D': What is the third gene with a pathogenic variant found in the patient (if any)?": "Information not found.",
    "Regarding patient 'D': What is the DNA-level mutation? (Primary mutation)": "Based on the information contained within the provided document:\n\nThe document identifies Patient D as having the p.D620N mutation (Figure 1, Table 1, Table 2). The text specifies that the p.D620N mutation corresponds to the DNA-level change **c.1858G>A** in the VPS35 gene (page 2, Genetic Analysis; page 4, Discussion). Table 1 further confirms Patient D is heterozygous for this change (A/G).\n\nTherefore, the DNA-level mutation for Patient D is **c.1858G>A**.",
    "Regarding patient 'D': What is the protein-level effect of the mutation?": "Based on the information contained within the provided document, the protein-level effect of the mutation in patient 'D' is a p.D620N substitution. This is identified as a heterozygous missense mutation where the amino acid Aspartic acid (D) at position 620 is replaced by Asparagine (N).",
    "Regarding patient 'D': What is the zygosity of the first mutation?": "Based on the information contained within the provided document:\n\nPatient D is identified as the patient with Sporadic PD (SPD) who carried the p.D620N mutation (Figure 1 legend refers to 1 SPD patient; Page 4 first paragraph identifies Patient D as having no family history of PD; Table 1 and Table 2 include Patient D).\n\nThe Results section on page 2 states: \"We detected the **heterozygous** missense p.D620N mutation in 3 unrelated patients with ADPD and 1 patient with SPD\".\n\nFurthermore, Table 1, which shows haplotype analysis for mutation carriers including patient D, lists the genotype for 'VPS35 p.D620N' for patient D as 'A/G', which indicates heterozygosity.\n\nThe Discussion section on page 4 also states: \"We detected the **heterozygous** p.D620N mutation of VPS35 in 3 ADPD families and 1 SPD patient...\".\n\nThe document confirms that patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35 (page 3, paragraph below Figure 1). Therefore, the p.D620N mutation is the mutation in question for patient D.\n\nThe zygosity of the p.D620N mutation in patient D is heterozygous.",
    "Regarding patient 'D': Second mutation (cDNA), if any?": "Based *only* on the information contained within the provided document:\n\nPatient D was found to have the heterozygous p.D620N mutation in the VPS35 gene (corresponding to c.1858G>A). The document states: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\"\n\nTherefore, regarding a second mutation for patient 'D', the answer is: **None** (No other variants were detected in the exons of VPS35).",
    "Regarding patient 'D': Second mutation protein change?": "Information not found",
    "Regarding patient 'D': Zygosity of second mutation?": "Information not found",
    "Regarding patient 'D': Third mutation (cDNA), if any?": "Information not found",
    "Regarding patient 'D': Third mutation protein change?": "Information not found",
    "Regarding patient 'D': Zygosity of third mutation?": "Information not found.\n\nRationale: The document identifies only one specific mutation (p.D620N in the VPS35 gene) for patient D. Table 1 indicates this mutation is heterozygous (A/G). The document does not mention a \"third mutation\" for patient D.",
    "Regarding patient 'D': Which genome build/transcript was used?": "Based *only* on the information contained within the provided document:\n\nThe RefSeq accession number NM_018206.4 was used for the VPS35 gene analysis conducted in the study, which included patient D. However, the document does not specify a genome build.\n\nTherefore, the specific genome build information is not found in the document.",
    "Regarding patient 'D': What is the physical genomic location of the mutation?": "Information not found.\n\n*(Rationale: The document identifies the mutation in patient D as p.D620N (corresponding to c.1858G>A) in exon 15 of the VPS35 gene. Haplotype analysis uses markers on Chromosome 16 (e.g., D16S3105, Chr16_45.333M), strongly implying the gene is on this chromosome. However, the document does not explicitly state the chromosome number or the specific base pair coordinates for the VPS35 gene or the p.D620N mutation within the genome.)*",
    "Regarding patient 'D': Include this patient in MDSGene?": "Information not found",
    "Regarding patient 'D': Any additional comments about this patient?": "Based *only* on the information contained within the provided document:\n\nPatient D developed upper limb rest tremor at age 42 and had no family history of PD. This patient was categorized as having sporadic PD (SPD). At age 60, patient D underwent subthalamic nucleus deep brain stimulation (STN-DBS) due to disabling motor fluctuation and dyskinesia refractory to pharmacological treatment. Haplotype analysis suggests the p.D620N mutation in patient D likely occurred independently from the mutation found in patient AII-11 (family A). Patient D was born to nonconsanguineous parents. Clinical features listed in Table 2 include a disease duration of 21 years at the time of reporting, presence of resting tremor, bradykinesia, rigidity, gait disturbance, postural instability, clinical response to levodopa, wearing off, asymmetry at onset, and levodopa-induced dyskinesia. Brain MRI was within normal limits (WNL), and cardiac MIBG scintigraphy was not performed. Sleep benefit was unknown.",
    "Regarding patient 'D': What was the initial symptom of the patient?": "Based *only* on the information contained within the provided document:\n\nPatient D developed upper limb rest tremor at age 42.",
    "Regarding patient 'D': What was the second initial symptom of the patient (if applicable)?": "Based *only* on the information contained within the provided document:\n\nThe document states on page 4, \"Patient D, who developed upper limb rest tremor at age 42...\". This identifies the first initial symptom. Table 2 lists several symptoms present in patient D, including bradykinesia, rigidity, gait disturbance, and postural instability, but it does not specify the order in which these symptoms appeared after the initial tremor.\n\nTherefore, the information regarding the *second* initial symptom is not found in the document.\n\n**Information not found**",
    "Regarding patient 'D': What was the third initial symptom of the patient (if applicable)?": "Information not found.",
    "Regarding patient 'AII-12' from family 'Family A': Who is the first author and what is the publication year?": "Based *only* on the information contained within the provided document:\n\nThe first author is Maya Ando.\nThe publication year is 2012.",
    "Regarding patient 'AII-12' from family 'Family A': Any general comments about the study?": "Based on the information contained within the provided document:\n\nThe study identified patient 'AII-11' as the proband from 'Family A', a family with autosomal dominant Parkinson's disease (ADPD). Patient AII-11 was found to carry the heterozygous p.D620N mutation in the VPS35 gene. The study analyzed this patient's clinical features, including age at onset (62 years), symptoms (e.g., tremor-predominant PD, later cognitive dysfunction), and diagnostic test results (e.g., normal brain MRI, specific cardiac MIBG scintigraphy results). Haplotype analysis was performed on AII-11 and relatives, suggesting a potential shared founder for the mutation with Family B, but indicating AII-11's disease allele was on a different haplotype background compared to patient CII-3 and patient D. The study was able to determine the chromosomal phase of the mutation for patient AII-11. The patient's development of dementia after a long disease course (15 years) was noted as an observation from the study's cohort.",
    "Regarding patient 'AII-12' from family 'Family A': What is the family ID?": "Based on the information contained within the provided document:\n\nThe family ID is **A**.\n\n*   Figure 1 on page 3 shows the pedigree for 'Family A', which includes an individual labeled 'II-12' (implying patient AII-12).\n*   The text on page 4 mentions \"patient AII-11 (family A)\".",
    "Regarding patient 'AII-12' from family 'Family A': What is the individual ID within the family?": "Information not found.\n\nThe document mentions patient 'AII-11' from Family A (Figure 1A, Tables 1 and 2, text on pages 3 and 4), but there is no specific information or data presented for an individual identified as 'AII-12' from Family A. While Figure 1A shows an individual labeled 'II-12', the text and tables consistently use the identifier 'AII-11' when referring to the analyzed patient from Generation II of Family A.",
    "Regarding patient 'AII-12' from family 'Family A': Are the parents consanguineous?": "Based on the information contained within the provided document:\n\nPage 4, first paragraph of the Discussion section, states: \"All affected patients were born to noncon-sanguineous parents.\"\n\nFigure 1A shows that patient 'AII-12' is an affected patient (closed symbol) in family 'Family A'.\n\nTherefore, the parents of patient 'AII-12' were non-consanguineous.",
    "Regarding patient 'AII-12' from family 'Family A': Is there a family history of the disease?": "Based on the information in the document:\n\nYes, there is a family history of the disease for patient 'AII-12' from 'Family A'.\n\nFigure 1A shows the pedigree for Family A. Patient AII-12 is indicated as affected (filled circle). The pedigree shows that her father (I-1) and multiple siblings (II-3, II-4, II-6, II-8, II-11) were also affected. The text on page 3 further confirms that the father and siblings in this family were diagnosed with PD.",
    "Regarding patient 'AII-12' from family 'Family A': Number of mutation-negative but affected family members?": "Information not found",
    "Regarding patient 'AII-12' from family 'Family A': Number of mutation-negative and unaffected family members?": "Information not found.\n\nRationale: Figure 1A shows the pedigree for Family A, identifying patient AII-11 as the proband. Patient AII-12 is shown as an unaffected female sibling (open circle) who was analyzed (indicated by an asterisk). However, the text and tables only explicitly state the mutation status for the affected individuals (AII-11, BIII-8, CII-3, D) who were found to carry the p.D620N mutation. The document does not state the specific mutation result (positive or negative) for the analyzed, unaffected individual AII-12, nor does it state the mutation status of any other unaffected family members in Family A (who were not marked as analyzed). Therefore, the number of mutation-negative *and* unaffected family members cannot be determined solely from the provided information.",
    "Regarding patient 'AII-12' from family 'Family A': What is the sex of the individual?": "Based on Figure 1 (Pedigrees of families with the VPS35 p.D620N mutation) on page 3:\n\n*   The pedigree for Family A is shown in panel A.\n*   Individual AII-12 is represented by a square symbol.\n*   The legend for Figure 1 states: \"square, male\".\n\nTherefore, the sex of individual AII-12 is **male**.",
    "Regarding patient 'AII-12' from family 'Family A': What was the age at onset of symptoms? (Enter -99 if unknown)": "Information not found",
    "Regarding patient 'AII-12' from family 'Family A': What is the current age or age at last examination?": "Based on the information in the document:\n\nPatient AII-11 was a **77-year-old** man.\n\n(This information is found on page 3, in the \"Clinical Presentation\" section: \"Patient AII-11 was a 77-year-old man who developed right upper limb rest tremor at age 62.\")",
    "Regarding patient 'AII-12' from family 'Family A': Was the individual alive at last follow-up? (Y/N)": "Y",
    "Regarding patient 'AII-12' from family 'Family A': What was the disease duration in years?": "Based *only* on the information contained within the provided document:\n\nInformation not found.\n\nWhile Figure 1A shows an individual labeled 'AII-12' (indicated with an asterisk, meaning they were analyzed), no specific clinical details, including disease duration, are provided for this individual in the text or tables. Table 2 provides details for patient 'AII-11', but not 'AII-12'.",
    "Regarding patient 'AII-12' from family 'Family A': Did the patient have parkinsonism?": "Yes, patient 'AII-11' from 'Family A' did have parkinsonism.\n\nThe document provides the following information:\n*   Figure 1A shows the pedigree for Family A, including patient AII-11.\n*   Table 2 lists clinical features for patient AII-11, including resting tremor, bradykinesia, rigidity, gait disturbance, postural instability, and clinical response to levodopa, which are characteristic signs of parkinsonism.\n*   The \"Clinical Presentation\" section states, \"Patient AII-11 was a 77-year-old man who developed right upper limb rest tremor at age 62.\" (Page 3)\n*   The Discussion section mentions, \"...patient AII-11, who had PD for 15 years.\" (Page 4) Parkinson's disease (PD) is a form of parkinsonism.",
    "Regarding patient 'AII-12' from family 'Family A': Any non-motor symptoms associated with parkinsonism?": "Based on the information contained within the provided document:\n\nFor patient 'AII-11' from 'Family A', the following non-motor symptoms associated with parkinsonism are mentioned:\n\n*   Orthostatic hypotension (+)\n*   Incontinence (+)\n*   Sleep benefit (+)\n*   Progressive dysphagia (requiring gastrostomy)\n*   Cognitive dysfunction (developed after 13 years of disease duration, at age 75)",
    "Regarding patient 'AII-12' from family 'Family A': Any autonomic symptoms present?": "Yes, patient AII-11 presented with the following autonomic symptoms according to Table 2:\n\n*   Orthostatic hypotension (+)\n*   Incontinence (+)\n*   Urinary urgency (+)\n\nAdditionally, cardiac MIBG scintigraphy, which assesses cardiac sympathetic nerve function (part of the autonomic nervous system), was performed and showed specific results (H/M ratio 2.38/2.68; washout ratio, 4.15%).",
    "Regarding patient 'AII-12' from family 'Family A': Was depression present?": "Information not found.",
    "Regarding patient 'AII-12' from family 'Family A': Did the patient have dementia or significant cognitive impairment?": "Information not found.\n\nThe document provides clinical details for patient AII-11 from Family A, stating this patient \"developed cognitive dysfunction without hallucination\" at age 75. However, the document does not provide any clinical information, including cognitive status, for patient AII-12 from Family A. Figure 1A indicates patient AII-12 is an unaffected individual who was analyzed genetically, but no further details are given.",
    "Regarding patient 'AII-12' from family 'Family A': List all *motor* symptoms observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Rigidity: yes; Tremor: no; Bradykinesia: yes.": "Based *only* on the information contained within the provided document (specifically Table 2):\n\nResting tremor: yes\nBradykinesia: yes\nRigidity: yes\nGait disturbance: yes\nPostural instability: yes\nWearing off: yes\nAsymmetry at onset: yes\nLevodopa-induced dyskinesia: yes\nDystonia at onset: yes\nHyperreflexia: yes\nGaze palsy: no",
    "Regarding patient 'AII-12' from family 'Family A': List all *non-motor* symptoms (like cognitive, autonomic, psychiatric, sleep, sensory) observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Depression: yes; Anosmia: no; RBD: yes; Constipation: yes.": "Based *only* on the information contained within the provided document:\n\nHere are the non-motor symptoms observed in patient 'AII-11' from 'Family A', based on Table 2 and the text description on page 3:\n\n*   Orthostatic hypotension: yes\n*   Incontinence: yes\n*   Urinary urgency: yes\n*   Sleep benefit: yes\n*   Hyperreflexia: yes\n*   Hallucination: no\n*   Other psychosis: no\n*   Dementia: no\n*   Cognitive dysfunction: yes (Text notes the patient \"developed cognitive dysfunction\")\n*   Dysphagia: yes (Text notes \"progressive dysphagia\")\n\n*(Note: Information on other potential non-motor symptoms like sensory issues (e.g., anosmia, pain) or specific sleep disorders (e.g., RBD) was not found in the document for this patient.)*",
    "Regarding patient 'AII-12' from family 'Family A': What is the first gene with a pathogenic variant found in the patient?": "Based on the information contained within the provided document:\n\nFigure 1A shows the pedigree for Family A. Individuals AII-11 and AII-12 are both marked with an asterisk, which the figure caption indicates means they were \"analyzed for the p.D620N mutation and/or haplotype\".\n\nHowever, Table 1 (\"Haplotype analysis of VPS35 p.D620N mutation carriers\"), Table 2 (\"Clinical features of patients with p.D620N mutation\"), and the detailed text descriptions (e.g., page 3, \"One disease allele was detected by analyzing patient AII-11...\", page 3, \"Patients AII-11 and BIII-8...\", page 3, \"Patient AII-11 was a 77-year-old man...\", page 4, \"We were able to determine the chromosomal phase only in patient AII-11 (family A)\") explicitly provide genetic and clinical details only for patient **AII-11** from Family A, identifying the **VPS35** gene with the p.D620N mutation.\n\nThere is no specific information presented about the results of the analysis for patient **AII-12**.\n\nTherefore, the answer is: Information not found.",
    "Regarding patient 'AII-12' from family 'Family A': What is the second gene with a pathogenic variant found in the patient (if any)?": "Information not found.\n\nRationale: The document identifies patient AII-11 from Family A as having the p.D620N mutation in the VPS35 gene (Page 3, Table 1, Fig 1A). It explicitly states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (Page 3, paragraph 1). While Figure 1A indicates patient AII-12 (a sibling of AII-11) was also analyzed and affected, the document does not provide specific genetic findings for AII-12 beyond the family having the VPS35 mutation. Furthermore, the study focuses on VPS35 and does not report finding pathogenic variants in any *other* genes for the patients studied, including those in Family A.",
    "Regarding patient 'AII-12' from family 'Family A': What is the third gene with a pathogenic variant found in the patient (if any)?": "Information not found.",
    "Regarding patient 'AII-12' from family 'Family A': What is the DNA-level mutation? (Primary mutation)": "Based *only* on the information contained within the provided document:\n\nThe document identifies patient 'AII-11' from Family A as having the p.D620N mutation (Table 1, Figure 1A). On page 4, left column, third paragraph, the document states: \"Based on haplotype analysis reported in previous studies, the substitution of VPS35 c.1858G>A (p.D620N) occurs from independent mutational events.\" This links the protein-level change p.D620N, found in patient AII-11 of Family A, to the DNA-level change c.1858G>A.\n\nTherefore, the DNA-level mutation (Primary mutation) for patient AII-11 from Family A is **c.1858G>A** in the VPS35 gene.\n\n*(Note: The question asks about 'AII-12', however, the document consistently refers to and provides data for patient 'AII-11' from Family A. The answer assumes AII-11 is the intended patient based on the available information in the document).*",
    "Regarding patient 'AII-12' from family 'Family A': What is the protein-level effect of the mutation?": "Based on the information in the document:\n\nPatient AII-11 from Family A carries the **p.D620N** mutation in the VPS35 gene (Figure 1, Table 1). The notation 'p.D620N' signifies the protein-level effect: a substitution where the amino acid Aspartic acid (D) at position 620 is replaced by Asparagine (N). This is also referred to as the \"p.D620N substitution\" in the Abstract and Conclusion.",
    "Regarding patient 'AII-12' from family 'Family A': What is the zygosity of the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe document identifies patient 'AII-11' from 'Family A' (Figure 1, Table 1, Table 2).\n\nPage 2, under the 'Results' section ('Detection of p.D620N Mutation'), states: \"We detected the **heterozygous** missense p.D620N mutation in 3 unrelated patients with ADPD...\". Patient AII-11 is one of these ADPD patients (Table 1 refers to AII-11 as a mutation carrier from Family A, described in Figure 1A as having ADPD).\n\nPage 4, in the first paragraph of the 'Discussion' section, states: \"We detected the **heterozygous** p.D620N mutation of VPS35 in 3 ADPD families...\".\n\nThe document also confirms on page 3, left column, that \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" This indicates the p.D620N mutation is the only one found in the VPS35 gene for this patient in this study.\n\nTherefore, the zygosity of the mutation (p.D620N) found in patient AII-11 is **heterozygous**.",
    "Regarding patient 'AII-12' from family 'Family A': Second mutation (cDNA), if any?": "Based *only* on the information contained within the provided document:\n\nThe document states on page 3, first paragraph under 'Results': \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Patient AII-12 is indicated as analyzed in Figure 1A (asterisk) and belongs to Family A which carries the p.D620N mutation. Therefore, according to the document, no second mutation was found in the exons of VPS35 for this patient.\n\nAnswer: None found in exons of VPS35.",
    "Regarding patient 'AII-12' from family 'Family A': Second mutation protein change?": "Information not found.",
    "Regarding patient 'AII-12' from family 'Family A': Zygosity of second mutation?": "Information not found",
    "Regarding patient 'AII-12' from family 'Family A': Third mutation (cDNA), if any?": "Based on the information in the document:\n\nPatient AII-11 (from Family A, Fig 1A) was found to have the heterozygous p.D620N mutation (Page 3, Results section and Table 1). The corresponding cDNA mutation is identified as c.1858G>A (Page 2, second paragraph of the main text).\n\nThe text on Page 3 states: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\"\n\nTherefore, only one mutation (c.1858G>A) was identified for patient AII-11 in the VPS35 gene exons according to this document, and no other variants were found in the exons. Information regarding a *third* mutation is not found.\n\nAnswer: Information not found",
    "Regarding patient 'AII-12' from family 'Family A': Third mutation protein change?": "Information not found.\n\nThe document identifies patient 'AII-11' (not AII-12, based on Figure 1A and Tables 1 & 2) from Family A as having the heterozygous p.D620N mutation in the VPS35 gene. The text explicitly states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, no information regarding a second or third mutation protein change for this patient in the VPS35 gene is provided in the document.",
    "Regarding patient 'AII-12' from family 'Family A': Zygosity of third mutation?": "Information not found",
    "Regarding patient 'AII-12' from family 'Family A': Which genome build/transcript was used?": "Based *only* on the information contained within the provided document:\n\nThe RefSeq accession number **NM_018206.4** was used for the *VPS35* gene analysis.\n\nThe specific genome build is not mentioned in the document.",
    "Regarding patient 'AII-12' from family 'Family A': What is the physical genomic location of the mutation?": "Information not found",
    "Regarding patient 'AII-12' from family 'Family A': Include this patient in MDSGene?": "Information not found.",
    "Regarding patient 'AII-12' from family 'Family A': Any additional comments about this patient?": "Based *only* on the information contained within the provided document:\n\nPatient AII-12 is shown in the pedigree for Family A (Figure 1A). He is a male sibling of patient AII-11 and is affected with Parkinson's Disease (PD). He was analyzed for the p.D620N mutation and/or haplotype. As one of the affected siblings in Family A, he presented with levodopa-responsive typical parkinsonism, specifically upper limb tremor and small-step gait.\n\nNo other specific comments about patient AII-12 are provided in the document.",
    "Regarding patient 'AII-12' from family 'Family A': What was the initial symptom of the patient?": "Information not found.\n\nThe document provides clinical details for patient 'AII-11' from Family A (developed right upper limb rest tremor at age 62), but it does not contain information about the specific initial symptom for patient 'AII-12'. Figure 1A identifies AII-12 as an affected member of Family A who was genetically analyzed, but no further clinical description is given for this specific individual in the text or tables.",
    "Regarding patient 'AII-12' from family 'Family A': What was the second initial symptom of the patient (if applicable)?": "Information not found.\n\nThe document states that patient AII-11 \"developed right upper limb rest tremor at age 62.\" This is identified as the initial symptom at onset. The document does not specify the second symptom that appeared.",
    "Regarding patient 'AII-12' from family 'Family A': What was the third initial symptom of the patient (if applicable)?": "Information not found.",
    "Regarding patient 'AIII-5' from family 'Family A': Who is the first author and what is the publication year?": "Based only on the information contained within the provided document:\n\nThe first author of the document which mentions patient 'AIII-5' from 'Family A' (in Figure 1) is Maya Ando. The publication year of this document is 2012.",
    "Regarding patient 'AIII-5' from family 'Family A': Any general comments about the study?": "Information not found.",
    "Regarding patient 'AIII-5' from family 'Family A': What is the family ID?": "Based on the information provided in the document, specifically in Figure 1 which shows the pedigree for 'Family A', the family ID is **A**.",
    "Regarding patient 'AIII-5' from family 'Family A': What is the individual ID within the family?": "Based on Figure 1A on page 3, the individual ID for patient 'AIII-5' within family 'Family A' is **III-5**.",
    "Regarding patient 'AIII-5' from family 'Family A': Are the parents consanguineous?": "Based on the information provided in the document:\n\nOn page 4, under the \"Discussion\" section but concluding the description of the clinical presentation of the studied patients, the text states: \"All affected patients were born to noncon-sanguineous parents.\"\n\nFigure 1A shows the pedigree for Family A, and individual AIII-5 is marked as an affected patient (closed symbol). Therefore, according to the statement on page 4, the parents of patient AIII-5 were non-consanguineous.\n\nThe answer is: No, the parents were not consanguineous.",
    "Regarding patient 'AIII-5' from family 'Family A': Is there a family history of the disease?": "Based on the information in Figure 1A (Pedigree of Family A), patient AIII-5 is indicated by a closed circle, signifying they are affected. This patient has affected parents (AII-11 and AII-12, both closed symbols), an affected sibling (AIII-6, closed symbol), and affected individuals in earlier generations (e.g., AI-4, AII-1, AII-2, AII-3, AII-6, AII-8, AII-10).\n\nTherefore, yes, there is a family history of the disease for patient AIII-5.",
    "Regarding patient 'AIII-5' from family 'Family A': Number of mutation-negative but affected family members?": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': Number of mutation-negative and unaffected family members?": "Information not found.",
    "Regarding patient 'AIII-5' from family 'Family A': What is the sex of the individual?": "Based on the information in Figure 1 on page 3:\n\nThe pedigree for Family A shows individuals arranged by generation (Roman numerals I, II, III) and position within the generation (Arabic numerals). Individual AIII-5 is in the third generation, position 5. The symbol used for this individual is a circle. The legend for Figure 1 states: \"square, male; circle, female\".\n\nTherefore, the sex of individual AIII-5 from Family A is **Female**.",
    "Regarding patient 'AIII-5' from family 'Family A': What was the age at onset of symptoms? (Enter -99 if unknown)": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': What is the current age or age at last examination?": "Information not found.\n\nThe document provides a pedigree for Family A (Figure 1A), which includes individual AIII-5. The symbol for AIII-5 indicates an affected, deceased female. However, the asterisk symbol, indicating individuals analyzed for the mutation and/or haplotype, is not present for AIII-5. The text and tables describe clinical details for other individuals (AII-11, BIII-8, CII-3, D), but no specific age or examination details for AIII-5 are mentioned.",
    "Regarding patient 'AIII-5' from family 'Family A': Was the individual alive at last follow-up? (Y/N)": "Y",
    "Regarding patient 'AIII-5' from family 'Family A': What was the disease duration in years?": "Based on the provided document:\n\nPatient 'AIII-5' is shown in the pedigree for 'Family A' (Figure 1A on page 3). The symbol for AIII-5 is an open circle. According to the figure legend, an open symbol represents an *unaffected* family member.\n\nThe document does not provide disease duration for unaffected individuals. Therefore, the information regarding disease duration for patient AIII-5 is not found in the document.\n\n**Answer:** Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': Did the patient have parkinsonism?": "Based on the information in the document:\n\nPatient 'AIII-5' from family 'Family A' is represented in Figure 1A on page 3. The symbol used for this individual is an open circle. According to the legend for Figure 1, an \"open symbol\" indicates an \"unaffected family member\". In the context of this study on Parkinson's Disease (a form of parkinsonism), this means the patient did not have the condition.\n\nTherefore, the patient AIII-5 did not have parkinsonism.",
    "Regarding patient 'AIII-5' from family 'Family A': Any non-motor symptoms associated with parkinsonism?": "Information not found.",
    "Regarding patient 'AIII-5' from family 'Family A': Any autonomic symptoms present?": "Information not found.",
    "Regarding patient 'AIII-5' from family 'Family A': Was depression present?": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': Did the patient have dementia or significant cognitive impairment?": "Information not found.",
    "Regarding patient 'AIII-5' from family 'Family A': List all *motor* symptoms observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Rigidity: yes; Tremor: no; Bradykinesia: yes.": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': List all *non-motor* symptoms (like cognitive, autonomic, psychiatric, sleep, sensory) observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Depression: yes; Anosmia: no; RBD: yes; Constipation: yes.": "Based *only* on the information contained within the provided document:\n\nOrthostatic hypotension: yes\nIncontinence: yes\nUrinary urgency: no\nSleep benefit: yes\nHallucination: no\nOther psychosis: no\nDementia: yes",
    "Regarding patient 'AIII-5' from family 'Family A': What is the first gene with a pathogenic variant found in the patient?": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': What is the second gene with a pathogenic variant found in the patient (if any)?": "Information not found.",
    "Regarding patient 'AIII-5' from family 'Family A': What is the third gene with a pathogenic variant found in the patient (if any)?": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': What is the DNA-level mutation? (Primary mutation)": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': What is the protein-level effect of the mutation?": "Based on the information in the document:\n\nPatient AIII-5 is shown as an affected individual (closed circle) in the pedigree for Family A in Figure 1. The study detected the heterozygous missense p.D620N mutation in 3 families with autosomal dominant Parkinson's Disease (ADPD), including Family A (as indicated by the results linking the p.D620N mutation to the families shown in Figure 1 and discussed in the text).\n\nTherefore, the protein-level effect of the mutation in patient AIII-5 is **p.D620N**, which represents a substitution where the amino acid Aspartic acid (D) at position 620 is replaced by Asparagine (N). The document explicitly refers to this as a \"missense p.D620N mutation\" (page 2) and a \"p.D620N substitution\" (page 5).",
    "Regarding patient 'AIII-5' from family 'Family A': What is the zygosity of the first mutation?": "Information not found.",
    "Regarding patient 'AIII-5' from family 'Family A': Second mutation (cDNA), if any?": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': Second mutation protein change?": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': Zygosity of second mutation?": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': Third mutation (cDNA), if any?": "Information not found.",
    "Regarding patient 'AIII-5' from family 'Family A': Third mutation protein change?": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': Zygosity of third mutation?": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': Which genome build/transcript was used?": "Based only on the information contained within the provided document:\n\nThe transcript used for VPS35 analysis was RefSeq accession number NM_018206.4.\n\nThe specific genome build used is not mentioned in the document.",
    "Regarding patient 'AIII-5' from family 'Family A': What is the physical genomic location of the mutation?": "Based *only* on the information contained within the provided document:\n\nThe mutation affecting members of Family A, including patient AIII-5 (who was analyzed according to Figure 1), is identified as p.D620N (c.1858G>A) located in exon 15 of the *VPS35* gene. Haplotype analysis used markers flanking the *VPS35* gene on Chromosome 16 (indicated by marker names such as D16S3105 and Chr16_45.XXXM).\n\nHowever, the document does not provide the precise physical genomic coordinates (e.g., base pair position on Chromosome 16) for this mutation. Therefore, the specific physical genomic location is:\n\nInformation not found",
    "Regarding patient 'AIII-5' from family 'Family A': Include this patient in MDSGene?": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': Any additional comments about this patient?": "Information not found",
    "Regarding patient 'AIII-5' from family 'Family A': What was the initial symptom of the patient?": "Information not found.",
    "Regarding patient 'AIII-5' from family 'Family A': What was the second initial symptom of the patient (if applicable)?": "Information not found.",
    "Regarding patient 'AIII-5' from family 'Family A': What was the third initial symptom of the patient (if applicable)?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': Who is the first author and what is the publication year?": "Based *only* on the information contained within the provided document:\n\nThe first author is Maya Ando and the publication year is 2012.",
    "Regarding patient 'AIII-6' from family 'Family A': Any general comments about the study?": "Information not found.",
    "Regarding patient 'AIII-6' from family 'Family A': What is the family ID?": "Based on the information in Figure 1, patient 'AIII-6' is shown within the pedigree labeled 'A'. Therefore, the family ID is 'A'.",
    "Regarding patient 'AIII-6' from family 'Family A': What is the individual ID within the family?": "Based on the information in the document, specifically Figure 1A on page 3, the individual ID for 'AIII-6' within Family A is **6**.",
    "Regarding patient 'AIII-6' from family 'Family A': Are the parents consanguineous?": "Based *only* on the information contained within the provided document:\n\nThe pedigree for Family A is shown in Figure 1A on page 3. Patient AIII-6 is the sixth individual shown in the third generation (row III). The parents of AIII-6 are individuals AII-10 and AII-11. In standard pedigree notation, a consanguineous marriage is indicated by a double horizontal line connecting the parents. The line connecting AII-10 and AII-11 in Figure 1A is a single horizontal line, indicating a non-consanguineous marriage.\n\nAdditionally, the text at the end of the first paragraph on page 4 states: \"All affected patients were born to noncon-sanguineous parents.\" Patient AII-11 (the father of AIII-6) is an affected patient.\n\nTherefore, based on the pedigree symbol and the text, the parents of patient AIII-6 are **not consanguineous**.",
    "Regarding patient 'AIII-6' from family 'Family A': Is there a family history of the disease?": "Based on the pedigree for Family A shown in Figure 1 on page 3, patient AIII-6 has multiple affected relatives. Specifically, their father (AII-11) is affected, their paternal grandfather (AI-1) is affected, and several paternal uncles/aunts (AII-2, AII-3, AII-4, AII-6, AII-8, AII-10) are also indicated as affected.\n\nTherefore, yes, there is a family history of the disease for patient AIII-6 from Family A.",
    "Regarding patient 'AIII-6' from family 'Family A': Number of mutation-negative but affected family members?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': Number of mutation-negative and unaffected family members?": "Information not found.\n\nThe document provides a pedigree for Family A in Figure 1. It shows patient AIII-6 as an unaffected individual (open square). It also shows other unaffected family members (open symbols), such as AIII-5 and AII-12. Individual AII-12 has an asterisk, indicating analysis for the mutation and/or haplotype, but the specific result (mutation-negative or positive) is not explicitly stated for this individual within the document. The document does not state whether AIII-6 or AIII-5 were tested for the mutation. Therefore, the exact number of family members of AIII-6 who are confirmed as both mutation-negative and unaffected cannot be determined solely from the information provided.",
    "Regarding patient 'AIII-6' from family 'Family A': What is the sex of the individual?": "Based on the information in Figure 1 (pedigree chart A and its legend) on page 3, the symbol for individual AIII-6 is a circle. The legend specifies that a circle represents a female.\n\nTherefore, the sex of individual AIII-6 from Family A is **female**.",
    "Regarding patient 'AIII-6' from family 'Family A': What was the age at onset of symptoms? (Enter -99 if unknown)": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': What is the current age or age at last examination?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': Was the individual alive at last follow-up? (Y/N)": "Based *only* on the information contained within the provided document:\n\nIn Figure 1A, the pedigree for Family A is shown. Individual AIII-6 is represented by an open circle (unaffected female) with an asterisk (analyzed for mutation/haplotype). According to the figure legend, a forward slash through a symbol indicates deceased individuals. The symbol for AIII-6 does not have a forward slash.\n\nTherefore, based on the pedigree representation in the document, the answer is:\nY",
    "Regarding patient 'AIII-6' from family 'Family A': What was the disease duration in years?": "Information not found.\n\n(The pedigree chart in Figure 1A shows individual AIII-6 as an unaffected female. No clinical details, including disease duration, are provided for this specific individual in the document.)",
    "Regarding patient 'AIII-6' from family 'Family A': Did the patient have parkinsonism?": "Based on the pedigree chart for Family A shown in Figure 1A:\n\n*   Individual AIII-6 is represented by an open circle.\n*   The figure legend states that an open symbol represents an \"unaffected family member\".\n*   The study focuses on Parkinson's disease (PD), a form of parkinsonism. Therefore, \"unaffected\" in this context means the individual does not have PD/parkinsonism according to the family history presented.\n\nTherefore, patient AIII-6 from Family A did not have parkinsonism.",
    "Regarding patient 'AIII-6' from family 'Family A': Any non-motor symptoms associated with parkinsonism?": "Information not found.",
    "Regarding patient 'AIII-6' from family 'Family A': Any autonomic symptoms present?": "Information not found.",
    "Regarding patient 'AIII-6' from family 'Family A': Was depression present?": "Information not found.",
    "Regarding patient 'AIII-6' from family 'Family A': Did the patient have dementia or significant cognitive impairment?": "Information not found.",
    "Regarding patient 'AIII-6' from family 'Family A': List all *motor* symptoms observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Rigidity: yes; Tremor: no; Bradykinesia: yes.": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': List all *non-motor* symptoms (like cognitive, autonomic, psychiatric, sleep, sensory) observed in the patient and state if they were present (yes/no). Format as 'Symptom Name: yes/no', separated by semicolons or newlines. Examples: Depression: yes; Anosmia: no; RBD: yes; Constipation: yes.": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': What is the first gene with a pathogenic variant found in the patient?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': What is the second gene with a pathogenic variant found in the patient (if any)?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': What is the third gene with a pathogenic variant found in the patient (if any)?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': What is the DNA-level mutation? (Primary mutation)": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': What is the protein-level effect of the mutation?": "Based *only* on the information contained within the provided document:\n\nThe document identifies the mutation detected in Family A (specifically in patient AII-11, the proband) as the \"heterozygous missense p.D620N mutation\" (page 2, Results; page 3, Results). This describes the protein-level effect as a missense mutation, resulting in the substitution of the amino acid Aspartic acid (D) with Asparagine (N) at position 620 of the VPS35 protein.\n\nThe document does not explicitly state that patient AIII-6 was analyzed for or carries this mutation (indicated by the lack of an asterisk by AIII-6 in Figure 1A, page 3). However, the protein-level effect *of the mutation found in Family A* is the p.D620N missense substitution.",
    "Regarding patient 'AIII-6' from family 'Family A': What is the zygosity of the first mutation?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': Second mutation (cDNA), if any?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': Second mutation protein change?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': Zygosity of second mutation?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': Third mutation (cDNA), if any?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': Third mutation protein change?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': Zygosity of third mutation?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': Which genome build/transcript was used?": "Information not found.",
    "Regarding patient 'AIII-6' from family 'Family A': What is the physical genomic location of the mutation?": "Information not found.",
    "Regarding patient 'AIII-6' from family 'Family A': Include this patient in MDSGene?": "Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': Any additional comments about this patient?": "Based *only* on the information contained within the provided document:\n\nPatient AIII-6 from Family A is shown in the pedigree in Figure 1A as an unaffected female. The asterisk by her symbol indicates that this individual was analyzed for the p.D620N mutation and/or haplotype. No other specific comments about patient AIII-6 are provided in the document.",
    "Regarding patient 'AIII-6' from family 'Family A': What was the initial symptom of the patient?": "Information not found.",
    "Regarding patient 'AIII-6' from family 'Family A': What was the second initial symptom of the patient (if applicable)?": "Based *only* on the information contained within the provided document:\n\nPatient AIII-6 is identified in the pedigree chart for Family A (Figure 1A) as an affected individual (closed square). The text on page 3 under \"Clinical Presentation\" mentions that the nephew of patient AII-11 (who appears to be AIII-6 based on the pedigree) \"developed parkinsonism in his early fifties.\" However, the document does not list specific symptoms, initial or otherwise, for patient AIII-6.\n\nTherefore, the information regarding the second initial symptom of patient AIII-6 is not found in the document.\n\n**Answer:** Information not found",
    "Regarding patient 'AIII-6' from family 'Family A': What was the third initial symptom of the patient (if applicable)?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': What is the study design of this article?": "Based *only* on the information within the provided document:\n\nThe study design involved screening for 7 reported nonsynonymous missense variants of the *VPS35* gene, including p.D620N, in different groups of Japanese individuals: 300 index patients with autosomal dominant Parkinson's disease (ADPD), 433 patients with sporadic Parkinson's disease (SPD), and 579 controls. The screening was performed using direct sequencing or high-resolution melting (HRM) analysis. For patients identified with the p.D620N mutation (such as AII-11 from Family A), haplotype analysis was performed, and clinical features were described. This represents a **genetic screening study** incorporating elements of a **case-control study** (comparing mutation frequency in PD patients vs. controls) and **case series/family analysis** (describing clinical features and haplotypes of mutation carriers).",
    "Regarding patient 'AII-11' from family 'Family A': What genetic methods were used in this study?": "Based on the information contained within the provided document:\n\nThe genetic methods used in the study that were applied to patient 'AII-11' from 'Family A' include:\n\n1.  **PCR direct sequencing:** This method was used to screen index patients with autosomal dominant PD (like AII-11) for 7 specific variants of VPS35, including the p.D620N mutation which was detected in AII-11.\n2.  **Analysis of all exons of VPS35:** The document states that \"All exons of VPS35 were also analyzed in patients with the p.D620N mutation\" (which includes AII-11). (Note: The specific method for the full exon analysis is referenced externally and not detailed within this document).\n3.  **Haplotype analysis:** The document explicitly states that haplotype analysis was performed for patient AII-11 to determine the disease allele and chromosomal phase. Results for AII-11 are shown in Table 1.",
    "Regarding patient 'AII-11' from family 'Family A': What is the lower age limit for study inclusion (if any)?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': What is the upper age limit for study inclusion (if any)?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': Are there any additional comments about the study methodology?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': What is the abbreviation of the disease or condition diagnosed in this patient?": "Based *only* on the information contained within the provided document:\n\nThe document states on page 4, right column, second paragraph: \"...similar to patient AII-11, who had PD for 15 years.\"\n\nThe abbreviation for Parkinson's disease used throughout the document (e.g., in the Abstract and on page 2, first paragraph) is PD.\n\nTherefore, the abbreviation of the disease diagnosed in patient AII-11 is **PD**.",
    "Regarding patient 'AII-11' from family 'Family A': What is the key clinical information about this patient?": "Based on the information contained within the provided document:\n\nThe key clinical information about patient AII-11 from Family A is as follows:\n\n*   **Genetics:** Carries the heterozygous p.D620N mutation in the VPS35 gene.\n*   **Demographics:** Male.\n*   **Age at Onset:** 62 years.\n*   **Symptoms/Signs:** Developed right upper limb rest tremor at onset. Presented with resting tremor, bradykinesia, rigidity, gait disturbance, postural instability, asymmetry at onset, orthostatic hypotension, incontinence, and sleep benefit. Responded clinically to levodopa and experienced wearing off. Did not have levodopa-induced dyskinesia, dystonia at onset, hyperreflexia, hallucination, other psychosis, or gaze palsy.\n*   **Disease Progression:** Disease duration was 15 years at the time of assessment detailed in Table 2. He developed progressive dysphagia requiring gastrostomy at age 75, followed by cognitive dysfunction (dementia) without hallucination.\n*   **Imaging/Tests:** Brain MRI was within normal limits (WNL). Cardiac MIBG scintigraphy performed at age 76 showed specific H/M ratios and washout ratio (H/M ratio (E/L), 2.38/2.68; washout ratio, 4.15%). Single-photon emission computed tomography (SPECT) of cerebral blood flow showed no reduction in the basal ganglia.\n*   **Family History:** Belongs to Family A with autosomal dominant Parkinson's disease (ADPD). His father and 4 of 8 siblings were diagnosed with PD.",
    "Regarding patient 'AII-11' from family 'Family A': What is the patient's ethnicity?": "Based *only* on the information contained within the provided document:\n\nThe document studies mutations in \"Japanese patients\" (Page 2, Subjects section). It identifies patient AII-11 as belonging to Family A (Page 4, Discussion section: \"patient AII-11 (family A)\"). Family A is described as one of the \"Japanese ADPD families\" (Page 4, Discussion section).\n\nTherefore, the patient's ethnicity is **Japanese**.",
    "Regarding patient 'AII-11' from family 'Family A': What is the patient's country of origin?": "Based on the information contained within the provided document:\n\nThe study subjects were described as \"Japanese patients with autosomal-dominant PD (ADPD)\", \"Japanese patients with SPD\", and \"healthy Japanese subjects\" (Page 2, Subjects). Patient AII-11 is part of Family A, which is one of the ADPD families studied (Figure 1, Table 1, Table 2). The Discussion section also refers to \"Japanese ADPD families A and B\" (Page 4).\n\nTherefore, the patient's country of origin is **Japan**.",
    "Regarding patient 'AII-11' from family 'Family A': What is the patient's sex/gender?": "Based on the information contained within the document:\n\n*   Figure 1A shows the pedigree for Family A. Patient II-11 (the 'A' is implied by the figure label 'A') is represented by a square symbol. The figure legend states: \"square, male\".\n*   Page 3, under the heading \"Clinical Presentation\", states: \"Patient AII-11 was a 77-year-old man...\"\n\nTherefore, the patient's sex/gender is **Male**.",
    "Regarding patient 'AII-11' from family 'Family A': Is this patient the index case in the family?": "Based on the information in the document:\n\nNo, patient 'AII-11' from family 'Family A' is not the index case.\n\n*Supporting information from the document:*\nFigure 1A shows the pedigree for Family A. The caption for Figure 1 states that an arrow indicates the proband (index case). In the pedigree for Family A, the arrow points to individual AII-1, not AII-11. Individual AII-11 is marked with an asterisk, indicating they were analyzed for the mutation and/or haplotype.",
    "Regarding patient 'AII-11' from family 'Family A': How many affected individuals in the family have heterozygous mutations?": "Based *only* on the information contained within the provided document:\n\nPatient AII-11 from Family A was found to have the heterozygous missense p.D620N mutation (Page 3, Results section and Figure 1A legend indicating AII-11 was analyzed). Patient AII-11 is an affected individual (Figure 1A, closed symbol).\n\nFigure 1A shows that three other affected individuals in Family A were also analyzed for the mutation (individuals II-12, III-1, and III-2, indicated by asterisks and closed symbols). However, the document does not explicitly state the results of the analysis for these three individuals (i.e., whether they were confirmed to have the heterozygous mutation).\n\nTherefore, based *only* on the information provided, we can confirm that **one** affected individual (AII-11) in Family A has a heterozygous mutation.",
    "Regarding patient 'AII-11' from family 'Family A': How many affected individuals in the family have homozygous mutations?": "Based on the information provided in the document:\n\n1.  Family A is described as having autosomal dominant Parkinson's disease (ADPD) (Figure 1A legend and page 4, Discussion section referring to 3 ADPD families).\n2.  Patient AII-11 is the proband from Family A (Figure 1A, arrow points to AII-11).\n3.  The study detected the p.D620N mutation in patient AII-11 (Table 1).\n4.  The \"Results\" section (page 2, right column) states: \"We detected the **heterozygous** missense p.D620N mutation in 3 unrelated patients with ADPD...\".\n5.  The \"Discussion\" section (page 4, left column) states: \"We detected the **heterozygous** p.D620N mutation of VPS35 in 3 ADPD families...\". Family A is one of these families.\n\nThe document explicitly states that the mutation found in the ADPD families, including Family A (patient AII-11), was heterozygous. There is no information in the document indicating that any affected individual in Family A had a homozygous mutation.\n\nTherefore, based *only* on the information contained within the provided document, the number of affected individuals in Family A who have homozygous mutations is 0.",
    "Regarding patient 'AII-11' from family 'Family A': How many unaffected individuals in the family have heterozygous mutations?": "Based on the information contained within the provided document:\n\nFigure 1A shows the pedigree for Family A. An asterisk (*) indicates individuals analyzed for the p.D620N mutation and/or haplotype. Open symbols represent unaffected individuals.\n\nIn Family A, individual AII-12 is shown as unaffected (open circle) and analyzed (asterisk). However, the text does not state the result of this analysis for AII-12, specifically whether this unaffected individual carries the heterozygous mutation. The text focuses on the mutation carriers who are affected (AII-11, BIII-8, CII-3, D) and uses relatives primarily for haplotype analysis related to the proband (AII-11).\n\nTherefore, the document does not state how many unaffected individuals in Family A have heterozygous mutations.\n\nInformation not found",
    "Regarding patient 'AII-11' from family 'Family A': How many unaffected individuals in the family have homozygous mutations?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': How many affected individuals in the family have wildtype (no mutations)?": "Based on the information contained within the provided document:\n\nFigure 1A shows the pedigree for Family A. Closed symbols indicate affected individuals. Patient AII-11 is indicated by an arrow and has a closed symbol, meaning they are affected. The text on page 3 states, \"We detected the heterozygous missense p.D620N mutation in 3 unrelated patients with ADPD... Patient AII-11... carried at least the same single allele [mutation]\". This confirms patient AII-11 is affected *and* has the mutation, not the wildtype genotype.\n\nThe pedigree shows an autosomal dominant inheritance pattern for Parkinson's disease (PD) associated with the VPS35 p.D620N mutation in this family. In such cases, affected individuals are expected to carry the mutation. The document does not mention any affected individuals in Family A who tested negative for the mutation (i.e., had the wildtype genotype).\n\nTherefore, based only on the provided document, the number of affected individuals in Family A stated to have the wildtype genotype is 0.",
    "Regarding patient 'AII-11' from family 'Family A': How many unaffected individuals in the family have wildtype (no mutations)?": "Information not found.\n\n**Reasoning:**\n1.  Figure 1A shows the pedigree for Family A.\n2.  Unaffected individuals are represented by open symbols (circles for females, squares for males).\n3.  Individuals analyzed for the p.D620N mutation and/or haplotype are marked with an asterisk (*).\n4.  In Family A (Fig 1A), the unaffected individuals marked with an asterisk are AII-12 and AII-13.\n5.  While these two unaffected individuals were analyzed, the document text and figure legend do not state the *results* of the p.D620N mutation analysis for them. We cannot determine from the provided information whether they carry the mutation (asymptomatic carriers) or are wildtype (no mutation).\n6.  Therefore, the exact number of unaffected individuals confirmed to be wildtype is not specified in the document.",
    "Regarding patient 'AII-11' from family 'Family A': What is the clinical status of the patient?": "Based on the information in the provided document:\n\nPatient AII-11 from Family A is a male who carries the heterozygous VPS35 p.D620N mutation. His clinical status includes:\n\n*   **Diagnosis:** Parkinson's Disease (PD)\n*   **Age at Onset:** 62 years\n*   **Disease Duration (at time of reporting):** 15 years (reported as 77 years old)\n*   **Key Symptoms/Features:**\n    *   Developed right upper limb rest tremor at age 62.\n    *   Experienced resting tremor, bradykinesia, rigidity, gait disturbance, and postural instability.\n    *   Showed clinical response to levodopa, but experienced wearing off and levodopa-induced dyskinesia.\n    *   Had asymmetry at onset.\n    *   Developed orthostatic hypotension, incontinence, and experienced sleep benefit.\n    *   Did not have dystonia at onset, hyperreflexia, hallucination, other psychosis, or gaze palsy.\n    *   Developed progressive dysphagia requiring gastrostomy at age 75.\n    *   Developed cognitive dysfunction/dementia later in the disease course (after 15 years).\n*   **Imaging/Tests:**\n    *   Brain MRI was Within Normal Limits (WNL).\n    *   Cardiac MIBG scintigraphy (performed at age 76) showed specific H/M ratios and washout ratio (H/M ratio (E/L), 2.38/2.68; washout ratio, 4.15%). (The text also generally describes patients having normal cardiac MIBG scintigraphy).\n    *   Single-photon emission computed tomography of cerebral blood flow showed no reduction in blood flow in the basal ganglia.",
    "Regarding patient 'AII-11' from family 'Family A': What was the age at examination (AAE) for this patient?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': What was the age at onset (AAO) of symptoms for this patient?": "Based on the information in the document:\n\nThe age at onset (AAO) for patient AII-11 was 62 years. This information is found in Table 2 under the column 'AII-11' and the row 'Age at disease onset (y)', as well as in the text under the 'Clinical Presentation' section on page 3 (\"Patient AII-11 was a 77-year-old man who developed right upper limb rest tremor at age 62.\").",
    "Regarding patient 'AII-11' from family 'Family A': What is the disease duration for this patient?": "Based on the information contained within the provided document:\n\nThe disease duration for patient 'AII-11' is listed in Table 2 (\"Clinical features of patients with p.D620N mutation\") as **15 years**.",
    "Regarding patient 'AII-11' from family 'Family A': At what age was the patient diagnosed?": "Information not found.\n\nThe document provides the 'Age at disease onset (y)' for patient AII-11 as 62 (Table 2, page 3). However, it does not explicitly state the age at which the patient was diagnosed.",
    "Regarding patient 'AII-11' from family 'Family A': At what age did the patient die (if applicable)?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': Which human genome version was used for variant reporting?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What is the physical genomic location of the first mutation?": "Information not found.\n\nThe document identifies the mutation in patient AII-11 as p.D620N (also described as c.1858G>A) in the VPS35 gene. Table 1 and the text indicate this gene is on Chromosome 16 (based on markers like D16S#### and Chr16_##.###M), but the precise base pair coordinate for this specific mutation (c.1858G>A) is not provided within the document.",
    "Regarding patient 'AII-11' from family 'Family A': What is the reference allele for the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe mutation identified in patient AII-11 is the p.D620N mutation, which corresponds to the nucleotide change c.1858G>A (page 4, first column, second paragraph). In this notation, the letter before the \">\" symbol represents the reference allele.\n\nTherefore, the reference allele for this mutation is **G**.",
    "Regarding patient 'AII-11' from family 'Family A': What is the observed (mutant) allele for the first mutation?": "Based on Table 1, the allele listed for patient 'AII-11' for the 'VPS35 p.D620N' mutation is 'A'.",
    "Regarding patient 'AII-11' from family 'Family A': What is the genomic-level notation for the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe document states on page 2, under Genetic Analysis, that the p.D620N mutation corresponds to c.1858G>A using the RefSeq accession number NM_018206.4 for VPS35. On page 3, Figure 1 indicates patient AII-11 from Family A was analyzed and found to have the p.D620N mutation. Table 1 also explicitly lists \"VPS35 p.D620N\" for patient AII-11. Page 4 reiterates the substitution as \"VPS35 c.1858G>A (p.D620N)\". The text mentions this is the mutation detected in patient AII-11 and that no other variants in VPS35 exons were found in patients carrying this mutation.\n\nTherefore, the genomic-level notation (specifically, the coding DNA notation provided) for the first (and only mentioned) mutation in patient AII-11 is:\n\n**c.1858G>A**",
    "Regarding patient 'AII-11' from family 'Family A': What is the original alias or alternate notation for the first mutation as reported in the article?": "Based *only* on the information contained within the provided document:\n\nThe original alias or alternate notation for the first mutation (p.D620N) reported in the article for patient AII-11 is **c.1858G>A**.\n\n*   *(Page 2, Introduction): \"Mutation of c.1858G>A (p.D620N) was identified...\"*\n*   *(Page 2, Genetic Analysis): \"...genotyped for c.1858G>A (p.D620N) mutation...\"*\n*   *(Page 4, Discussion): \"...the substitution of VPS35 c.1858G>A (p.D620N)...\"*",
    "Regarding patient 'AII-11' from family 'Family A': What is the standardized alias for the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe standardized alias for the mutation found in patient 'AII-11' from family 'Family A' is **p.D620N**.\n\n*   Figure 1A shows the pedigree for Family A, identifying patient AII-11.\n*   Table 1 is titled \"Haplotype analysis of VPS35 p.D620N mutation carriers\" and includes data for patient AII-11. The row \"VPS35 p.D620N\" indicates patient AII-11 has the mutation allele (A).\n*   The text on page 3 states: \"One disease allele was detected by analyzing patient AII-11 and his relatives.\"\n*   The text on page 3, first paragraph, first column states: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" This confirms p.D620N is the only mutation detected in this patient within the study's scope, making it the first (and only) reported mutation for AII-11.",
    "Regarding patient 'AII-11' from family 'Family A': What is the genotype of the first mutation?": "Based *only* on the information provided in the document:\n\nThe document states in the Results section (page 2) \"We detected the heterozygous missense p.D620N mutation in 3 unrelated patients with ADPD...\". Figure 1A identifies patient AII-11 as the proband in Family A, one of the families studied. Table 1 lists patient AII-11 as a carrier of the \"VPS35 p.D620N\" mutation, showing the mutant allele 'A' (representing the c.1858G>A change). The text on page 3 also states \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\". Therefore, the genotype of the first (and only reported) mutation in patient AII-11 is **heterozygous p.D620N**.",
    "Regarding patient 'AII-11' from family 'Family A': What type of mutation is the first variant?": "Based on the information contained within the provided document:\n\nThe first variant identified in patient 'AII-11' from family 'Family A' is the p.D620N mutation. The document explicitly describes this mutation type as a **missense** mutation (see page 2, Results section: \"We detected the heterozygous missense p.D620N mutation...\").",
    "Regarding patient 'AII-11' from family 'Family A': What is the gnomAD v2.1.1 frequency for the first mutation?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What is the gnomAD v4.0.0 frequency for the first mutation?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': What is the physical genomic location of the second mutation?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What is the reference allele for the second mutation?": "Information not found.\n\nThe document identifies patient AII-11 from Family A as having the heterozygous p.D620N mutation in the VPS35 gene. It explicitly states on page 3: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, based solely on this document, there is no information provided about a *second* mutation for patient AII-11.",
    "Regarding patient 'AII-11' from family 'Family A': What is the observed (mutant) allele for the second mutation?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What is the genomic-level notation for the second mutation?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What is the original alias or alternate notation for the second mutation as reported in the article?": "Information not found.\n\nThe document states that patient AII-11 (from Family A) carries the heterozygous p.D620N mutation in the VPS35 gene. It explicitly mentions (page 3, paragraph under Figure 1): \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" This indicates that only one mutation (p.D620N, also referred to as c.1858G>A on page 4) was identified in this patient within the VPS35 gene according to the study. Therefore, information about a *second* mutation for patient AII-11 is not contained within the document.",
    "Regarding patient 'AII-11' from family 'Family A': What is the standardized alias for the second mutation?": "Information not found.\n\nBased on the document:\n*   Patient AII-11 from Family A was analyzed for the VPS35 p.D620N mutation (Figure 1A, Table 1).\n*   Table 1 shows patient AII-11 has the 'A' allele for the 'VPS35 p.D620N' mutation (indicating the presence of the c.1858G>A change leading to p.D620N).\n*   The text on page 3 states: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\"\n\nThe document identifies only one mutation (p.D620N) in patient AII-11 within the VPS35 gene and explicitly states no other variants were found in the exons. Therefore, information regarding a second mutation for this patient is not present in the document.",
    "Regarding patient 'AII-11' from family 'Family A': What is the genotype of the second mutation?": "Based on the information contained within the document:\n\nPatient AII-11 was found to have the heterozygous p.D620N mutation in the VPS35 gene. The document states: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" (Page 3, left column, paragraph 2).\n\nTherefore, based *only* on the information in the document, no second mutation was identified in patient AII-11.\n\nThe answer is: **Information not found**",
    "Regarding patient 'AII-11' from family 'Family A': What type of mutation is the second variant?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What is the gnomAD v2.1.1 frequency for the second mutation?": "Information not found.\n\nThe document identifies patient AII-11 from Family A as having the p.D620N mutation in the VPS35 gene (Table 1 and Figure 1). It also states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, according to this document, there is no second mutation reported for patient AII-11 in the VPS35 gene. Furthermore, the document does not contain any frequency data from the gnomAD database.",
    "Regarding patient 'AII-11' from family 'Family A': What is the gnomAD v4.0.0 frequency for the second mutation?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What is the physical genomic location of the third mutation?": "Information not found.\n\nThe document identifies patient AII-11 from Family A as having the heterozygous p.D620N mutation in the VPS35 gene (Table 1, Figure 1, page 3). It also states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (page 3). Therefore, the document does not mention a \"third mutation\" for this patient. Additionally, while the document provides regional haplotype markers (Table 1) placing the VPS35 gene on Chromosome 16 around 45 Mb, it does not state the specific physical base pair coordinate for the p.D620N mutation itself.",
    "Regarding patient 'AII-11' from family 'Family A': What is the reference allele for the third mutation?": "Information not found.\n\nThe document identifies patient AII-11 from Family A as carrying the heterozygous missense p.D620N mutation (c.1858G>A) in the VPS35 gene. It explicitly states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" and \"The remaining variants analyzed in this study were not identified in any patients.\" Therefore, the document does not provide information about a third mutation for this patient.",
    "Regarding patient 'AII-11' from family 'Family A': What is the observed (mutant) allele for the third mutation?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What is the genomic-level notation for the third mutation?": "Information not found.\n\nThe document states that patient AII-11 carries the heterozygous p.D620N mutation (also referred to as c.1858G>A) in the VPS35 gene. It explicitly mentions, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, according to this document, there is no second or third mutation identified in the VPS35 gene for this patient. Furthermore, while the cDNA-level notation (c.1858G>A) is provided for the single mutation found, the genomic-level notation is not specified in the text.",
    "Regarding patient 'AII-11' from family 'Family A': What is the standardized alias for the third mutation?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What is the genotype of the third mutation?": "Information not found.\n\nThe document states that patient AII-11 carries the p.D620N mutation in the VPS35 gene. It further specifies, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, based *only* on the information provided, only one mutation (p.D620N) is identified for patient AII-11 within the VPS35 gene, and no information about a \"third mutation\" is available.",
    "Regarding patient 'AII-11' from family 'Family A': What type of mutation is the third variant?": "Information not found.\n\nThe document states that patient AII-11 carries the p.D620N mutation. It also states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, based only on the information in the document, patient AII-11 does not have a third variant.",
    "Regarding patient 'AII-11' from family 'Family A': What is the gnomAD v2.1.1 frequency for the third mutation?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': What is the gnomAD v4.0.0 frequency for the third mutation?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have motor symptoms?": "Based on the information contained within the document:\n\nYes, patient 'AII-11' has motor symptoms.\n\nTable 2 on page 3 explicitly lists the following motor symptoms as present (+) for patient AII-11:\n*   Resting tremor\n*   Bradykinesia\n*   Rigidity\n*   Gait disturbance\n*   Postural instability\n\nAdditionally, the \"Clinical Presentation\" section on page 3 states: \"Patient AII-11 was a 77-year-old man who developed right upper limb rest tremor at age 62.\" Tremor is a motor symptom.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have parkinsonism symptoms?": "Based on the information contained within the provided document:\n\nYes, patient 'AII-11' from 'Family A' has parkinsonism symptoms.\n\nTable 2, which details the clinical features of patients with the p.D620N mutation, lists patient AII-11 and indicates the presence (+) of Resting tremor, Bradykinesia, Rigidity, Gait disturbance, and Postural instability. Furthermore, the \"Clinical Presentation\" section explicitly states, \"Patient AII-11 was a 77-year-old man who developed right upper limb rest tremor at age 62.\" These are all symptoms characteristic of parkinsonism.",
    "Regarding patient 'AII-11' from family 'Family A': What is the first motor assessment scale used?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': What is the score on the first motor assessment scale?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': What is the second motor assessment scale used (if any)?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What is the score on the second motor assessment scale?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have non-motor symptoms of parkinsonism?": "Yes, according to the document, patient 'AII-11' from 'Family A' has non-motor symptoms of parkinsonism.\n\nSpecifically, Table 2 lists the following for patient AII-11:\n*   Orthostatic hypotension: +\n*   Incontinence: +\n*   Sleep benefit: +\n\nAdditionally, the text under \"Clinical Presentation\" states that at age 75, patient AII-11 \"underwent gastrostomy for progressive dysphagia, then developed cognitive dysfunction without hallucination.\" Both dysphagia and cognitive dysfunction are considered non-motor symptoms.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have olfactory dysfunction?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': What non-motor symptom assessment scale was used?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have bradykinesia?": "Based on the information in Table 2, \"Clinical features of patients with p.D620N mutation\", patient AII-11 has a '+' symbol listed for the 'Bradykinesia' feature.\n\nTherefore, the patient AII-11 has bradykinesia.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have tremor?": "Based on the information in the provided document:\n\nYes, patient AII-11 has tremor. Table 2 on page 3 lists clinical features, and for patient AII-11, the row for \"Resting tremor\" shows a '+', indicating presence. The text under \"Clinical Presentation\" on page 3 also states, \"Patient AII-11 was a 77-year-old man who developed right upper limb rest tremor at age 62.\"",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have resting tremor?": "Based on the information in the document:\n\nYes, patient 'AII-11' has resting tremor.\n\n*   Table 2, under the column for patient 'AII-11', shows a '+' symbol next to the row labeled 'Resting tremor'.\n*   The 'Clinical Presentation' section on page 3 states: \"Patient AII-11 was a 77-year-old man who developed right upper limb rest tremor at age 62.\"",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have action tremor?": "Information not found.\n\nThe document states in Table 2 and the Clinical Presentation section on page 3 that patient AII-11 has 'Resting tremor' and developed \"right upper limb rest tremor\", but it does not contain information about whether this patient specifically has action tremor.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have postural tremor?": "Information not found.\n\nThe document provides clinical features for patient AII-11 in Table 2 and the accompanying text. Table 2 indicates the presence (+) of 'Resting tremor' and 'Postural instability' for patient AII-11. The text further specifies that patient AII-11 \"developed right upper limb rest tremor\". However, the document does not explicitly state whether patient AII-11 has 'postural tremor'.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have dystonic tremor?": "Based on the information in the document:\n\nTable 2 on page 3 lists the clinical features of patients with the p.D620N mutation. For patient AII-11, the table lists:\n*   Resting tremor: +\n*   Dystonia at onset: +\n\nThe table does not explicitly state whether patient AII-11 has \"dystonic tremor\". It lists tremor and dystonia as separate features.\n\nTherefore, the answer is:\nInformation not found",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have rigidity?": "Based on the information in Table 2, under the 'Patient ID' column for 'AII-11', the row labelled 'Rigidity' shows a '+' sign.\n\nTherefore, the patient AII-11 has rigidity.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have postural instability?": "Based on the information in Table 2, 'Clinical features of patients with p.D620N mutation', patient AII-11 has a '+' listed for 'Postural instability'.\n\nTherefore, the answer is: Yes, the patient has postural instability.",
    "Regarding patient 'AII-11' from family 'Family A': How does the patient respond to levodopa treatment?": "Based on the information in the provided document, patient AII-11 showed a clinical response to levodopa. The patient also experienced wearing-off and levodopa-induced dyskinesia.",
    "Regarding patient 'AII-11' from family 'Family A': How is the levodopa response quantified?": "Information not found.\n\n*Rationale:* Table 2 indicates a '+' under 'Clinical response to levodopa' for patient AII-11, signifying a positive response. However, the table and the accompanying text do not specify *how* this response was quantified (e.g., using a specific scale, percentage improvement, subjective assessment criteria).",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have dyskinesia?": "Based on the information in the document:\n\nYes, patient AII-11 has levodopa-induced dyskinesia. Table 2 on page 3 lists clinical features for patients with the p.D620N mutation. In the row for \"Levodopa-induced dyskinesia\" and the column for patient \"AII-11\", there is a \"+\" sign, indicating the presence of this symptom.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have dystonia?": "Based on the information in Table 2 (\"Clinical features of patients with p.D620N mutation\") on page 3, patient AII-11 has a \"+\" sign in the row for \"Dystonia at onset\".\n\nTherefore, yes, patient AII-11 has dystonia (at onset).",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have hyperreflexia?": "Based on the information contained within the provided document:\n\nNo, patient 'AII-11' does not have hyperreflexia. Table 2 on page 3 lists clinical features for patients with the p.D620N mutation. In the row for 'Hyperreflexia', the column for patient 'AII-11' shows a minus sign ('-'), indicating the absence of this feature.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have diurnal fluctuations?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have sleep benefit?": "Based on the information in Table 2, patient 'AII-11' has a '+' listed in the row for 'Sleep benefit'. Therefore, the patient does have sleep benefit.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have motor fluctuations?": "Based on the information in Table 2, under the 'Patient ID' column 'AII-11', the row 'Wearing off' shows a '+' symbol, and the row 'Levodopa-induced dyskinesia' also shows a '+' symbol. Both wearing off and levodopa-induced dyskinesia are types of motor fluctuations.\n\nTherefore, the patient AII-11 does have motor fluctuations.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have depression?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What depression assessment scale was used and what was the score?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have anxiety?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What anxiety assessment scale was used and what was the score?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have psychotic symptoms?": "Based on the information in Table 2 (\"Clinical features of patients with p.D620N mutation\") and the text description on page 3 (\"Clinical Presentation\"):\n\n*   Table 2 indicates 'âˆ’' (negative) for both 'Hallucination' and 'Other psychosis' for patient AII-11.\n*   The text on page 3 states that patient AII-11 \"developed cognitive dysfunction without hallucination.\"\n\nTherefore, the patient AII-11 does not have psychotic symptoms.",
    "Regarding patient 'AII-11' from family 'Family A': What psychotic symptoms assessment scale was used and what was the score?": "Information not found.\n\nThe document provides clinical features for patient AII-11 in Table 2, including entries for 'Hallucination' and 'Other psychosis', both marked as absent ('-'). However, it does not specify the name of any assessment scale used for psychotic symptoms nor does it provide a score from such a scale.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have sleep disorders?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have cognitive decline?": "Based on the information contained within the provided document:\n\nYes, the patient AII-11 developed cognitive dysfunction. The 'Clinical Presentation' section on page 3 states: \"At age 75, he underwent gastrostomy for progressive dysphagia, then developed cognitive dysfunction without hallucination.\"",
    "Regarding patient 'AII-11' from family 'Family A': What subdomains of cognitive function are affected (if any)?": "Based *only* on the information contained within the provided document:\n\nThe document states on page 3, under 'Clinical Presentation', that patient AII-11 \"developed cognitive dysfunction without hallucination\" at age 75. Table 2 on page 3 also indicates \"+\" for 'Dementia' for patient AII-11.\n\nHowever, the document does not specify which *subdomains* of cognitive function (e.g., memory, executive function, attention, language, visuospatial skills) were affected by this cognitive dysfunction or dementia.\n\nTherefore, the answer is: Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': What cognitive assessment scale was used and what was the score?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have autonomic symptoms?": "Yes, patient 'AII-11' has autonomic symptoms.\n\nTable 2 (\"Clinical features of patients with p.D620N mutation\") lists the following for patient AII-11:\n*   Orthostatic hypotension: +\n*   Incontinence: +\n\nBoth orthostatic hypotension and incontinence are types of autonomic symptoms.",
    "Regarding patient 'AII-11' from family 'Family A': Does the patient have atypical parkinsonian features?": "Based on the information contained within the provided document:\n\nThe document describes the clinical features of patient AII-11 in Table 2 and the accompanying text. The text on page 4 states: \"The clinical symptoms of our patients with VPS35 mutation closely resembled the idiopathic PD form, with tremor-dominant dopa-responsive parkinsonism.\" Furthermore, the conclusion on page 5 refers to \"patients with PD, especially ADPD or tremor-predominant PD\". The features listed for AII-11 in Table 2 (resting tremor, bradykinesia, rigidity, gait disturbance, postural instability, clinical response to levodopa) are characteristic of typical Parkinson's disease. The document does not state that patient AII-11 has atypical parkinsonian features; rather, it compares the symptoms to typical idiopathic PD.\n\nTherefore, the answer is **No**, the patient does not have atypical parkinsonian features according to the descriptions provided in the document.",
    "Regarding patient 'AII-11' from family 'Family A': What is the pathogenicity classification for the first mutation?": "Based on the information contained within the provided document:\n\nThe document states that patient AII-11 from Family A carries the p.D620N mutation in the VPS35 gene (Table 1, Figure 1, page 3). The text mentions this specific mutation multiple times in the context of pathogenicity:\n\n*   Page 2: \"One missense mutation has been reported to be pathogenic for PD.[3,4] Mutation of c.1858G>A (p.D620N)...\"\n*   Page 3: \"The p.D620N has been reported previously as a pathogenic mutation for familial PD.[3,4,6]\"\n*   Page 4: \"VPS35 has been reported as the pathogenic gene for ADPD, and only 1 mutation, p.D620N, has been reported...\"\n\nSince p.D620N is the only mutation identified for patient AII-11 in this document, it is considered the \"first\" mutation in this context. The document explicitly refers to this mutation as having been previously reported as pathogenic.\n\nTherefore, the pathogenicity classification for the first (and only mentioned) mutation for patient AII-11 is **pathogenic**.",
    "Regarding patient 'AII-11' from family 'Family A': What is the pathogenicity classification for the second mutation?": "Information not found.\n\nThe document states that patient AII-11 carries the heterozygous p.D620N mutation. It also explicitly mentions, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, according to this document, no second mutation was identified in patient AII-11.",
    "Regarding patient 'AII-11' from family 'Family A': What is the pathogenicity classification for the third mutation?": "Information not found.\n\nThe document states that patient AII-11 carries the heterozygous p.D620N mutation in the VPS35 gene. It further states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, based only on the provided text, there is no mention of a third mutation for patient AII-11.",
    "Regarding patient 'AII-11' from family 'Family A': What is the CADD score for the first mutation?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What is the CADD score for the second mutation?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': What is the CADD score for the third mutation?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What functional evidence supports the pathogenicity of the first mutation?": "Information not found.",
    "Regarding patient 'AII-11' from family 'Family A': What functional evidence supports the pathogenicity of the second mutation?": "Information not found.\n\nBased on the document, patient AII-11 was identified as carrying the heterozygous p.D620N mutation in the VPS35 gene (Page 3, paragraph 3 and Table 1). The text explicitly states: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (Page 3, paragraph 3). Therefore, the document does not report a second mutation for patient AII-11, nor does it provide functional evidence for one.",
    "Regarding patient 'AII-11' from family 'Family A': What functional evidence supports the pathogenicity of the third mutation?": "Information not found",
    "Regarding patient 'AII-11' from family 'Family A': What is the entry identifier for this data?": "Based only on the information contained within the provided document:\n\nThe entry identifier used for this patient in the tables and text is **AII-11**. This is listed under the 'Patient ID' heading in Table 1 and Table 2.",
    "Regarding patient 'AII-11' from family 'Family A': Any additional general comments about this data?": "Based *only* on the information contained within the provided document:\n\nPatient AII-11 from Family A is a male proband carrying the heterozygous p.D620N mutation in the VPS35 gene.\n\n**Clinical Features (Table 2 & Page 3 Text):**\n*   Age at disease onset: 62 years.\n*   Disease duration at time of report: 15 years (was 77 years old at time of report).\n*   Symptoms: Resting tremor (initial symptom, right upper limb), bradykinesia, rigidity, gait disturbance, postural instability.\n*   Response to levodopa: Positive, but experienced wearing off and levodopa-induced dyskinesia.\n*   Other motor/non-motor symptoms: Asymmetry at onset, orthostatic hypotension, incontinence, urinary urgency, sleep benefit. Developed progressive dysphagia requiring gastrostomy at age 75, and later developed cognitive dysfunction without hallucination.\n*   Investigations: Brain MRI was within normal limits (WNL). Cardiac MIBG scintigraphy performed at age 76 showed an H/M ratio (E/L) of 2.38/2.68 and a washout ratio of 4.15%. Single-photon emission computed tomography (SPECT) of cerebral blood flow showed no reduction in the basal ganglia.\n\n**Family History (Figure 1A & Page 3 Text):**\n*   Diagnosed with autosomal dominant Parkinson's disease (ADPD).\n*   His father and 4 of 8 siblings were diagnosed with PD, presenting with levodopa-responsive typical parkinsonism (upper limb tremor and small-step gait).\n*   His nephew and niece were also diagnosed with PD; the nephew developed parkinsonism in his early fifties.\n*   Born to nonconsanguineous parents.\n\n**Genetic/Haplotype Data (Table 1 & Page 3/4 Text):**\n*   Carries the heterozygous p.D620N mutation; no other variants were found in the exons of VPS35.\n*   Haplotype analysis was performed, and the disease allele was determined. The chromosomal phase was determined for this patient.\n*   Patient AII-11 and patient BIII-8 (from Family B) carried at least the same single allele for the tested microsatellites flanking VPS35, suggesting a possible shared founder (though phase for BIII-8 was undetermined).\n*   The haplotype for the disease allele in AII-11 was different from that of patients CII-3 and D at marker D16S3105.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the study design of this article?": "Based on the information in the document:\n\nThe study screened Japanese patients with autosomal dominant Parkinson's disease (ADPD), patients with sporadic Parkinson's disease (SPD), and control subjects for mutations in the VPS35 gene, particularly the p.D620N mutation. The methods used included direct sequencing, high-resolution melting (HRM) analysis, and haplotype analysis. The study aimed to determine the incidence (frequency) of these mutations in the specified Japanese populations and to describe the clinical features and genetic background (haplotypes) of the patients identified with the mutation, including patient BIII-8.\n\nTherefore, the study design is a **genetic screening and frequency study**, incorporating **case-control** elements (comparing mutation frequency in patients vs. controls) and **clinical/haplotype analysis** of mutation carriers.",
    "Regarding patient 'BIII-8' from family 'Family B': What genetic methods were used in this study?": "Based on the information contained within the provided document:\n\nThe study used several genetic methods on the patient cohort which included patient BIII-8. These methods are described in the \"Genetic Analysis\" section (page 2) and mentioned elsewhere:\n\n1.  **PCR direct sequencing:** Used to examine 7 specific variants of VPS35 in patients with Autosomal Dominant Parkinson's Disease (ADPD) and Sporadic Parkinson's Disease (SPD).\n2.  **High-resolution melting (HRM) analysis:** Used as an additional method to genotype the p.D620N mutation in SPD patients and controls, and potentially also used for the initial screening of ADPD patients like BIII-8 (the abstract mentions screening variants \"by direct sequencing or high-resolution melting (HRM) analysis\").\n3.  **Sequencing of all VPS35 exons:** Performed for patients found to have the p.D620N mutation (which included BIII-8, as indicated by their inclusion in Tables 1 and 2) to check for other variants.\n4.  **Haplotype analysis:** Performed on the VPS35 flanking region for patients carrying the p.D620N mutation, including patient BIII-8 (results shown in Table 1).",
    "Regarding patient 'BIII-8' from family 'Family B': What is the lower age limit for study inclusion (if any)?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the upper age limit for study inclusion (if any)?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': Are there any additional comments about the study methodology?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the abbreviation of the disease or condition diagnosed in this patient?": "Based *only* on the information contained within the provided document:\n\nThe text on page 3, under the heading 'Clinical Presentation', describes relatives of patient BIII-8: \"The mother and aunts of patient BIII-8 [...] also developed PD (Fig. 1B, C).\" Figure 1B shows patient BIII-8 as an affected member (closed symbol) within Family B. Table 2 lists clinical features for patient BIII-8 consistent with the disease being studied. The title and abstract identify the disease studied in relation to the VPS35 mutation as Parkinson's Disease, abbreviated as PD.\n\nTherefore, the abbreviation of the disease diagnosed in patient BIII-8's family members (and strongly implied for BIII-8, who is shown as affected and included in the clinical analysis of mutation carriers) is **PD**.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the key clinical information about this patient?": "Based *only* on the information contained within the provided document:\n\nThe key clinical information about patient BIII-8 from Family B is:\n\n*   **Age at disease onset:** 55 years.\n*   **Disease duration (at time of study):** 2 years.\n*   **Symptoms/Signs:**\n    *   Presence of resting tremor, bradykinesia, rigidity, asymmetry at onset, and sleep benefit.\n    *   Absence of gait disturbance, postural instability, wearing off, orthostatic hypotension, incontinence, urinary urgency, levodopa-induced dyskinesia, dystonia at onset, hyperreflexia, hallucination, other psychosis, dementia, and gaze palsy.\n*   **Treatment Response:** Showed a positive clinical response to levodopa.\n*   **Imaging:** Brain MRI was within normal limits (WNL). Cardiac MIBG scintigraphy was not performed.\n*   **Initial Symptom Mentioned:** Developed upper limb rest tremor at age 55.\n*   **Genetic Mutation:** Carries the VPS35 p.D620N mutation.\n*   **Family History:** Mother and aunts also affected with PD (Figure 1B and text).",
    "Regarding patient 'BIII-8' from family 'Family B': What is the patient's ethnicity?": "Based on the information contained within the provided document:\n\nThe study subjects are explicitly identified as \"Japanese patients\" (Page 2, Subjects section: \"The study subjects were 308 Japanese patients...\"). Patient BIII-8 is a member of Family B, one of the families included in this study cohort (Figure 1, Table 1, Table 2). The discussion also refers to \"Japanese ADPD families A and B\" (Page 4, left column).\n\nTherefore, the patient's ethnicity is **Japanese**.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the patient's country of origin?": "Based on the information contained within the provided document:\n\nThe study focuses on **Japanese** patients (Title, Abstract, Subjects section on page 2). Patient BIII-8 is part of Family B, one of the families included in the study (Figure 1, Page 3). Haplotype analysis discussed on page 3 explicitly refers to the \"Japanese patients\" including AII-11 and BIII-8.\n\nTherefore, the patient's country of origin is **Japan**.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the patient's sex/gender?": "Based on Figure 1B in the provided document, patient 'BIII-8' is represented by a square symbol. According to the figure caption, a square symbol represents a male.\n\nTherefore, the patient's sex/gender is **male**.",
    "Regarding patient 'BIII-8' from family 'Family B': Is this patient the index case in the family?": "Based on the information in the document:\n\nFigure 1 on page 3 shows the pedigrees for families with the VPS35 p.D620N mutation. The caption for Figure 1 states that the arrow indicates the proband (index case). Looking at the pedigree for Family B, patient BIII-8 is marked with an asterisk (indicating analysis), but there is no arrow pointing to this individual.\n\nTherefore, based only on the provided document, patient BIII-8 is not the index case in Family B.",
    "Regarding patient 'BIII-8' from family 'Family B': How many affected individuals in the family have heterozygous mutations?": "Based *only* on the information contained within the provided document:\n\nFigure 1B shows the pedigree for Family B. Affected individuals are indicated by filled symbols. The asterisk (*) indicates individuals analyzed for the p.D620N mutation and/or haplotype. In Family B, only individual III-8 (patient BIII-8) is marked with an asterisk among the affected individuals.\n\nTable 1 provides haplotype analysis for patient BIII-8. Under the row \"VPS35 p.D620N\", the genotype for BIII-8 is listed as \"A/G\". This indicates a heterozygous state for the p.D620N mutation (c.1858G>A).\n\nThe document does not provide mutation analysis results for the other affected individuals in Family B (II-1, II-3, II-5). Therefore, based only on the provided text and figures, only one affected individual in Family B (BIII-8) is confirmed to have a heterozygous mutation.\n\nAnswer: 1",
    "Regarding patient 'BIII-8' from family 'Family B': How many affected individuals in the family have homozygous mutations?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': How many unaffected individuals in the family have heterozygous mutations?": "Information not found.\n\nThe document identifies patient BIII-8 as affected and carrying the heterozygous p.D620N mutation (Fig. 1, Table 1, Table 2). Figure 1 indicates individuals analyzed for the mutation with an asterisk (*). In Family B (Fig. 1B), only the affected individual BIII-8 is marked with an asterisk. The document does not provide information on whether any unaffected individuals in Family B were tested for the mutation or what their results were. The text on page 4 also mentions that \"detailed genetic analyses of other family members are needed in future studies\" to determine the chromosomal phase for families B and C, implying these analyses were not performed for this study.",
    "Regarding patient 'BIII-8' from family 'Family B': How many unaffected individuals in the family have homozygous mutations?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': How many affected individuals in the family have wildtype (no mutations)?": "Information not found.\n\n**Reasoning:**\n\n1.  Figure 1B shows the pedigree for Family B. Affected individuals are marked with closed symbols (II-1, II-2, II-4, II-5, and III-8).\n2.  Patient BIII-8 is the proband (indicated by the arrow) and is affected.\n3.  The asterisk (*) next to BIII-8 indicates this individual was analyzed for the p.D620N mutation and/or haplotype (according to the Figure 1 legend).\n4.  Table 1 confirms patient BIII-8 has the heterozygous p.D620N mutation (genotype A/G). Therefore, BIII-8 is affected and *not* wildtype.\n5.  The document does not state whether the other affected individuals in Family B (II-1, II-2, II-4, II-5) were genetically analyzed for the mutation. The absence of an asterisk next to them in Figure 1 suggests they were not analyzed *in this study*.\n6.  Therefore, based *only* on the provided document, we know one affected individual (BIII-8) has the mutation, but the mutation status (mutated or wildtype) of the other four affected individuals is not specified. We cannot determine if any affected individuals are wildtype.",
    "Regarding patient 'BIII-8' from family 'Family B': How many unaffected individuals in the family have wildtype (no mutations)?": "Information not found.\n\nThe document provides the pedigree for Family B (Figure 1B), which includes patient BIII-8 (proband, affected). The pedigree shows several unaffected individuals (open symbols). However, the legend for Figure 1 indicates that only individuals marked with an asterisk (*) were analyzed for the p.D620N mutation and/or haplotype. In Family B, only individuals II-7 (affected) and BIII-8 (affected) are marked with an asterisk. The text confirms analysis was performed on BIII-8 but does not provide information on the genetic status (wildtype or mutation carrier) of the unaffected members of Family B.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the clinical status of the patient?": "Based on the information in the document:\n\nPatient BIII-8 from Family B is affected with Parkinson's Disease (PD), carrying the heterozygous p.D620N mutation in the VPS35 gene.\n\nThe clinical features reported for patient BIII-8 are:\n*   Age at disease onset: 55 years\n*   Disease duration at time of report: 2 years\n*   Presence (+) of: Resting tremor, Bradykinesia, Rigidity, Clinical response to levodopa, Asymmetry at onset, Sleep benefit.\n*   Absence (-) of: Gait disturbance, Postural instability, Wearing off, Orthostatic hypotension, Incontinence, Urinary urgency, Levodopa-induced dyskinesia, Dystonia at onset, Hyperreflexia, Hallucination, Other psychosis, Dementia, Gaze palsy.\n*   Brain MRI: Within normal limits (WNL).\n*   Cardiac MIBG scintigraphy: Not performed.\n\nThe text also mentions that patient BIII-8 developed upper limb rest tremor at age 55.",
    "Regarding patient 'BIII-8' from family 'Family B': What was the age at examination (AAE) for this patient?": "Information not found.\n\nWhile Table 2 on page 3 provides the 'Age at disease onset (y)' (55) and 'Disease duration (y)' (2) for patient BIII-8, it does not explicitly state the 'Age at Examination (AAE)'.",
    "Regarding patient 'BIII-8' from family 'Family B': What was the age at onset (AAO) of symptoms for this patient?": "Based on the information in Table 2, 'Clinical features of patients with p.D620N mutation', the Age at disease onset (y) for patient 'BIII-8' is 55.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the disease duration for this patient?": "Based on the information in Table 2 ('Clinical features of patients with p.D620N mutation'), the disease duration for patient 'BIII-8' is **2 years**.",
    "Regarding patient 'BIII-8' from family 'Family B': At what age was the patient diagnosed?": "Based *only* on the information contained within the provided document:\n\nThe document provides the \"Age at disease onset (y)\" for patient BIII-8 as 55 (Table 2). However, it does not explicitly state the \"Age at diagnosis\" for this patient.\n\nTherefore, the answer is: Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': At what age did the patient die (if applicable)?": "Based *only* on the information contained within the provided document:\n\nThe document provides information about patient BIII-8 from Family B, including their status as an affected male (Fig. 1B), their age at disease onset (55 years), and their disease duration at the time of reporting (2 years) (Table 2). The pedigree symbol for BIII-8 in Figure 1B is not marked with a forward slash, which the caption indicates is used for deceased individuals. There is no mention of patient BIII-8's death or age at death in the text or tables.\n\nTherefore, the answer is:\nInformation not found",
    "Regarding patient 'BIII-8' from family 'Family B': Which human genome version was used for variant reporting?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the physical genomic location of the first mutation?": "Information not found.\n\nThe document identifies that patient BIII-8 from Family B carries the heterozygous p.D620N mutation (also described as c.1858G>A) in exon 15 of the VPS35 gene. Table 1 provides haplotype data with markers on Chromosome 16 (e.g., Chr16_45.333M), indicating the gene's chromosomal region. However, the precise physical genomic coordinate (i.e., the specific base pair number on Chromosome 16) for the c.1858G>A mutation is not stated within the provided text.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the reference allele for the first mutation?": "Based on the information in the document:\n\n1.  Patient 'BIII-8' from 'Family B' is listed as a carrier of the p.D620N mutation (Table 1, Figure 1B).\n2.  Table 1 shows the genotype for patient BIII-8 at the 'VPS35 p.D620N' locus as 'A/G'.\n3.  Page 2, under 'Genetic Analysis', specifies that the p.D620N mutation corresponds to the nucleotide change c.1858G>A.\n4.  In the standard notation 'c.1858G>A', the first letter ('G') represents the reference allele, and the second letter ('A') represents the mutated allele.\n\nTherefore, the reference allele for the p.D620N mutation (c.1858G>A) is G.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the observed (mutant) allele for the first mutation?": "Based on the information in the document:\n\n*   Patient BIII-8 is listed in Table 1, \"Haplotype analysis of VPS35 p.D620N mutation carriers\".\n*   In Table 1, the row \"VPS35 p.D620N\" shows the genotype for patient BIII-8 as \"A/G\".\n*   Page 2, under \"Genetic Analysis\", describes the p.D620N mutation as c.1858G>A. This indicates that 'G' is the reference (wild-type) allele and 'A' is the mutant allele.\n*   Therefore, the observed mutant allele for patient BIII-8 is 'A'.\n\nThe observed (mutant) allele for the first mutation (p.D620N) in patient BIII-8 is A.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the genomic-level notation for the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe genomic-level notation for the mutation found in patient 'BIII-8' from 'Family B' is **c.1858G>A**.\n\n*   *Supporting evidence:*\n    *   Page 2, Results section: \"We detected the heterozygous missense p.D620N mutation in 3 unrelated patients with ADPD...\" Figure 1 identifies Family B as ADPD and patient BIII-8 as analyzed.\n    *   Page 2, left column, paragraph 4: \"Mutation of c.1858G>A (p.D620N) was identified...\"\n    *   Page 3, Table 1: Lists patient BIII-8 and indicates the VPS35 mutation as p.D620N with genotype A/G (confirming heterozygosity for the mutation, which corresponds to c.1858G>A).\n    *   Page 3, left column, paragraph 2: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" This indicates c.1858G>A (p.D620N) is the mutation identified in this patient in the VPS35 gene within this study.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the original alias or alternate notation for the first mutation as reported in the article?": "Based *only* on the information contained within the provided document:\n\nThe document identifies patient BIII-8 from Family B as having the p.D620N mutation (Table 1, Table 2, Fig 1). The article provides an alternate notation for this specific mutation. On page 2, in the third paragraph discussing previously reported mutations, it states: \"Mutation of c.1858G>A (p.D620N) was identified...\". This notation is repeated elsewhere, explicitly linking the protein change (p.D620N) to the DNA change (c.1858G>A).\n\nTherefore, the original alias or alternate notation for the mutation reported in patient BIII-8 is **c.1858G>A**.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the standardized alias for the first mutation?": "Based on the information contained within the provided document:\n\nThe standardized alias for the first (and only mentioned) mutation in patient 'BIII-8' from family 'Family B' is **p.D620N**.\n\n*   Table 1 shows the genotype for patient BIII-8 at the locus \"VPS35 p.D620N\" as \"A/G\", indicating the presence of this mutation.\n*   The text on page 3 states: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" This confirms p.D620N is the only relevant mutation found in this patient within the scope of the study described.\n*   The document consistently uses \"p.D620N\" as the alias for this specific missense mutation.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the genotype of the first mutation?": "Based on the information in the document:\n\nThe genotype of the first (and only reported) mutation for patient 'BIII-8' from 'Family B' is **A/G** for the VPS35 p.D620N mutation (as shown in Table 1).",
    "Regarding patient 'BIII-8' from family 'Family B': What type of mutation is the first variant?": "Based *only* on the information contained within the provided document:\n\nThe document states on page 2, under the Results section: \"We detected the heterozygous **missense** p.D620N mutation in 3 unrelated patients with ADPD...\". Patient BIII-8 is listed in Table 1 and Table 2 as a carrier of the p.D620N mutation and belongs to Family B (Figure 1). The Abstract also refers to screening for \"nonsynonymous missense variants of VPS35, including p.D620N\". Therefore, the type of the p.D620N mutation found in patient BIII-8 is a missense mutation.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the gnomAD v2.1.1 frequency for the first mutation?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the gnomAD v4.0.0 frequency for the first mutation?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the physical genomic location of the second mutation?": "Information not found.\n\nThe document identifies patient BIII-8 as having the heterozygous p.D620N mutation in the VPS35 gene (Table 1, Page 3). It also states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (Page 3, left column, first paragraph). The document does not mention a second mutation being found in patient BIII-8, nor its location.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the reference allele for the second mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the observed (mutant) allele for the second mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the genomic-level notation for the second mutation?": "Information not found\n\nBased on the document, patient BIII-8 from Family B was found to carry the heterozygous p.D620N mutation in the VPS35 gene (Table 1). The text on page 3 also states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, according to this document, only one mutation was identified in this patient, and information about a second mutation is not provided.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the original alias or alternate notation for the second mutation as reported in the article?": "Based on the information contained within the provided document:\n\nThe document states on page 3, under the \"Results\" section: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\"\n\nPatient BIII-8 from Family B is identified as carrying the p.D620N mutation (Table 1, Figure 1). Since the document explicitly states that no other variants were found in these patients, there is no information about a second mutation for patient BIII-8 reported in the article.\n\nTherefore, the answer is:\nInformation not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the standardized alias for the second mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the genotype of the second mutation?": "Based *only* on the information contained within the provided document:\n\nPatient BIII-8 was found to have the heterozygous missense p.D620N mutation (Table 1 shows the genotype at this position as A/G). The document states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" (Page 3, left column).\n\nTherefore, according to the document, no second mutation was found in the exons of VPS35 for patient BIII-8. The information regarding the genotype of a *second* mutation is not found.\n\nInformation not found",
    "Regarding patient 'BIII-8' from family 'Family B': What type of mutation is the second variant?": "Information not found.\n\nThe document states that patient BIII-8 carries the heterozygous p.D620N mutation in the VPS35 gene (Table 1). It also mentions (page 3, left column, first paragraph under \"Results\") that \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, the document does not identify a second variant for patient BIII-8.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the gnomAD v2.1.1 frequency for the second mutation?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the gnomAD v4.0.0 frequency for the second mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the physical genomic location of the third mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the reference allele for the third mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the observed (mutant) allele for the third mutation?": "Information not found.\n\nThe document identifies patient BIII-8 from Family B as having the heterozygous p.D620N mutation (genotype A/G) in the VPS35 gene (Table 1 and surrounding text). It explicitly states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (Page 3, paragraph under Figure 1). Therefore, based only on the provided document, there is no information about a *third* mutation for this patient; only the p.D620N mutation is reported.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the genomic-level notation for the third mutation?": "Information not found.\n\nThe document identifies patient BIII-8 from Family B as carrying the heterozygous p.D620N mutation in the VPS35 gene (Table 1, Figure 1B). The corresponding genomic-level notation mentioned in the text (page 2) is c.1858G>A. However, the text explicitly states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (page 3). Therefore, the document only reports this single mutation for patient BIII-8 and does not contain information about a third mutation.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the standardized alias for the third mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the genotype of the third mutation?": "Based *only* on the information contained within the provided document:\n\nThe document identifies patient BIII-8 as carrying the heterozygous p.D620N mutation in the VPS35 gene (Table 1 shows genotype A/G). It also explicitly states on page 3: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\"\n\nTherefore, according to this document, only one mutation was found in patient BIII-8. Information regarding a *third* mutation for patient BIII-8 is not found.\n\nInformation not found",
    "Regarding patient 'BIII-8' from family 'Family B': What type of mutation is the third variant?": "Information not found.\n\nRationale: The document identifies patient BIII-8 from Family B (Figure 1, page 3). Table 1 (page 3) and the associated text indicate that patient BIII-8 carries the p.D620N mutation. The \"Results\" section (page 3) states, \"We detected the heterozygous missense p.D620N mutation...\". It also states, \"The remaining variants analyzed in this study were not identified in any patients.\" While the study screened for 7 specific variants (listed on page 2), only the p.D620N variant was reported as being found in patient BIII-8. The document does not mention a \"third variant\" being found in this specific patient.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the gnomAD v2.1.1 frequency for the third mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the gnomAD v4.0.0 frequency for the third mutation?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have motor symptoms?": "Based *only* on the information contained within the provided document:\n\nYes, patient BIII-8 from Family B has motor symptoms.\n\n*   Page 3, under the \"Clinical Presentation\" section, states: \"Patients BIII-8 and CII-3 both developed upper limb rest tremor at ages 34 and 55, respectively.\" Tremor is a motor symptom.\n*   Additionally, Table 2 on page 3 lists clinical features for patient BIII-8, including positive (+) signs for Resting tremor, Bradykinesia, Rigidity, Gait disturbance, and Postural instability, all of which are motor symptoms characteristic of Parkinson's disease.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have parkinsonism symptoms?": "Yes, patient BIII-8 has parkinsonism symptoms.\n\nTable 2 (\"Clinical features of patients with p.D620N mutation\") lists patient BIII-8 and indicates the presence (+) of the following symptoms:\n*   Resting tremor\n*   Bradykinesia\n*   Rigidity\n*   Gait disturbance\n*   Postural instability\n*   Clinical response to levodopa\n*   Asymmetry at onset\n\nThe text under \"Clinical Presentation\" also states: \"Patients BIII-8 and CII-3 both developed upper limb rest tremor at ages 34 and 55, respectively.\"",
    "Regarding patient 'BIII-8' from family 'Family B': What is the first motor assessment scale used?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the score on the first motor assessment scale?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the second motor assessment scale used (if any)?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the score on the second motor assessment scale?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have non-motor symptoms of parkinsonism?": "Based on the information in Table 2 (\"Clinical features of patients with p.D620N mutation\") on page 3:\n\nPatient BIII-8 is listed as having the following statuses for potential non-motor symptoms:\n*   Orthostatic hypotension: - (absent)\n*   Incontinence: - (absent)\n*   Urinary urgency: - (absent)\n*   Sleep benefit: + (present)\n*   Hyperreflexia: - (absent)\n*   Hallucination: - (absent)\n*   Other psychosis: - (absent)\n*   Dementia: - (absent)\n*   Gaze palsy: - (absent)\n\nTherefore, according to the table, patient BIII-8 does not have orthostatic hypotension, incontinence, urinary urgency, hyperreflexia, hallucination, other psychosis, dementia, or gaze palsy, but does experience sleep benefit.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have olfactory dysfunction?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': What non-motor symptom assessment scale was used?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have bradykinesia?": "Based on the information in Table 2 (\"Clinical features of patients with p.D620N mutation\"), patient BIII-8 has a \"+\" sign listed next to the \"Bradykinesia\" row.\n\nTherefore, the patient **does** have bradykinesia.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have tremor?": "Based on the information contained within the provided document:\n\nYes, patient 'BIII-8' from family 'Family B' has tremor.\n\nTable 2, \"Clinical features of patients with p.D620N mutation\", lists patient 'BIII-8'. In the row for \"Resting tremor\", there is a \"+\" symbol under the column for BIII-8, indicating the presence of resting tremor. Additionally, the text on page 3 under \"Clinical Presentation\" states, \"Patients BIII-8 and CII-3 both developed upper limb rest tremor at ages 34 and 55, respectively.\"",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have resting tremor?": "Based on the information contained within the document:\n\nYes, patient 'BIII-8' has resting tremor.\n\nTable 2 on page 3 lists the clinical features of patients with the p.D620N mutation. For patient BIII-8, the row corresponding to \"Resting tremor\" shows a \"+\", indicating the presence of this symptom. Additionally, the text under \"Clinical Presentation\" on page 3 states: \"Patients BIII-8 and CII-3 both developed upper limb rest tremor...\".",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have action tremor?": "Based only on the information contained within the provided document:\n\nTable 2 on page 3 lists clinical features for patients with the p.D620N mutation, including patient BIII-8. While the table indicates that patient BIII-8 has \"Resting tremor\" (indicated by a '+'), it does not list \"action tremor\" as a clinical feature for any patient, nor is action tremor mentioned specifically for patient BIII-8 in the text description under \"Clinical Presentation\".\n\nTherefore, the answer is:\n**Information not found**",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have postural tremor?": "Information not found.\n\n**Reasoning:**\nTable 2 provides clinical features for patient BIII-8. While it lists \"Resting tremor\" (present, indicated by '+') and \"Postural instability\" (absent, indicated by '-'), it does not specifically mention \"Postural tremor\" for this patient. The text on page 3 also describes patient BIII-8 as having developed \"upper limb rest tremor\" but does not mention postural tremor. Therefore, the document does not contain the specific information needed to answer the question about postural tremor for patient BIII-8.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have dystonic tremor?": "Based on the information in the provided document:\n\nTable 2 on page 3 lists the clinical features of patients with the p.D620N mutation. For patient 'BIII-8', the row labeled 'Dystonia at onset' shows a minus sign ('-'), indicating its absence. The table does not specifically list 'dystonic tremor', but it does indicate the absence of dystonia at onset for this patient.\n\nTherefore, based only on the provided document, patient BIII-8 did not have dystonia at onset. The document does not explicitly state whether the patient developed dystonic tremor later, but it is not listed as a feature. The most direct answer based on the available clinical features table is no.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have rigidity?": "Based on the information in Table 2, \"Clinical features of patients with p.D620N mutation\", patient 'BIII-8' has a '+' sign listed for the clinical feature 'Rigidity'.\n\nTherefore, the answer is: Yes, the patient has rigidity.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have postural instability?": "Based on the information in the document:\n\nTable 2 on page 3, \"Clinical features of patients with p.D620N mutation\", lists clinical features for several patients, including 'BIII-8'. In the row labeled \"Postural instability\", the entry for patient 'BIII-8' is '-'.\n\nTherefore, the patient BIII-8 does not have postural instability according to this document.",
    "Regarding patient 'BIII-8' from family 'Family B': How does the patient respond to levodopa treatment?": "Based on the information in Table 2 ('Clinical features of patients with p.D620N mutation'), patient 'BIII-8' shows a positive clinical response to levodopa, indicated by a '+' in the row 'Clinical response to levodopa'.",
    "Regarding patient 'BIII-8' from family 'Family B': How is the levodopa response quantified?": "Information not found.\n\nThe document indicates in Table 2 that patient BIII-8 had a 'Clinical response to levodopa', marked with a '+', but it does not describe how this response was quantified (e.g., using a specific scale, percentage improvement, etc.).",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have dyskinesia?": "Based on the information provided in the document:\n\nIn Table 2, \"Clinical features of patients with p.D620N mutation\", the row for \"Levodopa-induced dyskinesia\" under the column for patient \"BIII-8\" shows a 'â€“' symbol.\n\nTherefore, according to the document, patient BIII-8 does not have levodopa-induced dyskinesia.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have dystonia?": "Based on the information in Table 2 ('Clinical features of patients with p.D620N mutation'), patient BIII-8 did not have dystonia at onset. The entry for 'Dystonia at onset' for patient BIII-8 is '-'.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have hyperreflexia?": "Based on the information provided in Table 2, 'Clinical features of patients with p.D620N mutation', the entry for 'Hyperreflexia' in the column for patient 'BIII-8' is '-'. This symbol indicates the absence of the feature.\n\nTherefore, the patient BIII-8 does not have hyperreflexia.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have diurnal fluctuations?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have sleep benefit?": "Based on the information in Table 2, \"Clinical features of patients with p.D620N mutation\", patient 'BIII-8' is listed in the second patient column. The row for \"Sleep benefit\" shows a '+' symbol under the column for patient 'BIII-8'.\n\nTherefore, the patient BIII-8 does have sleep benefit.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have motor fluctuations?": "Based on the information in the provided document, specifically Table 2 ('Clinical features of patients with p.D620N mutation'), patient BIII-8 shows a '+' sign for 'Wearing off'. Wearing off is a type of motor fluctuation.\n\nTherefore, the answer is: Yes, the patient has motor fluctuations (specifically 'Wearing off').",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have depression?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': What depression assessment scale was used and what was the score?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have anxiety?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What anxiety assessment scale was used and what was the score?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have psychotic symptoms?": "Based on the information in Table 2 ('Clinical features of patients with p.D620N mutation'), patient BIII-8 has a 'âˆ’' symbol listed for both 'Hallucination' and 'Other psychosis'.\n\nTherefore, based only on the provided document, patient BIII-8 does not have psychotic symptoms.",
    "Regarding patient 'BIII-8' from family 'Family B': What psychotic symptoms assessment scale was used and what was the score?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have sleep disorders?": "Information not found.\n\nWhile Table 2 on page 3 mentions 'Sleep benefit' (+ sign) for patient BIII-8, this refers to the improvement of parkinsonian symptoms after sleep, not the presence or absence of a sleep disorder itself (such as insomnia, REM sleep behavior disorder, etc.). The document does not provide specific information on whether patient BIII-8 suffers from sleep disorders.",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have cognitive decline?": "Based on the information in Table 2, under the column for patient 'BIII-8', the row corresponding to 'Dementia' shows a '-' symbol, indicating its absence.\n\nTherefore, based only on the provided document, the patient BIII-8 does not have dementia, which is a form of cognitive decline.",
    "Regarding patient 'BIII-8' from family 'Family B': What subdomains of cognitive function are affected (if any)?": "Based on the information contained within the provided document:\n\nTable 2 on page 3 lists clinical features for patient BIII-8. Under the cognitive-related categories, it indicates the following for patient BIII-8:\n*   Hallucination: - (Absent)\n*   Other psychosis: - (Absent)\n*   Dementia: - (Absent)\n\nThe table does not specify any affected subdomains of cognitive function for patient BIII-8. Therefore, the information regarding which specific subdomains of cognitive function are affected (if any) for patient BIII-8 is not found in the document.\n\nInformation not found",
    "Regarding patient 'BIII-8' from family 'Family B': What cognitive assessment scale was used and what was the score?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have autonomic symptoms?": "Based *only* on the information contained within the provided document:\n\nTable 2 on page 3 lists clinical features for patient BIII-8. Under the rows related to autonomic symptoms:\n*   Orthostatic hypotension: -\n*   Incontinence: -\n*   Urinary urgency: -\n\nThe symbol '-' indicates the absence of the symptom according to the table's likely convention (where '+' indicates presence).\n\nTherefore, the answer is: **No**",
    "Regarding patient 'BIII-8' from family 'Family B': Does the patient have atypical parkinsonian features?": "Based on the information in the document:\n\nTable 2 details the clinical features of patient BIII-8. The symptoms listed (Resting tremor, Bradykinesia, Rigidity, Gait disturbance, Postural instability, Clinical response to levodopa, Wearing off, Asymmetry at onset, Urinary urgency, Levodopa-induced dyskinesia, Sleep benefit) are generally consistent with Parkinson's Disease.\n\nFurthermore, the text states:\n*   Abstract: \"Patients with the VPS35 mutation showed typical tremor-predominant PD.\"\n*   Page 4, Discussion: \"The clinical symptoms of our patients with VPS35 mutation closely resembled the idiopathic PD form, with tremor-dominant dopa-responsive parkinsonism.\"\n\nThe document explicitly describes the features associated with the mutation in these patients, including BIII-8, as typical PD or resembling idiopathic PD. It does not state that patient BIII-8 has atypical parkinsonian features.\n\nTherefore, the answer is: No, the document describes the patient as having features resembling typical/idiopathic Parkinson's disease, not atypical parkinsonian features.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the pathogenicity classification for the first mutation?": "Based on the information contained within the provided document:\n\nThe mutation identified in patient 'BIII-8' from family 'Family B' is p.D620N (Table 1, Table 2, Fig 1). The document states that this mutation \"has been reported to be pathogenic for PD\" (Page 2, Introduction) and \"has been reported previously as a pathogenic mutation for familial PD\" (Page 3, Results).\n\nTherefore, the pathogenicity classification for the first (and only mentioned) mutation for patient BIII-8 is **pathogenic**.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the pathogenicity classification for the second mutation?": "Information not found.\n\nThe document states that patient BIII-8 carries the heterozygous p.D620N mutation (Table 1, page 3). It also states in the Results section (page 3): \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" This indicates that, based on the analysis performed in this study, only one mutation (p.D620N) was identified in patient BIII-8 within the VPS35 gene. Therefore, there is no information about a second mutation or its pathogenicity classification for this patient in the provided document.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the pathogenicity classification for the third mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the CADD score for the first mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the CADD score for the second mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What is the CADD score for the third mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What functional evidence supports the pathogenicity of the first mutation?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': What functional evidence supports the pathogenicity of the second mutation?": "Information not found",
    "Regarding patient 'BIII-8' from family 'Family B': What functional evidence supports the pathogenicity of the third mutation?": "Information not found.",
    "Regarding patient 'BIII-8' from family 'Family B': What is the entry identifier for this data?": "Based on the information in the document:\n\nThe entry identifier used for patient 'BIII-8' from family 'Family B' in Table 1 and Table 2 is **BIII-8**.",
    "Regarding patient 'BIII-8' from family 'Family B': Any additional general comments about this data?": "Based *only* on the information contained within the provided document:\n\nRegarding the data for patient 'BIII-8' from family 'Family B', haplotype analysis indicated that BIII-8 shared at least one allele with patient AII-11 in the flanking region of VPS35. However, a general comment about this data is that the chromosomal phase for patient BIII-8 could not be determined, making it inconclusive whether the p.D620N mutation shared a common founder between families A and B.",
    "Regarding patient 'CII-3' from family 'Family C': What is the study design of this article?": "Based on the information in the document:\n\nThe study screened 7 reported nonsynonymous missense variants of the VPS35 gene in 300 Japanese index patients with autosomal dominant Parkinson's Disease (ADPD) and 433 patients with sporadic PD (SPD) using direct sequencing or high-resolution melting (HRM) analysis. Additionally, 579 controls were screened for the p.D620N mutation using HRM analysis. Haplotype analysis was performed on mutation carriers (including patient CII-3), and the clinical features of these patients were described. This represents a **genetic screening study** of patient cohorts (ADPD, SPD) and controls, combined with **haplotype analysis** and **clinical description** of the mutation-positive cases identified.",
    "Regarding patient 'CII-3' from family 'Family C': What genetic methods were used in this study?": "Based *only* on the information contained within the provided document:\n\nThe study detected the p.D620N mutation in patient CII-3 (an ADPD patient). The general methods used for screening patients included **direct sequencing or high-resolution melting (HRM) analysis** (Abstract, Page 1). Specifically for ADPD patients, **PCR direct sequencing** was used to examine 7 variants (Genetic Analysis, Page 2).\n\nBecause patient CII-3 carried the p.D620N mutation, **all exons of VPS35 were also analyzed** in this patient using a referenced method (Genetic Analysis, Page 2). Additionally, **haplotype analysis** was performed on patient CII-3 (Table 1, Page 3; Text discussion, Page 4).",
    "Regarding patient 'CII-3' from family 'Family C': What is the lower age limit for study inclusion (if any)?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What is the upper age limit for study inclusion (if any)?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': Are there any additional comments about the study methodology?": "Based on the information within the provided document:\n\nThe document discusses the haplotype analysis performed on patients, including CII-3 from Family C. It notes that while the p.D620N mutation was identified, determining the chromosomal phase for Family C (and Family B) was inconclusive based on the individuals studied. It states, \"To determine the chromosomal phase of families B and C, detailed genetic analyses of other family members are needed in future studies.\" This comment relates to the limitations and future directions of the haplotype analysis methodology concerning Family C.",
    "Regarding patient 'CII-3' from family 'Family C': What is the abbreviation of the disease or condition diagnosed in this patient?": "Based *only* on the information provided in the document:\n\nThe document links the VPS35 mutation (found in patient CII-3) to Parkinson's disease. The abbreviation used for Parkinson's disease throughout the document (e.g., Abstract, Introduction, Discussion) is **PD**.",
    "Regarding patient 'CII-3' from family 'Family C': What is the key clinical information about this patient?": "Based on the information contained within the provided document:\n\nThe key clinical information about patient CII-3 from Family C is:\n\n*   **Age at disease onset:** 34 years.\n*   **Disease duration (at time of report):** 7 years.\n*   **Symptoms/Signs:** Positive for resting tremor (specifically developed upper limb rest tremor at age 34), bradykinesia, rigidity, gait disturbance, and postural instability.\n*   **Treatment Response:** Showed clinical response to levodopa, experienced wearing off, and had sleep benefit.\n*   **Other features:** Had asymmetry at onset. Negative for orthostatic hypotension, incontinence, levodopa-induced dyskinesia, dystonia at onset, hyperreflexia, hallucination, other psychosis, dementia, and gaze palsy.\n*   **Imaging:** Brain MRI was within normal limits (WNL). Cardiac MIBG scintigraphy was not performed.\n*   **Family History:** Father also developed PD.\n*   **Genetics:** Carries the heterozygous p.D620N mutation in the VPS35 gene. Haplotype analysis suggests this mutation likely occurred independently compared to Family A and patient D.",
    "Regarding patient 'CII-3' from family 'Family C': What is the patient's ethnicity?": "Based on the information contained within the document:\n\nThe study screened \"Japanese patients with autosomal-dominant PD (ADPD)\" and \"Japanese patients with SPD (sporadic PD)\". Patient CII-3 is identified as belonging to Family C (Figure 1), which is one of the families with ADPD where the p.D620N mutation was detected. The haplotype analysis (Table 1, Page 3) and clinical description (Table 2, Page 3) include CII-3 as one of the patients studied. The discussion section also refers to \"Japanese patients\" when discussing the findings, including the haplotype results for the families studied.\n\nTherefore, based on the description of the study population, patient CII-3 is **Japanese**.",
    "Regarding patient 'CII-3' from family 'Family C': What is the patient's country of origin?": "Based on the information contained within the provided document:\n\nThe study focuses on \"Japanese Patients with Typical Parkinson's Disease\" (Title). The Methods section under \"Subjects\" states: \"The study subjects were 308 Japanese patients (300 index patients) with ADPD...\". Patient CII-3 is listed as one of the patients carrying the p.D620N mutation identified within this study group (Table 1, Table 2, Figure 1C). Therefore, based on the description of the study population, patient CII-3 is Japanese.\n\nAnswer: Japan",
    "Regarding patient 'CII-3' from family 'Family C': What is the patient's sex/gender?": "Based on the information in the document:\n\nPatient CII-3 is shown in the pedigree chart for Family C (Figure 1C on page 3). The symbol used for patient CII-3 is a square. According to the figure legend, a square symbol represents a male.\n\nTherefore, the patient's sex/gender is **male**.",
    "Regarding patient 'CII-3' from family 'Family C': Is this patient the index case in the family?": "Based on the information in the document:\n\nFigure 1 presents the pedigrees of the families studied. The legend for Figure 1 states that the arrow indicates the proband (index case). In the pedigree for Family C, the arrow points to individual II-5, not individual CII-3.\n\nTherefore, patient CII-3 from Family C is **not** the index case in the family.",
    "Regarding patient 'CII-3' from family 'Family C': How many affected individuals in the family have heterozygous mutations?": "Based on the information contained within the provided document:\n\nPatient CII-3 from Family C is confirmed to have the heterozygous p.D620N mutation (Table 1 shows genotype A/G). The father of patient CII-3 (individual CI-1 in Figure 1C) is also affected, but the document does not state that this individual was genetically analyzed (CI-1 is not marked with an asterisk in Figure 1C, and Table 1 does not list results for CI-1).\n\nTherefore, based *only* on the document, **one** affected individual (CII-3) in Family C is stated to have a heterozygous mutation.",
    "Regarding patient 'CII-3' from family 'Family C': How many affected individuals in the family have homozygous mutations?": "Based *only* on the information contained within the provided document:\n\nThe document states on page 2, under \"Results - Detection of p.D620N Mutation\": \"We detected the **heterozygous** missense p.D620N mutation in 3 unrelated patients with ADPD...\". Family C is one of these ADPD families (Figure 1C).\n\nTable 1 (\"Haplotype analysis of VPS35 p.D620N mutation carriers\") shows the genotype for patient CII-3 for the VPS35 p.D620N mutation as \"A/G\", indicating a heterozygous state.\n\nThe document discusses only the detection of heterozygous p.D620N mutations in the affected individuals studied. There is no mention of any affected individual in Family C (or any other family studied) having homozygous mutations.\n\nTherefore, the number of affected individuals in Family C with homozygous mutations is 0.",
    "Regarding patient 'CII-3' from family 'Family C': How many unaffected individuals in the family have heterozygous mutations?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': How many unaffected individuals in the family have homozygous mutations?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': How many affected individuals in the family have wildtype (no mutations)?": "Based on the information in the document:\n\n1.  Figure 1C shows the pedigree for Family C.\n2.  Closed symbols represent affected individuals. In Family C, individuals I-1 and II-3 are affected.\n3.  The study detected the heterozygous p.D620N mutation in 3 patients with autosomal dominant PD (ADPD), including patient CII-3 from Family C (page 3, first column; Table 1 confirms CII-3 has the A/G genotype for p.D620N, indicating presence of the mutation).\n4.  Since CII-3 is affected and has the mutation, and his father (I-1) is also affected in this ADPD family, I-1 is also presumed to carry the mutation (and is marked with an asterisk in Figure 1C, indicating analysis).\n5.  The question asks how many *affected* individuals in Family C have the *wildtype* genotype (no mutations).\n6.  Both affected individuals identified (I-1 and II-3) carry the p.D620N mutation.\n\nTherefore, the number of affected individuals in Family C who have the wildtype genotype (no mutations) is 0.",
    "Regarding patient 'CII-3' from family 'Family C': How many unaffected individuals in the family have wildtype (no mutations)?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What is the clinical status of the patient?": "Based on the information in the document:\n\nPatient CII-3 from Family C has the following clinical status:\n\n*   Carries the VPS35 p.D620N mutation.\n*   Age at disease onset was 34 years.\n*   Disease duration at the time of the study was 7 years.\n*   Developed upper limb rest tremor at onset.\n*   Clinical features include: resting tremor, bradykinesia, rigidity, gait disturbance, and postural instability.\n*   Showed a clinical response to levodopa.\n*   Experienced wearing off and levodopa-induced dyskinesia.\n*   Showed asymmetry at onset and sleep benefit.\n*   Did not exhibit orthostatic hypotension, incontinence, urinary urgency, dystonia at onset, hyperreflexia, hallucination, other psychosis, dementia, or gaze palsy at the time of assessment.\n*   Brain MRI was within normal limits (WNL).\n*   Cardiac MIBG scintigraphy was not performed.\n*   The patient's father also developed PD.",
    "Regarding patient 'CII-3' from family 'Family C': What was the age at examination (AAE) for this patient?": "Information not found.\n\nWhile Table 2 on page 3 provides the 'Age at disease onset (y)' as 34 and the 'Disease duration (y)' as 7 for patient CII-3, it does not explicitly state the 'Age at examination (AAE)'.",
    "Regarding patient 'CII-3' from family 'Family C': What was the age at onset (AAO) of symptoms for this patient?": "Based on the information in the provided document, specifically in Table 2 on page 3, the Age at disease onset (y) for patient 'CII-3' was 34.",
    "Regarding patient 'CII-3' from family 'Family C': What is the disease duration for this patient?": "Based on the information in Table 2, the disease duration for patient 'CII-3' is 7 years.",
    "Regarding patient 'CII-3' from family 'Family C': At what age was the patient diagnosed?": "Information not found.\n\n(The document provides the 'Age at disease onset (y)' for patient CII-3 as 34 in Table 2, but does not state the age at diagnosis.)",
    "Regarding patient 'CII-3' from family 'Family C': At what age did the patient die (if applicable)?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': Which human genome version was used for variant reporting?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What is the physical genomic location of the first mutation?": "Information not found.\n\nThe document identifies the mutation in patient CII-3 as p.D620N (c.1858G>A) in exon 15 of the VPS35 gene (RefSeq NM_018206.4). While haplotype analysis provides markers flanking the gene on chromosome 16, some with megabase coordinates (e.g., Chr16_45.333M), the specific physical base pair location of the c.1858G>A mutation itself on the chromosome is not stated in the provided text.",
    "Regarding patient 'CII-3' from family 'Family C': What is the reference allele for the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe document identifies patient CII-3 from Family C as having the p.D620N mutation in the VPS35 gene (Table 1, Table 2, Fig 1C). The text describes this specific mutation at the nucleotide level as \"c.1858G>A\" (Page 2, Left Column, 4th paragraph; Page 2, Right Column, Genetic Analysis section; Page 4, Right Column, 2nd paragraph). In the standard notation \"c.1858G>A\", the letter preceding the \">\" indicates the reference allele.\n\nTherefore, the reference allele for the mutation found in patient CII-3 is **G**.",
    "Regarding patient 'CII-3' from family 'Family C': What is the observed (mutant) allele for the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe document identifies that patient CII-3 from Family C carries the heterozygous missense p.D620N mutation in the VPS35 gene. Table 1 shows the genotype for \"VPS35 p.D620N\" for patient CII-3 as 'A/G'. The text on page 2 clarifies that the p.D620N mutation corresponds to the nucleotide change c.1858G>A. Therefore, the observed (mutant) allele is 'A'.",
    "Regarding patient 'CII-3' from family 'Family C': What is the genomic-level notation for the first mutation?": "Based on the information contained within the document:\n\nThe mutation identified in patient CII-3 is p.D620N. The document provides the corresponding coding DNA level notation for this mutation. On page 2, under Genetic Analysis, it states: \"...genotyped for c.1858G>A (p.D620N) mutation...\". On page 4, under Discussion, it refers to: \"...the substitution of VPS35 c.1858G>A (p.D620N)...\".\n\nTherefore, the coding DNA level notation (which is often used in place of strict genomic notation in such papers when the g. coordinate is not specified) for the mutation is:\n\n**c.1858G>A**",
    "Regarding patient 'CII-3' from family 'Family C': What is the original alias or alternate notation for the first mutation as reported in the article?": "Based on the information in the provided document:\n\nThe mutation found in patient CII-3 is reported as p.D620N. The article also provides the nucleotide level notation for this mutation. On page 2, in the second paragraph of the introduction, it states: \"Mutation of c.1858G>A (p.D620N) was identified...\". On page 4, in the first paragraph of the Discussion, it mentions: \"...the substitution of VPS35 c.1858G>A (p.D620N)...\".\n\nTherefore, the original alias or alternate notation for the p.D620N mutation as reported in the article is **c.1858G>A**.",
    "Regarding patient 'CII-3' from family 'Family C': What is the standardized alias for the first mutation?": "Based on the information contained within the provided document:\n\nThe standardized alias for the mutation found in patient 'CII-3' from family 'Family C' is **p.D620N**.",
    "Regarding patient 'CII-3' from family 'Family C': What is the genotype of the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe genotype for the VPS35 p.D620N mutation in patient CII-3 is A/G, indicating a heterozygous state. This is shown in Table 1.",
    "Regarding patient 'CII-3' from family 'Family C': What type of mutation is the first variant?": "Based *only* on the information contained within the provided document:\n\nThe first variant identified in patient 'CII-3' from family 'Family C' is the heterozygous **missense** p.D620N mutation in the VPS35 gene.",
    "Regarding patient 'CII-3' from family 'Family C': What is the gnomAD v2.1.1 frequency for the first mutation?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the gnomAD v4.0.0 frequency for the first mutation?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What is the physical genomic location of the second mutation?": "Information not found.\n\nThe document states that patient CII-3 has the heterozygous missense p.D620N mutation in the VPS35 gene. It also explicitly mentions, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, based solely on the information within the document, there is no mention of a second mutation for patient CII-3, nor its physical genomic location.",
    "Regarding patient 'CII-3' from family 'Family C': What is the reference allele for the second mutation?": "Information not found.\n\nThe document identifies patient CII-3 from family C as having the heterozygous p.D620N mutation (c.1858G>A) in the VPS35 gene (Table 1, Fig 1, page 3). The text states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" (page 3, Results section). Therefore, the document does not provide information about a *second* mutation for patient CII-3.",
    "Regarding patient 'CII-3' from family 'Family C': What is the observed (mutant) allele for the second mutation?": "Information not found.\n\nThe document states that patient CII-3 carries the heterozygous p.D620N mutation in the VPS35 gene. It further states: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, based *only* on the information provided, no second mutation was identified for patient CII-3.",
    "Regarding patient 'CII-3' from family 'Family C': What is the genomic-level notation for the second mutation?": "Information not found.\n\nThe document states that patient CII-3 has the p.D620N mutation in the VPS35 gene (Table 1, Table 2). It also explicitly states on page 3, paragraph 2: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, according to this document, no second mutation was identified for patient CII-3.",
    "Regarding patient 'CII-3' from family 'Family C': What is the original alias or alternate notation for the second mutation as reported in the article?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the standardized alias for the second mutation?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the genotype of the second mutation?": "Information not found.\n\nRationale: The document identifies patient CII-3 from Family C as having the heterozygous p.D620N mutation (genotype A/G) in the VPS35 gene (Table 1, page 3). It also states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (page 3, Results section). Therefore, according to this document, no second mutation was identified in patient CII-3.",
    "Regarding patient 'CII-3' from family 'Family C': What type of mutation is the second variant?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the gnomAD v2.1.1 frequency for the second mutation?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the gnomAD v4.0.0 frequency for the second mutation?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What is the physical genomic location of the third mutation?": "Information not found.\n\nThe document identifies the mutation in patient CII-3 as p.D620N (c.1858G>A) located in exon 15 of the VPS35 gene. It also provides haplotype data indicating the gene is on chromosome 16, near markers like D16S3105 and between Chr16_45.333M and Chr16_45.615M. However, the specific physical genomic coordinate (i.e., the exact base pair position on chromosome 16) for the c.1858G>A nucleotide change is not explicitly stated in the text.",
    "Regarding patient 'CII-3' from family 'Family C': What is the reference allele for the third mutation?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the observed (mutant) allele for the third mutation?": "Based *only* on the information contained within the provided document:\n\nThe document states on page 3 (\"Detection of p.D620N Mutation\") that \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" This indicates that patient CII-3, who carries the p.D620N mutation (as shown in Fig 1 and Table 1), was only found to have this single mutation within the VPS35 gene according to this study's analysis.\n\nTherefore, the document does not provide information about a *third* mutation for patient CII-3.\n\nInformation not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the genomic-level notation for the third mutation?": "Information not found.\n\nThe document states that patient CII-3 has the heterozygous p.D620N mutation (genomic notation c.1858G>A, mentioned on page 2) in the VPS35 gene. It also explicitly states on page 3, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" Therefore, based only on this document, there is no information about a second or third mutation for patient CII-3.",
    "Regarding patient 'CII-3' from family 'Family C': What is the standardized alias for the third mutation?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the genotype of the third mutation?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What type of mutation is the third variant?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What is the gnomAD v2.1.1 frequency for the third mutation?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the gnomAD v4.0.0 frequency for the third mutation?": "Information not found.\n\nRationale:\n1.  The document identifies patient CII-3 from Family C as having the heterozygous p.D620N mutation in the VPS35 gene (Figure 1, Table 1, Table 2, page 3 paragraph 1).\n2.  The document explicitly states on page 3, paragraph 1: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" This indicates only one mutation (p.D620N) was reported for patient CII-3 in this study. Therefore, there is no \"third mutation\" mentioned for this patient within the document.\n3.  The document text does not contain the term \"gnomAD\" or provide any frequency data from the gnomAD database, let alone specifically version 4.0.0.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have motor symptoms?": "Yes, patient 'CII-3' from family 'Family C' does have motor symptoms.\n\nAccording to Table 2 (\"Clinical features of patients with p.D620N mutation\") on page 3, patient CII-3 presents with the following motor symptoms:\n*   Resting tremor (+)\n*   Bradykinesia (+)\n*   Rigidity (+)\n*   Gait disturbance (+)\n*   Postural instability (+)\n\nThe text under \"Clinical Presentation\" on page 3 also states: \"Patients BIII-8 and CII-3 both developed upper limb rest tremor at ages 34 and 55, respectively.\" Tremor is a motor symptom.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have parkinsonism symptoms?": "Yes, patient CII-3 from family C has parkinsonism symptoms.\n\nTable 2 (\"Clinical features of patients with p.D620N mutation\") lists the following symptoms as present ('+') for patient CII-3:\n*   Resting tremor\n*   Bradykinesia\n*   Rigidity\n*   Gait disturbance\n*   Postural instability\n\nThese are characteristic symptoms of parkinsonism. The text on page 3 also states, \"Patients BIII-8 and CII-3 both developed upper limb rest tremor at ages 34 and 55, respectively.\"",
    "Regarding patient 'CII-3' from family 'Family C': What is the first motor assessment scale used?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the score on the first motor assessment scale?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What is the second motor assessment scale used (if any)?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the score on the second motor assessment scale?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have non-motor symptoms of parkinsonism?": "Based on the information contained within the provided document, specifically Table 2, patient CII-3 did *not* exhibit the following non-motor symptoms at the time of assessment:\n\n*   Orthostatic hypotension (-)\n*   Incontinence (-)\n*   Urinary urgency (-)\n*   Sleep benefit (-)\n*   Hallucination (-)\n*   Other psychosis (-)\n*   Dementia (-)\n\nTherefore, based on the specific non-motor symptoms listed and assessed in Table 2 for patient CII-3, the patient does not have those non-motor symptoms.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have olfactory dysfunction?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What non-motor symptom assessment scale was used?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have bradykinesia?": "Based on the information in Table 2, patient CII-3 does have bradykinesia, indicated by the \"+\" symbol in that row.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have tremor?": "Based on the information in the provided document:\n\nYes, patient 'CII-3' from family 'Family C' has tremor.\n\nTable 2, \"Clinical features of patients with p.D620N mutation\", shows a '+' symbol in the row for \"Resting tremor\" under the column for patient \"CII-3\". Additionally, the \"Clinical Presentation\" section on page 3 states: \"Patients BIII-8 and CII-3 both developed upper limb rest tremor...\".",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have resting tremor?": "Based on the information in Table 2 ('Clinical features of patients with p.D620N mutation'), patient 'CII-3' has a '+' listed for the feature 'Resting tremor'.\n\nTherefore, the patient does have resting tremor.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have action tremor?": "Based *only* on the information contained within the provided document:\n\nTable 2 lists clinical features for patient CII-3. Under the tremor category, it lists \"Resting tremor\" and indicates its presence with a \"+\". The document does not contain a specific entry or statement regarding \"action tremor\" for patient CII-3.\n\nTherefore, the answer is: **Information not found**.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have postural tremor?": "Information not found.\n\n**Reasoning:**\nTable 2 on page 3 lists clinical features for patient CII-3. It indicates the patient has Resting tremor (+) and Postural instability (+). However, it does not specifically list \"Postural tremor\" as a feature, nor does it state whether patient CII-3 exhibited this specific type of tremor. The text description of CII-3 on page 3 only mentions \"upper limb rest tremor\". Therefore, based solely on the provided document, we cannot determine if patient CII-3 has postural tremor.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have dystonic tremor?": "Based on the information provided in the document:\n\n*   Table 2 lists the clinical features of patient CII-3.\n*   The row 'Dystonia at onset' for patient CII-3 shows a '-' sign, indicating absence.\n*   The row 'Resting tremor' for patient CII-3 shows a '+' sign, indicating presence.\n*   The document does not explicitly state whether the tremor experienced by patient CII-3 is dystonic tremor, nor does it mention dystonia occurring at any point other than onset.\n\nTherefore, the information to specifically confirm or deny the presence of *dystonic tremor* for patient CII-3 is not found in the document.\n\n**Information not found**",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have rigidity?": "Based on the information in Table 2, \"Clinical features of patients with p.D620N mutation\", patient CII-3 has a '+' listed in the row for 'Rigidity'.\n\nTherefore, the patient CII-3 does have rigidity.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have postural instability?": "Based on the information in Table 2, under the column for patient 'CII-3', the row corresponding to 'Postural instability' shows a '+'.\n\nTherefore, the patient CII-3 does have postural instability.",
    "Regarding patient 'CII-3' from family 'Family C': How does the patient respond to levodopa treatment?": "Based on the information in Table 2 (\"Clinical features of patients with p.D620N mutation\") on page 3, patient CII-3 shows a clinical response to levodopa, indicated by a '+' sign in that row under the CII-3 column.",
    "Regarding patient 'CII-3' from family 'Family C': How is the levodopa response quantified?": "Based *only* on the information contained within the provided document:\n\nIn Table 2 ('Clinical features of patients with p.D620N mutation'), the row 'Clinical response to levodopa' for patient 'CII-3' shows a '+' symbol. The document does not provide any further detail or explanation on how this response was specifically measured or quantified.\n\nTherefore, the answer is: **Information not found**.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have dyskinesia?": "Based on the information in Table 2, \"Clinical features of patients with p.D620N mutation\", patient CII-3 has a 'âˆ’' symbol next to the row \"Levodopa-induced dyskinesia\".\n\nTherefore, the answer is: No, the patient does not have levodopa-induced dyskinesia according to Table 2.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have dystonia?": "Based on the information in Table 2, \"Clinical features of patients with p.D620N mutation\", the entry for patient 'CII-3' in the row 'Dystonia at onset' is 'â€“'. In the context of the table where '+' indicates presence, 'â€“' indicates absence.\n\nTherefore, the patient CII-3 does not have dystonia at onset.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have hyperreflexia?": "Based on the information in Table 2, patient CII-3 does not have hyperreflexia (indicated by '-').",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have diurnal fluctuations?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have sleep benefit?": "Based on the information in Table 2 on page 3, patient 'CII-3' does have sleep benefit, indicated by the \"+\" symbol in the corresponding row.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have motor fluctuations?": "Based on the information contained within the provided document:\n\nNo, patient 'CII-3' does not have motor fluctuations. Table 2 on page 3 lists clinical features for patient CII-3. Under this patient's column, the entry for 'Wearing off' is '-' (absent) and the entry for 'Levodopa-induced dyskinesia' is '-' (absent). These are key types of motor fluctuations.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have depression?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What depression assessment scale was used and what was the score?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have anxiety?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What anxiety assessment scale was used and what was the score?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have psychotic symptoms?": "Based on the information in Table 2 ('Clinical features of patients with p.D620N mutation'), patient 'CII-3' has a '-' listed for both 'Hallucination' and 'Other psychosis'.\n\nTherefore, according to the document, the patient CII-3 does not have psychotic symptoms.",
    "Regarding patient 'CII-3' from family 'Family C': What psychotic symptoms assessment scale was used and what was the score?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have sleep disorders?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have cognitive decline?": "Based on the information in Table 2 on page 3, under the column for patient 'CII-3', the row labeled 'Dementia' indicates '-'.\n\nTherefore, according to the document, patient CII-3 does not have dementia.",
    "Regarding patient 'CII-3' from family 'Family C': What subdomains of cognitive function are affected (if any)?": "Based *only* on the information contained within the provided document:\n\nTable 2 lists clinical features for patient CII-3. Regarding cognitive function, it notes the following:\n*   Hallucination: â€“ (negative/absent)\n*   Other psychosis: â€“ (negative/absent)\n*   Dementia: â€“ (negative/absent)\n\nThe document does not provide further details or assessment results regarding specific *subdomains* of cognitive function (such as memory, attention, executive function, visuospatial skills, language) for patient CII-3. It only indicates the absence of dementia, hallucinations, and psychosis according to the listed clinical features.\n\nTherefore, the answer is:\n**Information not found**",
    "Regarding patient 'CII-3' from family 'Family C': What cognitive assessment scale was used and what was the score?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have autonomic symptoms?": "Based on the information in Table 2 on page 3, patient CII-3 is listed with the following information regarding specific autonomic symptoms:\n\n*   Orthostatic hypotension: -\n*   Incontinence: -\n*   Urinary urgency: -\n\nThe '-' symbol indicates the absence of these specific symptoms.\n\nTherefore, based only on the information provided in the document, patient CII-3 does not have the listed autonomic symptoms (orthostatic hypotension, incontinence, urinary urgency).",
    "Regarding patient 'CII-3' from family 'Family C': Does the patient have atypical parkinsonian features?": "Based on the information contained within the provided document:\n\nNo, the patient CII-3 does not have atypical parkinsonian features according to the document.\n\n*   **Table 2** lists the clinical features for patient CII-3, which include resting tremor, bradykinesia, rigidity, gait disturbance, postural instability, clinical response to levodopa, and asymmetry at onset. Features often associated with atypical parkinsonism like orthostatic hypotension, incontinence, hyperreflexia, hallucination, dementia, and gaze palsy are explicitly marked as absent (-) for this patient.\n*   The **Abstract** states: \"Patients with the VPS35 mutation showed typical tremor-predominant PD.\"\n*   The **Clinical Presentation** section (page 3) and **Discussion** (page 4) reinforce this, stating: \"The clinical symptoms of our patients with VPS35 mutation closely resembled the idiopathic PD form, with tremor-dominant dopa-responsive parkinsonism.\"\n\nTherefore, based only on the text provided, patient CII-3 is described as having features typical of Parkinson's disease, not atypical parkinsonian features.",
    "Regarding patient 'CII-3' from family 'Family C': What is the pathogenicity classification for the first mutation?": "Based on the information contained within the provided document:\n\nThe document identifies that patient CII-3 from Family C carries the p.D620N mutation in the VPS35 gene (Figure 1C, Table 1, Page 4 discussion). The document describes this mutation as follows:\n\n*   \"One missense mutation has been reported to be pathogenic for PD.3,4 Mutation of c.1858G>A (p.D620N) was identified...\" (Page 2, Introduction)\n*   \"The p.D620N has been reported previously as a pathogenic mutation for familial PD.\" (Page 3, Results)\n*   \"...potentially disease-associated variants of PD, in 300 Japanese index patients with autosomal dominant PD...\" (referring to screening including p.D620N) (Abstract)\n\nTherefore, the pathogenicity classification for the first (and only mentioned) mutation (p.D620N) for patient CII-3 is **pathogenic**.",
    "Regarding patient 'CII-3' from family 'Family C': What is the pathogenicity classification for the second mutation?": "Information not found.\n\nRationale: The document identifies patient CII-3 from Family C as having the heterozygous p.D620N mutation in the VPS35 gene (Table 1, Figure 1, Table 2). The text on page 3 explicitly states: \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35.\" This indicates that only one mutation (p.D620N) was found in this patient within the VPS35 gene according to the study's analysis. Therefore, the document does not contain information about a *second* mutation or its pathogenicity classification for patient CII-3.",
    "Regarding patient 'CII-3' from family 'Family C': What is the pathogenicity classification for the third mutation?": "Information not found.\n\nRationale: The document states that patient CII-3 carries the heterozygous p.D620N mutation in the VPS35 gene (Table 1, Figure 1). It also explicitly states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (Page 3). Therefore, based *only* on the provided document, there is no information about a third mutation for patient CII-3.",
    "Regarding patient 'CII-3' from family 'Family C': What is the CADD score for the first mutation?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the CADD score for the second mutation?": "Information not found",
    "Regarding patient 'CII-3' from family 'Family C': What is the CADD score for the third mutation?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What functional evidence supports the pathogenicity of the first mutation?": "Information not found.\n\nThe document identifies the p.D620N mutation in patient CII-3 (Table 1, Table 2) and discusses its potential pathogenicity based on previous reports and the general function of VPS35 protein (Pages 2, 4). However, it does not describe any *functional evidence* (e.g., cell-based assays, protein interaction studies, animal models) *generated within this specific study* to support the pathogenicity of this mutation. The discussion about potential functional impact (Page 4, right column) refers to the general role of VPS35 and cites other studies, rather than presenting new functional data from this research effort.",
    "Regarding patient 'CII-3' from family 'Family C': What functional evidence supports the pathogenicity of the second mutation?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What functional evidence supports the pathogenicity of the third mutation?": "Information not found.",
    "Regarding patient 'CII-3' from family 'Family C': What is the entry identifier for this data?": "Based on the information contained within the provided document, the identifier used for this patient's data is **CII-3**.\n\nThis identifier is used in:\n*   Figure 1, Pedigree C (labeled as II *3)\n*   The text discussing haplotype analysis (page 3, left column)\n*   Table 1 (Haplotype analysis) as a column header\n*   Table 2 (Clinical features) as a column header",
    "Regarding patient 'CII-3' from family 'Family C': Any additional general comments about this data?": "Based *only* on the information contained within the provided document:\n\nPatient CII-3 from Family C is the proband (index case) for that family (Figure 1). This patient carries the heterozygous p.D620N mutation in the VPS35 gene (Table 1, Figure 1). The age at disease onset was 34 years, and the disease duration at the time of reporting was 7 years (Table 2). Clinical features included resting tremor, bradykinesia, rigidity, gait disturbance, postural instability, asymmetry at onset, and a positive clinical response to levodopa. Several other features like wearing off, orthostatic hypotension, and dementia were absent (Table 2). The patient developed upper limb rest tremor at age 34 (Page 3, Clinical Presentation). The father of patient CII-3 also developed PD (Page 4, Figure 1C). Brain MRI was within normal limits, but cardiac MIBG scintigraphy was not performed (Table 2). Haplotype analysis indicated that patient CII-3 had a different genotype at the D16S3105 locus compared to patient AII-11, suggesting the p.D620N mutation in CII-3 likely occurred independently from the mutation in Family A (Page 3, Table 1, Discussion on page 4). The patient was born to nonconsanguineous parents (Page 4).",
    "Regarding patient 'D': What is the study design of this article?": "Based on the information in the document:\n\nThe study screened 300 Japanese index patients with autosomal dominant Parkinson's Disease (ADPD), 433 patients with sporadic Parkinson's Disease (SPD), and 579 controls for specific variants in the VPS35 gene using direct sequencing or high-resolution melting (HRM) analysis. Haplotype analysis and clinical characterization were performed on patients found to have the p.D620N mutation. Patient 'D' was identified as a patient with SPD carrying the p.D620N mutation through this screening process.\n\nTherefore, the study design is a **genetic screening study** comparing mutation frequencies in different patient groups (ADPD, SPD) and controls, followed by descriptive analysis (clinical features, haplotype analysis) of the mutation carriers identified.",
    "Regarding patient 'D': What genetic methods were used in this study?": "Based on the information contained within the document:\n\nPatient 'D' was classified as a patient with sporadic PD (SPD). The genetic methods used for SPD patients in this study, which would include patient 'D', were:\n\n1.  **PCR direct sequencing:** Used to examine 7 specific variants of VPS35 (p.M57I, p.I241M, p.P316S, p.R524W, p.D620N, p.A737V, and p.L774M).\n2.  **High-resolution melting (HRM) analysis:** Used specifically to genotype for the c.1858G>A (p.D620N) mutation.\n3.  **Analysis of all exons of VPS35:** Performed on patients found to have the p.D620N mutation (like patient D), using PCR direct sequencing.\n4.  **Haplotype analysis:** Performed on the VPS35 flanking region using microsatellite genotyping (analyzed with a 3130 Genetic analyzer and GeneMapper software).",
    "Regarding patient 'D': What is the lower age limit for study inclusion (if any)?": "Information not found.",
    "Regarding patient 'D': What is the upper age limit for study inclusion (if any)?": "Information not found.",
    "Regarding patient 'D': Are there any additional comments about the study methodology?": "Information not found",
    "Regarding patient 'D': What is the abbreviation of the disease or condition diagnosed in this patient?": "Based only on the information contained within the provided document:\n\nRegarding patient 'D', the abbreviation of the disease or condition diagnosed in this patient is **SPD**.\n\n*Rationale:*\nPage 4, right column, second paragraph states: \"Because the family history of patient D was unknown, she was categorized as SPD.\"\nThe abstract defines SPD as \"sporadic PD\".",
    "Regarding patient 'D': What is the key clinical information about this patient?": "Based *only* on the information contained within the provided document:\n\nPatient 'D' carried the heterozygous missense p.D620N mutation in the VPS35 gene. She developed upper limb rest tremor at age 42 and had no family history of Parkinson's Disease (PD), being categorized as sporadic PD (SPD). Her disease duration at the time of the study was 21 years. Clinically, she presented with resting tremor, bradykinesia, rigidity, gait disturbance, and postural instability, with asymmetry at onset. She responded well to levodopa but experienced wearing off and levodopa-induced dyskinesia. She also had urinary urgency and sleep benefit. She did not have orthostatic hypotension, incontinence, dystonia at onset, hyperreflexia, hallucination, other psychosis, dementia, or gaze palsy. Her brain MRI was within normal limits. Due to disabling motor fluctuation and dyskinesia refractory to pharmacological treatment, she underwent subthalamic nucleus deep brain stimulation (STN-DBS) at age 60.",
    "Regarding patient 'D': What is the patient's ethnicity?": "Based on the information contained within the provided document:\n\nPatient D is described as one of the \"Japanese patients\" screened in the study (page 2, Subjects; page 3, Haplotype analysis; page 4, Discussion). The study detected the p.D620N mutation in \"1 SPD patient with East Asian ancestry\" (page 4, Discussion), and Patient D is identified as the SPD patient with this mutation (page 3, Fig 1 legend; page 4, Discussion).\n\nTherefore, the patient's ethnicity is **Japanese** (or **East Asian** based on the phrasing on page 4).",
    "Regarding patient 'D': What is the patient's country of origin?": "Based *only* on the information contained within the provided document:\n\nThe study screened \"Japanese patients with autosomal-dominant PD (ADPD), Japanese patients with SPD [sporadic PD], and control subjects\" (Page 2, Patients and Methods). Patient D was identified as the one patient with SPD found to have the p.D620N mutation in this study (Page 3, Results; Page 4, Discussion). The abstract and discussion sections refer to the findings as relating to \"Japanese patients\" and \"Asian PD patients\", specifically noting the frequency of the mutation found in the Japanese ADPD and SPD cohorts screened. Haplotype analysis also discusses the characteristics of the \"Japanese patients with the p.D620N mutation\", a group which includes patient D.\n\nTherefore, patient D's country of origin is **Japan**.",
    "Regarding patient 'D': What is the patient's sex/gender?": "Based on the information contained within the provided document, patient 'D' is referred to using the pronoun 'She' (page 4, paragraph 1 and paragraph 4). Therefore, the patient's sex/gender is female.",
    "Regarding patient 'D': Is this patient the index case in the family?": "Based on the information provided in the document:\n\n*   Patient D is described as having Sporadic PD (SPD) (Abstract, page 1; Results, page 2; Discussion, page 4).\n*   Page 4, first paragraph states: \"Patient D, who developed upper limb rest tremor at age 42, had no family history of PD.\"\n*   Page 4, Discussion section states: \"Because the family history of patient D was unknown, she was categorized as SPD.\"\n*   Figure 1 shows pedigrees for families A, B, and C, where the proband (index case) is indicated by an arrow. Patients AII-11, BIII-8, and CII-3 are indicated as probands for their respective families. There is no pedigree shown for Patient D, nor are they indicated as a proband.\n\nAn index case (proband) is typically the first affected individual in a family who brings the condition to medical attention, initiating the study of that family. Since Patient D is described as having no family history of PD (or an unknown family history) and is classified as SPD, the document does not identify Patient D as the index case *in the family*.\n\nTherefore, the answer is: **No**, the document describes Patient D as having Sporadic PD with no known family history, not as the index case in the family.",
    "Regarding patient 'D': How many affected individuals in the family have heterozygous mutations?": "Information not found\n\n**Reasoning:**\nThe document identifies 'Patient D' as an individual with sporadic Parkinson's Disease (SPD) who possesses a heterozygous p.D620N mutation (Table 1, page 3; page 4 text). However, the text explicitly states that \"Patient D... had no family history of PD\" (page 4, first paragraph). Figure 1 (page 3), which depicts family pedigrees, includes families A, B, and C, but not D. Therefore, the document provides information only about Patient D themselves and does not mention or describe any affected family members of Patient D, nor does it provide information on the mutational status of any potential family members.",
    "Regarding patient 'D': How many affected individuals in the family have homozygous mutations?": "Information not found.\n\nThe document identifies Patient D as having sporadic PD (SPD) with no family history of PD mentioned. It states Patient D has a heterozygous p.D620N mutation. There is no information provided about any affected family members of Patient D, nor any mention of homozygous mutations within this family.",
    "Regarding patient 'D': How many unaffected individuals in the family have heterozygous mutations?": "Information not found",
    "Regarding patient 'D': How many unaffected individuals in the family have homozygous mutations?": "Information not found",
    "Regarding patient 'D': How many affected individuals in the family have wildtype (no mutations)?": "Information not found.",
    "Regarding patient 'D': How many unaffected individuals in the family have wildtype (no mutations)?": "Information not found",
    "Regarding patient 'D': What is the clinical status of the patient?": "Based on the information contained within the provided document:\n\nPatient 'D' is diagnosed with sporadic Parkinson's Disease (SPD) and carries the heterozygous p.D620N mutation in the VPS35 gene.\n\nClinical features include:\n*   Age at disease onset: 42 years.\n*   Disease duration at time of report: 21 years.\n*   Symptoms: Resting tremor (specifically upper limb rest tremor at onset), bradykinesia, rigidity, gait disturbance, and postural instability.\n*   Treatment response: Responded clinically to levodopa but experienced wearing off and levodopa-induced dyskinesia.\n*   Other features: Asymmetry at onset, urinary urgency. No orthostatic hypotension, incontinence, dystonia at onset, hyperreflexia, hallucination, other psychosis, dementia, or gaze palsy were noted. Sleep benefit was unknown.\n*   Imaging: Brain MRI was within normal limits (WNL). Cardiac MIBG scintigraphy was not performed.\n*   Intervention: Underwent subthalamic nucleus deep brain stimulation (STN-DBS) at age 60 due to disabling motor fluctuation and dyskinesia refractory to pharmacological treatment.\n*   Family History: Patient D had no family history of PD.",
    "Regarding patient 'D': What was the age at examination (AAE) for this patient?": "Information not found.",
    "Regarding patient 'D': What was the age at onset (AAO) of symptoms for this patient?": "Based on the information in the document:\n\n*   **Table 2 (Clinical features of patients with p.D620N mutation):** Lists patient 'D' and shows the 'Age at disease onset (y)' as 42.\n*   **Page 4, Discussion section, first paragraph:** States, \"Patient D, who developed upper limb rest tremor at age 42, had no family history of PD.\"\n\nThe age at onset (AAO) of symptoms for patient 'D' was 42 years.",
    "Regarding patient 'D': What is the disease duration for this patient?": "Based on the information in Table 2 (\"Clinical features of patients with p.D620N mutation\"), the disease duration for patient 'D' is **21 years**.",
    "Regarding patient 'D': At what age was the patient diagnosed?": "Information not found.\n\nThe document provides the \"Age at disease onset (y)\" for patient D as 42 (Table 2 and page 4), but it does not explicitly state the age at which the patient was diagnosed.",
    "Regarding patient 'D': At what age did the patient die (if applicable)?": "Information not found",
    "Regarding patient 'D': Which human genome version was used for variant reporting?": "Information not found",
    "Regarding patient 'D': What is the physical genomic location of the first mutation?": "Information not found.\n\nThe document identifies the mutation in patient D as p.D620N (also described as c.1858G>A) located in exon 15 of the VPS35 gene. Haplotype analysis provides locations of microsatellite markers flanking the gene on chromosome 16 (e.g., D16S3105, Chr16_45.333M). However, the specific base pair coordinate on chromosome 16 corresponding to the c.1858 position within the VPS35 gene is not provided in the document.",
    "Regarding patient 'D': What is the reference allele for the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe document identifies patient 'D' as having the p.D620N mutation (Table 1, Table 2, page 4 text). On page 2, in the 'Genetic Analysis' section, this mutation is specified at the nucleotide level as c.1858G>A. This notation indicates that the reference nucleotide is G and the variant nucleotide is A.\n\nTherefore, the reference allele for the mutation identified in patient 'D' is G.",
    "Regarding patient 'D': What is the observed (mutant) allele for the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe document states on page 2, under Genetic Analysis, that the p.D620N mutation corresponds to the nucleotide change c.1858G>A. Table 1 on page 3 shows that patient D has the genotype A/G for the VPS35 p.D620N mutation. Therefore, the observed (mutant) allele is A.",
    "Regarding patient 'D': What is the genomic-level notation for the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe genomic-level notation for the mutation found in patient 'D' is **c.1858G>A**.\n\n*Supporting information from the document:*\n*   Patient D is identified as one of the individuals carrying the VPS35 mutation (Table 1, Table 2, Page 3 text, Page 4 text).\n*   The specific mutation detected in the study subjects (including patient D) is consistently referred to as p.D620N at the protein level.\n*   The document provides the corresponding coding DNA level (genomic-level relative to the cDNA sequence) notation for this mutation on Page 2 (\"Genetic Analysis\" section) and Page 4 (\"Discussion\" section) as c.1858G>A.\n*   The document only reports this one mutation (c.1858G>A / p.D620N) being detected in patient D.",
    "Regarding patient 'D': What is the original alias or alternate notation for the first mutation as reported in the article?": "Based *only* on the information contained within the provided document:\n\nThe article reports the mutation for patient 'D' as p.D620N. An alternate notation provided for this mutation in the document is **c.1858G>A**. This notation is found on page 2 in the \"Genetic Analysis\" section and on page 4 in the \"Discussion\" section, where it is explicitly linked to p.D620N (e.g., \"c.1858G>A (p.D620N)\").",
    "Regarding patient 'D': What is the standardized alias for the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe standardized alias for the first (and only mentioned) mutation in patient 'D' is **p.D620N**.\n\n*   Table 1 shows patient D has the \"VPS35 p.D620N\" mutation (genotype A/G).\n*   Table 2 lists clinical features for patients with the \"p.D620N mutation\", including patient D.\n*   The text on page 3 confirms patient D has the p.D620N mutation.\n*   The text on page 4 identifies patient D as the \"1 SPD patient\" found to have the \"heterozygous p.D620N mutation\".",
    "Regarding patient 'D': What is the genotype of the first mutation?": "Based *only* on the information contained within the provided document:\n\nThe genotype for the VPS35 p.D620N mutation in patient D is listed in Table 1 as **A/G**.\n\n*Self-correction:* The document identifies only one mutation (p.D620N, which corresponds to c.1858G>A) in patient D within the VPS35 gene. Table 1 specifically lists the genotype at this position for patient D as A/G, indicating heterozygosity. The text further confirms, \"We detected the heterozygous missense p.D620N mutation... in 1 patient with SPD\" (page 2), and patient D is later identified as the SPD patient (page 4). It also states, \"Patients carrying the p.D620N mutation did not have any other variants in all exons of VPS35\" (page 3). Therefore, based only on the document, the genotype of the *identified* mutation in patient D is A/G.",
    "Regarding patient 'D': What type of mutation is the first variant?": "Based *only* on the information contained within the provided document:\n\nThe first variant identified in patient 'D' is the p.D620N mutation. The document explicitly describes this mutation type on page 2, in the Results section, stating: \"We detected the heterozygous **missense** p.D620N mutation in 3 unrelated patients with ADPD and 1 patient with SPD\". Patient D is identified as the patient with SPD (Sporadic PD) in Table 1, Table 2, and the text on pages 3 and 4.\n\nTherefore, the type of mutation for the first variant in patient 'D' is **missense**.",
    "Regarding patient 'D': What is the gnomAD v2.1.1 frequency for the first mutation?": "",
    "Regarding patient 'D': What is the gnomAD v4.0.0 frequency for the first mutation?": "",
    "Regarding patient 'D': What is the physical genomic location of the second mutation?": "",
    "Regarding patient 'D': What is the reference allele for the second mutation?": "",
    "Regarding patient 'D': What is the observed (mutant) allele for the second mutation?": "",
    "Regarding patient 'D': What is the genomic-level notation for the second mutation?": "",
    "Regarding patient 'D': What is the original alias or alternate notation for the second mutation as reported in the article?": "",
    "Regarding patient 'D': What is the standardized alias for the second mutation?": "",
    "Regarding patient 'D': What is the genotype of the second mutation?": "",
    "Regarding patient 'D': What type of mutation is the second variant?": "",
    "Regarding patient 'D': What is the gnomAD v2.1.1 frequency for the second mutation?": "",
    "Regarding patient 'D': What is the gnomAD v4.0.0 frequency for the second mutation?": "",
    "Regarding patient 'D': What is the physical genomic location of the third mutation?": "",
    "Regarding patient 'D': What is the reference allele for the third mutation?": "",
    "Regarding patient 'D': What is the observed (mutant) allele for the third mutation?": "",
    "Regarding patient 'D': What is the genomic-level notation for the third mutation?": "",
    "Regarding patient 'D': What is the standardized alias for the third mutation?": "",
    "Regarding patient 'D': What is the genotype of the third mutation?": "",
    "Regarding patient 'D': What type of mutation is the third variant?": "",
    "Regarding patient 'D': What is the gnomAD v2.1.1 frequency for the third mutation?": "",
    "Regarding patient 'D': What is the gnomAD v4.0.0 frequency for the third mutation?": "",
    "Regarding patient 'D': Does the patient have motor symptoms?": "",
    "Regarding patient 'D': Does the patient have parkinsonism symptoms?": "",
    "Regarding patient 'D': What is the first motor assessment scale used?": "",
    "Regarding patient 'D': What is the score on the first motor assessment scale?": "",
    "Regarding patient 'D': What is the second motor assessment scale used (if any)?": "",
    "Regarding patient 'D': What is the score on the second motor assessment scale?": "",
    "Regarding patient 'D': Does the patient have non-motor symptoms of parkinsonism?": "",
    "Regarding patient 'D': Does the patient have olfactory dysfunction?": "",
    "Regarding patient 'D': What non-motor symptom assessment scale was used?": "",
    "Regarding patient 'D': Does the patient have bradykinesia?": "",
    "Regarding patient 'D': Does the patient have tremor?": "",
    "Regarding patient 'D': Does the patient have resting tremor?": "",
    "Regarding patient 'D': Does the patient have action tremor?": "",
    "Regarding patient 'D': Does the patient have postural tremor?": "",
    "Regarding patient 'D': Does the patient have dystonic tremor?": "",
    "Regarding patient 'D': Does the patient have rigidity?": "",
    "Regarding patient 'D': Does the patient have postural instability?": "",
    "Regarding patient 'D': How does the patient respond to levodopa treatment?": "",
    "Regarding patient 'D': How is the levodopa response quantified?": "",
    "Regarding patient 'D': Does the patient have dyskinesia?": "",
    "Regarding patient 'D': Does the patient have dystonia?": "",
    "Regarding patient 'D': Does the patient have hyperreflexia?": "",
    "Regarding patient 'D': Does the patient have diurnal fluctuations?": "",
    "Regarding patient 'D': Does the patient have sleep benefit?": "",
    "Regarding patient 'D': Does the patient have motor fluctuations?": "",
    "Regarding patient 'D': Does the patient have depression?": "",
    "Regarding patient 'D': What depression assessment scale was used and what was the score?": "",
    "Regarding patient 'D': Does the patient have anxiety?": "",
    "Regarding patient 'D': What anxiety assessment scale was used and what was the score?": "",
    "Regarding patient 'D': Does the patient have psychotic symptoms?": "",
    "Regarding patient 'D': What psychotic symptoms assessment scale was used and what was the score?": "",
    "Regarding patient 'D': Does the patient have sleep disorders?": "",
    "Regarding patient 'D': Does the patient have cognitive decline?": "",
    "Regarding patient 'D': What subdomains of cognitive function are affected (if any)?": "",
    "Regarding patient 'D': What cognitive assessment scale was used and what was the score?": "",
    "Regarding patient 'D': Does the patient have autonomic symptoms?": "",
    "Regarding patient 'D': Does the patient have atypical parkinsonian features?": "",
    "Regarding patient 'D': What is the pathogenicity classification for the first mutation?": "",
    "Regarding patient 'D': What is the pathogenicity classification for the second mutation?": "",
    "Regarding patient 'D': What is the pathogenicity classification for the third mutation?": "",
    "Regarding patient 'D': What is the CADD score for the first mutation?": "",
    "Regarding patient 'D': What is the CADD score for the second mutation?": "",
    "Regarding patient 'D': What is the CADD score for the third mutation?": "",
    "Regarding patient 'D': What functional evidence supports the pathogenicity of the first mutation?": "",
    "Regarding patient 'D': What functional evidence supports the pathogenicity of the second mutation?": "",
    "Regarding patient 'D': What functional evidence supports the pathogenicity of the third mutation?": "",
    "Regarding patient 'D': What is the entry identifier for this data?": "",
    "Regarding patient 'D': Any additional general comments about this data?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the study design of this article?": "",
    "Regarding patient 'AII-12' from family 'Family A': What genetic methods were used in this study?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the lower age limit for study inclusion (if any)?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the upper age limit for study inclusion (if any)?": "",
    "Regarding patient 'AII-12' from family 'Family A': Are there any additional comments about the study methodology?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the abbreviation of the disease or condition diagnosed in this patient?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the key clinical information about this patient?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the patient's ethnicity?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the patient's country of origin?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the patient's sex/gender?": "",
    "Regarding patient 'AII-12' from family 'Family A': Is this patient the index case in the family?": "",
    "Regarding patient 'AII-12' from family 'Family A': How many affected individuals in the family have heterozygous mutations?": "",
    "Regarding patient 'AII-12' from family 'Family A': How many affected individuals in the family have homozygous mutations?": "",
    "Regarding patient 'AII-12' from family 'Family A': How many unaffected individuals in the family have heterozygous mutations?": "",
    "Regarding patient 'AII-12' from family 'Family A': How many unaffected individuals in the family have homozygous mutations?": "",
    "Regarding patient 'AII-12' from family 'Family A': How many affected individuals in the family have wildtype (no mutations)?": "",
    "Regarding patient 'AII-12' from family 'Family A': How many unaffected individuals in the family have wildtype (no mutations)?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the clinical status of the patient?": "",
    "Regarding patient 'AII-12' from family 'Family A': What was the age at examination (AAE) for this patient?": "",
    "Regarding patient 'AII-12' from family 'Family A': What was the age at onset (AAO) of symptoms for this patient?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the disease duration for this patient?": "",
    "Regarding patient 'AII-12' from family 'Family A': At what age was the patient diagnosed?": "",
    "Regarding patient 'AII-12' from family 'Family A': At what age did the patient die (if applicable)?": "",
    "Regarding patient 'AII-12' from family 'Family A': Which human genome version was used for variant reporting?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the physical genomic location of the first mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the reference allele for the first mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the observed (mutant) allele for the first mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the genomic-level notation for the first mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the original alias or alternate notation for the first mutation as reported in the article?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the standardized alias for the first mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the genotype of the first mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What type of mutation is the first variant?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the gnomAD v2.1.1 frequency for the first mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the gnomAD v4.0.0 frequency for the first mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the physical genomic location of the second mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the reference allele for the second mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the observed (mutant) allele for the second mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the genomic-level notation for the second mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the original alias or alternate notation for the second mutation as reported in the article?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the standardized alias for the second mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the genotype of the second mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What type of mutation is the second variant?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the gnomAD v2.1.1 frequency for the second mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the gnomAD v4.0.0 frequency for the second mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the physical genomic location of the third mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the reference allele for the third mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the observed (mutant) allele for the third mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the genomic-level notation for the third mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the standardized alias for the third mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the genotype of the third mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What type of mutation is the third variant?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the gnomAD v2.1.1 frequency for the third mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the gnomAD v4.0.0 frequency for the third mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have motor symptoms?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have parkinsonism symptoms?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the first motor assessment scale used?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the score on the first motor assessment scale?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the second motor assessment scale used (if any)?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the score on the second motor assessment scale?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have non-motor symptoms of parkinsonism?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have olfactory dysfunction?": "",
    "Regarding patient 'AII-12' from family 'Family A': What non-motor symptom assessment scale was used?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have bradykinesia?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have tremor?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have resting tremor?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have action tremor?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have postural tremor?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have dystonic tremor?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have rigidity?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have postural instability?": "",
    "Regarding patient 'AII-12' from family 'Family A': How does the patient respond to levodopa treatment?": "",
    "Regarding patient 'AII-12' from family 'Family A': How is the levodopa response quantified?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have dyskinesia?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have dystonia?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have hyperreflexia?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have diurnal fluctuations?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have sleep benefit?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have motor fluctuations?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have depression?": "",
    "Regarding patient 'AII-12' from family 'Family A': What depression assessment scale was used and what was the score?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have anxiety?": "",
    "Regarding patient 'AII-12' from family 'Family A': What anxiety assessment scale was used and what was the score?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have psychotic symptoms?": "",
    "Regarding patient 'AII-12' from family 'Family A': What psychotic symptoms assessment scale was used and what was the score?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have sleep disorders?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have cognitive decline?": "",
    "Regarding patient 'AII-12' from family 'Family A': What subdomains of cognitive function are affected (if any)?": "",
    "Regarding patient 'AII-12' from family 'Family A': What cognitive assessment scale was used and what was the score?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have autonomic symptoms?": "",
    "Regarding patient 'AII-12' from family 'Family A': Does the patient have atypical parkinsonian features?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the pathogenicity classification for the first mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the pathogenicity classification for the second mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the pathogenicity classification for the third mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the CADD score for the first mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the CADD score for the second mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the CADD score for the third mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What functional evidence supports the pathogenicity of the first mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What functional evidence supports the pathogenicity of the second mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What functional evidence supports the pathogenicity of the third mutation?": "",
    "Regarding patient 'AII-12' from family 'Family A': What is the entry identifier for this data?": "",
    "Regarding patient 'AII-12' from family 'Family A': Any additional general comments about this data?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the study design of this article?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What genetic methods were used in this study?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the lower age limit for study inclusion (if any)?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the upper age limit for study inclusion (if any)?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Are there any additional comments about the study methodology?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the abbreviation of the disease or condition diagnosed in this patient?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the key clinical information about this patient?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the patient's ethnicity?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the patient's country of origin?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the patient's sex/gender?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Is this patient the index case in the family?": "",
    "Regarding patient 'AIII-5' from family 'Family A': How many affected individuals in the family have heterozygous mutations?": "",
    "Regarding patient 'AIII-5' from family 'Family A': How many affected individuals in the family have homozygous mutations?": "",
    "Regarding patient 'AIII-5' from family 'Family A': How many unaffected individuals in the family have heterozygous mutations?": "",
    "Regarding patient 'AIII-5' from family 'Family A': How many unaffected individuals in the family have homozygous mutations?": "",
    "Regarding patient 'AIII-5' from family 'Family A': How many affected individuals in the family have wildtype (no mutations)?": "",
    "Regarding patient 'AIII-5' from family 'Family A': How many unaffected individuals in the family have wildtype (no mutations)?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the clinical status of the patient?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What was the age at examination (AAE) for this patient?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What was the age at onset (AAO) of symptoms for this patient?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the disease duration for this patient?": "",
    "Regarding patient 'AIII-5' from family 'Family A': At what age was the patient diagnosed?": "",
    "Regarding patient 'AIII-5' from family 'Family A': At what age did the patient die (if applicable)?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Which human genome version was used for variant reporting?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the physical genomic location of the first mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the reference allele for the first mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the observed (mutant) allele for the first mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the genomic-level notation for the first mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the original alias or alternate notation for the first mutation as reported in the article?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the standardized alias for the first mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the genotype of the first mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What type of mutation is the first variant?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the gnomAD v2.1.1 frequency for the first mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the gnomAD v4.0.0 frequency for the first mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the physical genomic location of the second mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the reference allele for the second mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the observed (mutant) allele for the second mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the genomic-level notation for the second mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the original alias or alternate notation for the second mutation as reported in the article?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the standardized alias for the second mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the genotype of the second mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What type of mutation is the second variant?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the gnomAD v2.1.1 frequency for the second mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the gnomAD v4.0.0 frequency for the second mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the physical genomic location of the third mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the reference allele for the third mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the observed (mutant) allele for the third mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the genomic-level notation for the third mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the standardized alias for the third mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the genotype of the third mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What type of mutation is the third variant?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the gnomAD v2.1.1 frequency for the third mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the gnomAD v4.0.0 frequency for the third mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have motor symptoms?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have parkinsonism symptoms?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the first motor assessment scale used?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the score on the first motor assessment scale?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the second motor assessment scale used (if any)?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the score on the second motor assessment scale?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have non-motor symptoms of parkinsonism?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have olfactory dysfunction?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What non-motor symptom assessment scale was used?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have bradykinesia?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have tremor?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have resting tremor?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have action tremor?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have postural tremor?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have dystonic tremor?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have rigidity?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have postural instability?": "",
    "Regarding patient 'AIII-5' from family 'Family A': How does the patient respond to levodopa treatment?": "",
    "Regarding patient 'AIII-5' from family 'Family A': How is the levodopa response quantified?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have dyskinesia?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have dystonia?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have hyperreflexia?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have diurnal fluctuations?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have sleep benefit?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have motor fluctuations?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have depression?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What depression assessment scale was used and what was the score?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have anxiety?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What anxiety assessment scale was used and what was the score?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have psychotic symptoms?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What psychotic symptoms assessment scale was used and what was the score?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have sleep disorders?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have cognitive decline?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What subdomains of cognitive function are affected (if any)?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What cognitive assessment scale was used and what was the score?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have autonomic symptoms?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Does the patient have atypical parkinsonian features?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the pathogenicity classification for the first mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the pathogenicity classification for the second mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the pathogenicity classification for the third mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the CADD score for the first mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the CADD score for the second mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the CADD score for the third mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What functional evidence supports the pathogenicity of the first mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What functional evidence supports the pathogenicity of the second mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What functional evidence supports the pathogenicity of the third mutation?": "",
    "Regarding patient 'AIII-5' from family 'Family A': What is the entry identifier for this data?": "",
    "Regarding patient 'AIII-5' from family 'Family A': Any additional general comments about this data?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the study design of this article?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What genetic methods were used in this study?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the lower age limit for study inclusion (if any)?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the upper age limit for study inclusion (if any)?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Are there any additional comments about the study methodology?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the abbreviation of the disease or condition diagnosed in this patient?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the key clinical information about this patient?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the patient's ethnicity?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the patient's country of origin?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the patient's sex/gender?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Is this patient the index case in the family?": "",
    "Regarding patient 'AIII-6' from family 'Family A': How many affected individuals in the family have heterozygous mutations?": "",
    "Regarding patient 'AIII-6' from family 'Family A': How many affected individuals in the family have homozygous mutations?": "",
    "Regarding patient 'AIII-6' from family 'Family A': How many unaffected individuals in the family have heterozygous mutations?": "",
    "Regarding patient 'AIII-6' from family 'Family A': How many unaffected individuals in the family have homozygous mutations?": "",
    "Regarding patient 'AIII-6' from family 'Family A': How many affected individuals in the family have wildtype (no mutations)?": "",
    "Regarding patient 'AIII-6' from family 'Family A': How many unaffected individuals in the family have wildtype (no mutations)?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the clinical status of the patient?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What was the age at examination (AAE) for this patient?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What was the age at onset (AAO) of symptoms for this patient?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the disease duration for this patient?": "",
    "Regarding patient 'AIII-6' from family 'Family A': At what age was the patient diagnosed?": "",
    "Regarding patient 'AIII-6' from family 'Family A': At what age did the patient die (if applicable)?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Which human genome version was used for variant reporting?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the physical genomic location of the first mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the reference allele for the first mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the observed (mutant) allele for the first mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the genomic-level notation for the first mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the original alias or alternate notation for the first mutation as reported in the article?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the standardized alias for the first mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the genotype of the first mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What type of mutation is the first variant?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the gnomAD v2.1.1 frequency for the first mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the gnomAD v4.0.0 frequency for the first mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the physical genomic location of the second mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the reference allele for the second mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the observed (mutant) allele for the second mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the genomic-level notation for the second mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the original alias or alternate notation for the second mutation as reported in the article?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the standardized alias for the second mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the genotype of the second mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What type of mutation is the second variant?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the gnomAD v2.1.1 frequency for the second mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the gnomAD v4.0.0 frequency for the second mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the physical genomic location of the third mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the reference allele for the third mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the observed (mutant) allele for the third mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the genomic-level notation for the third mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the standardized alias for the third mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the genotype of the third mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What type of mutation is the third variant?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the gnomAD v2.1.1 frequency for the third mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the gnomAD v4.0.0 frequency for the third mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have motor symptoms?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have parkinsonism symptoms?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the first motor assessment scale used?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the score on the first motor assessment scale?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the second motor assessment scale used (if any)?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the score on the second motor assessment scale?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have non-motor symptoms of parkinsonism?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have olfactory dysfunction?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What non-motor symptom assessment scale was used?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have bradykinesia?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have tremor?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have resting tremor?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have action tremor?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have postural tremor?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have dystonic tremor?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have rigidity?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have postural instability?": "",
    "Regarding patient 'AIII-6' from family 'Family A': How does the patient respond to levodopa treatment?": "",
    "Regarding patient 'AIII-6' from family 'Family A': How is the levodopa response quantified?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have dyskinesia?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have dystonia?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have hyperreflexia?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have diurnal fluctuations?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have sleep benefit?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have motor fluctuations?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have depression?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What depression assessment scale was used and what was the score?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have anxiety?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What anxiety assessment scale was used and what was the score?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have psychotic symptoms?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What psychotic symptoms assessment scale was used and what was the score?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have sleep disorders?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have cognitive decline?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What subdomains of cognitive function are affected (if any)?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What cognitive assessment scale was used and what was the score?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have autonomic symptoms?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Does the patient have atypical parkinsonian features?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the pathogenicity classification for the first mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the pathogenicity classification for the second mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the pathogenicity classification for the third mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the CADD score for the first mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the CADD score for the second mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the CADD score for the third mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What functional evidence supports the pathogenicity of the first mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What functional evidence supports the pathogenicity of the second mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What functional evidence supports the pathogenicity of the third mutation?": "",
    "Regarding patient 'AIII-6' from family 'Family A': What is the entry identifier for this data?": "",
    "Regarding patient 'AIII-6' from family 'Family A': Any additional general comments about this data?": ""
}